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Abstract 
Aim: The purpose of this study was to examine diarrhoea, enteral nutrition and 
aerobic intestinal microflora relationships in critically ill, emergency admission, 
adult intensive care unit (ICU) patients. 
Background: Relationships between diet and intestinal microbial flora have been 
debated for many years; however, these two relationships have been disconnectedly 
examined in relation to diarrhoea in enterally tube fed (ETF), critically ill patients in 
intensive care. Diarrhoea is a common complication observed in critical illness. 
Enteral tube feeding is often cited as the primary cause of diarrhoea; however, many 
other factors may be responsible for inducing diarrhoea in these patients. 
Complicating this issue is the plethora of definitions and faecal stool output tools 
used to define, identify and measure diarrhoea. Unlike the abundance of literature 
that has examined diarrhoea in ETF patients, no literature has examined the 
relationships between diarrhoea, enteral nutrition and aerobic intestinal microflora in 
emergency admission critically ill patients. 
Design: This research used a two-study approach to examine diarrhoea, enteral 
nutrition and aerobic intestinal microflora relationships. 
Study One: A retrospective, repeated measures, observational cohort study of 
critically ill patients’ medical records was conducted over five months to examine 
diarrhoea and associated diarrhoea risk factors. 
Study Two: A prospective, repeated measures, correlation cohort study of critically ill 
patients was conducted to examine the relationship(s) between diarrhoea, enteral 
nutrition and aerobic intestinal microflora. 
Population and sample: The study population of both Study One and Study Two 
comprised patients who were admitted to the ICU of an Australian metropolitan 
tertiary hospital. The sample for both studies was emergency admission, ETF, 
critically ill, adult patients (Study One n = 50, Study Two n = 101). 
Outcome measures: The unit of measure in Study One was diarrhoea and in Study 
Two, the unit of measure was aerobic intestinal microflora counts and diarrhoea. 
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Data collection and instruments: Data were collected for each day of the patient’s 
ICU admission to a maximum of 14 days into the patient’s critical illness experience 
or discharge from the ICU, whichever occurred first. Data collected in Study One 
and Two included the occurrence of diarrhoea, the number of events of diarrhoea, the 
duration of diarrhoea, the incidence rate of diarrhoea and associated diarrhoea risk 
factors including sample characteristics (age, gender, ICU length of stay, severity of 
illness scores), ETF (formula, duration, method of administration, associated bowel 
care) and ICU treatments (medications and clinical indicators). In addition, Study 
Two collected data on aerobic intestinal microflora. A study-specific data collection 
instrument containing eight key sections for Study One and 11 key sections for Study 
Two was developed for this research. 
Data analysis: Descriptive statistics of patient demographics were performed using 
means, standard deviations (SD), medians (Mdn) and percentages. Normality was 
assessed using the Kolmogorov-Smirnov test. Univariate and bivariate associations 
were assessed using the Pearson’s product–moment correlation coefficient or the 
Spearman Rho correlation coefficient. Univariate associations were analysed using 
the Chi square statistical test. The Kruskal-Wallis test was performed to examine the 
variance between skewed continuous variables across groups, while the Mann-
Whitney U test was used to explore non-parametric data. The Wilcoxon signed-rank 
test was used examine repeated measures data that was not normally distributed. 
Univariate relationships were examined using simple linear regression and 
multivariate relationships were examined using forced multivariate regression 
modelling. Generalised estimating equation (GEE) modelling was used to analyse 
variation across the repeated measures data. For all analyses, a p ≤ .05 was 
considered statistically significant. 
Results: Fifty patient medical records were retrospectively audited for the occurrence 
and period prevalence of diarrhoea and associated diarrhoea risk factors in Study 
One. In Study One, the period prevalence of diarrhoea was 78% (n = 39) and patients 
were admitted to the ICU for 644 patient admission days. The cumulative incidence 
rate of diarrhoea was 0.64 events per patient observation day, with the individual 
patient incidence rate of diarrhoea ranging from 0 to 2.90 events per patient 
observation day. Patients in Study One had a higher median acute physiology and 
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chronic health evaluation II (APACHE II) score (Mdn = 12). The median time delay 
from ICU admission to initial bowel activity was 114 hours. The majority of the 
sample received aperients (n = 44; 84%), prokinetics (n = 42; 84%), sedation (n = 42; 
88%) and antibiotic medications (n = 46; 92%). Furthermore, the majority of patients 
also experienced a derangement of clinical indicators including hyperglycaemia (n = 
46; 92%), hypoalbuminaemia (n = 47; 94%), elevated white cell count (WCC) (n = 
47; 94%) and elevated international normalised ratio (INR) (n = 40; 80%). 
The higher occurrence and higher diarrhoea incidence rate was associated with the 
higher occurrence of hypoalbuminaemia and infection and a longer duration of 
hypoalbuminaemia, hyperglycaemia and elevated INR. Combinations of antibiotic 
medications were associated with the increased occurrence and higher incidence rate 
of diarrhoea. 
In Study Two, the period prevalence of diarrhoea was 53% (n = 53) and participants 
were admitted to the ICU for 925 patient admission days. Diarrhoea was reported on 
166 patient admission days (18%) and 326 events of diarrhoea were observed over 
744 (44%) ETF days. The median time delay from ICU admission to initial bowel 
activity was 84 hours. Participants were acutely unwell with higher median 
APACHE II scores (Mdn = 27). The median ICU length of stay (LOS) was 7 days. 
Similar to Study One, the majority of Study Two participants received aperients (n = 
81; 80%), prokinetics (n = 78; 77%), hydrogen-2 (H2) antagonist (n = 89; 88%), 
sedation (n = 98; 97%) and antibiotic (n = 87; 86%) medications. 
Study participants were more likely to experience variation in their aerobic intestinal 
microflora (intestinal dysbiosis) if they were older, critically ill with a higher severity 
of illness score (APACHE II), experienced a higher incidence rate of diarrhoea, were 
exposed to a longer duration of antibiotic medications, and experienced 
hypoalbuminaemia over a longer period of time. 
Discussion: Frequently cited diarrhoea aetiologies in critical illness include ETF, 
medication exposure (aperients, prokinetics, H2 antagonists, antibiotics), and clinical 
indicator derangement (hypoalbuminaemia, hyperglycaemia, elevated WCC, 
elevated INR, infection). Although some variation in aerobic intestinal microflora 
was observed in this study, stark variations in these gut flora were observed between 
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patients. Higher diarrhoea incidence rates were observed in the current study when 
the patient received ETF, experienced a derangement of multiple clinical indicators, 
received multiple medications and experienced aerobic microflora dysbiosis. 
Conclusion: Intestinal dysbiosis has been demonstrated in ETF critically ill patients. 
The clinical implications of aerobic intestinal microflora disequilibrium in critically 
ill patients may predispose patients to an increased risk of diarrhoea in the ICU. 
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CHAPTER ONE: INTRODUCTION 
1.1 Overview 
The aim of this research is to explore the relationships between diarrhoea, enteral 
nutrition and aerobic intestinal microflora in emergency admission, critically ill adult 
intensive care unit (ICU) patients. Knowledge generated from this research will 
create a new foundation on which to base interventional studies that examine the 
intestinal health of critically ill, enterally tube-fed (ETF) patients who develop 
diarrhoea. This chapter contains an overview of the background issues relevant to 
this research. A brief description of the conceptual framework underpinning this 
research will be presented, followed by a description of the study aims and objectives 
and the significance of this research. Finally, an outline of the remaining chapters of 
this thesis will be presented. 
1.2 Background 
Diarrhoea has long been recognised as a common complication associated with 
critical illness, and it is the most commonly cited complication associated with 
enteral nutrition in both critically ill and non-critically ill patients (Bodoky & Kent-
Smith, 2009; Lee & Auyeung, 2003; Majid, Emery, & Whelan, 2012; Whelan & 
Schneider, 2011). The reported incidence of diarrhoea in tube-fed patients varies 
widely between 2% and 68% across all patient populations (Lee & Auyeung, 2003; 
Whelan et al., 2001; Whelan, Judd, & Taylor, 2003). This incidence, however, is 
reportedly more divergent in critically ill patients, ranging from 2% to 95% of all 
ETF critically ill patients and between 2% to 26% of ICU patient admission days 
(Majid et al., 2012; Whelan & Schneider, 2011). These prevalence rates have 
remained unchanged for more than 30 years (Bliss, Guenter, & Settle, 1992; Cataldi-
Betcher, Seltzer, Slocum, & Jones, 1983; DeMao et al., 1998). 
Extensive complications associated with diarrhoea have been identified in critically 
ill patients. Although not directly associated with mortality, diarrhoea has 
contributed to fluid and electrolyte imbalance, haemodynamic instability, impede 
nutritional therapy delivery, contaminate wounds, contribute to peri-anal skin 
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breakdown and increase ICU and hospital lengths of stay (LOS) in critically ill 
patients (Martin, 2007). Consequently, increased nursing workloads are required to 
care for the critically ill patient with diarrhoea. Psychologically, diarrhoea can be 
distressing to the patient, the patient’s family and health care staff. 
Critically ill patients exhibit a complex array of physiological and psychological 
needs. Management of intestinal health is a fundamental aspect of complex health 
care interventions for the critically ill patient, and nutritional therapy is pivotal to the 
maintenance of physiological parameters and intestinal health in both health and 
disease (Clark, 2009; McClave & Heyland, 2009; Radrizzani et al., 2006; Widlicka, 
2008). Enteral tube-feeding is thus a common practice in the ICU and is routinely 
administered to between 27% and 92% of all ICU patients (Luft, Beghetto, de Mello, 
& Polanczyk, 2008; McNaught, Woodcock, Anderson, & MacFie, 2005; Weisen, 
Van Gossum, & Preiser, 2006; Whelan, Hill, Preedy, Judd, & Taylor, 2006; Whelan 
et al., 2009). Early commencement of nutritional therapy, that is, within 24 to 48 
hours of admission to the ICU is standard practice (Bankhead et al., 2009; McClave 
et al., 2009). Early commencement of ETF is thought to preserve the gut’s 
immunological barrier; prevent malnutrition (Marshall & West, 2004); correct 
nutritional deficits and moderate the metabolic response (Cresci & Cue, 2008; 
Nguyen, Ching et al., 2007); reduce bacterial translocation, sepsis and multiorgan 
failure rates; improve wound healing (Artinian, Krayem, & DiGiovine, 2006; 
Bernard et al., 2004; Clark, 2009; Davies & Bellomo, 2004; Lopez-Herce, 2009; 
Lopez-Herce et al., 2008; Marshall & West, 2004; McClave & Heyland, 2009; 
Nguyen, Ching et al., 2007; Ukleja, 2010); facilitate splanchnic blood flow (Davies 
& Bellomo, 2004) and reduce mortality and health care associated costs (Btaiche et 
al., 2010; Clark, 2009; Lopez-Herce, 2009; Lopez-Herce et al., 2008; Smith & 
Fedyszen, 2009). 
Diarrhoea in ETF and unfed critically ill patients occurs in response to multiple 
factors (Meier, Burri, & Steuerwald, 2003; Thorson, Zimmaro Bliss, & Savik, 2008; 
Whelan, Judd, & Taylor, 2003). Studies have demonstrated that diarrhoea is 
associated with a range of variables in critical illness including certain patient 
characteristics (age, gender and diagnosis at ICU admission), responses to ICU 
treatments (medication exposure including stool softeners, prokinetics, opioids and 
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antibiotics) and clinical indicators (hypoalbuminaemia, hyperglycaemia, infection 
and elevated white cell counts [WCC], hypoperfusion, hypoxaemia, shock and 
electrolyte imbalance) (Bernard et al., 2004; Chapman, Nguyen & Fraser, 2007; 
Mutlu, Mutlu, & Factor, 2003). 
The reasons that critically ill ETF patients have a higher risk of developing diarrhoea 
remain unclear due to a number of limitations in the available evidence. Research 
findings in the field of diarrhoea and its associated risk factors in critical illness are 
difficult to interpret. Although diarrhoea is frequently examined in the context of 
critical illness, the patient cohorts examined are often dissimilar, as are the 
definitions of diarrhoea (Bishop et al., 2010; Thomas et al., 2003) and the wide range 
of diarrhoea risk factors examined in these studies. Further, dissimilarities between 
the time to commencement and duration of ETF in studies examined (Hegazi & 
Wischmeyer, 2011) make it difficult to quantify and define diarrhoea. 
Of the multitude of factors considered contributing to the development of diarrhoea 
in critically ill patients, microbial flora changes have been identified as being of 
significance. The lower GIT, specifically the large colon, is one of the most 
important and primary sites of intestinal colonisation (Prakash, Tomaro-Duchesneau, 
Saha, & Cantor, 2011). Microbial flora inhabiting the GIT include anaerobic and 
aerobic microflora with anaerobic bacteria being the most dominant (Fujimura et al., 
2010; Prakash et al., 2011; Sekirov et al., 2010). However, while there have been a 
number of studies that have examined the role of anaerobic microflora in health and 
ill health states, the role of aerobic intestinal microflora and their relationship with 
diarrhoea in ETF critically ill patients remain unexplored. The presence of intestinal 
microflora dysbiosis and disequilibrium is potentially one explanation for the wide 
variation in the reported diarrhoea prevalence rates in ETF critically ill patients. This 
research seeks to examine these relationships. 
The conceptual framework that underpins this study draws on a multiplicity of 
concepts. The conceptual framework comprises three elements: the central construct; 
that is, the ICU patient with diarrhoea; the ICU environment; and the critical illness 
experience. The influence of and relationships between diarrhoea, enteral nutrition 
and aerobic intestinal microflora in critically ill patients remains unexplored, despite 
reports of the incidence of diarrhoea in critical illness. These relationships are 
4 
examined using the research questions and hypotheses that were developed from the 
conceptual framework. A detailed discussion of the conceptual framework is 
presented in Chapter Two. 
1.3 Aims and objectives of the research 
The aim of this research was to explore the relationships between diarrhoea, enteral 
nutrition and aerobic intestinal microflora in emergency admission, critically ill adult 
ICU patients. 
The objectives of this research were to: 
 determine the period prevalence and incidence rate of diarrhoea in critically ill 
patients in the ICU; 
 examine ETF-associated diarrhoea risk factors in critically ill patients; 
 examine diarrhoea, enteral nutrition and aerobic intestinal microflora 
relationships in critically ill patients. 
Two studies were conducted to achieve the aim and objectives. Study One used a 
retrospective, repeated measures observational cohort design to examine the 
incidence of diarrhoea and associated diarrhoea risk factors in ETF, critically ill 
patients. Study One, a pilot study, examined the feasibility of the methodological 
approach and variables to be examined (i.e. diarrhoea, the ICU environment, ICU 
treatments (ETF and medications) and critical illness associated clinical indicators 
(Kumar, 2011) in a subsequent larger scale study, Study Two. Study Two used a 
prospective, correlation, cohort design to examine the relationships between 
diarrhoea, enteral nutrition and aerobic intestinal microflora in critically ill adult ICU 
patients. The two complementary studies enabled deeper understanding of the 
multiple factors associated with diarrhoea in the ETF critically ill patient. 
1.4 Significance of the research 
To date, no study has examined aerobic intestinal microflora as they naturally occur 
in ETF, emergency admission critically ill patients (Finegold, Attebery, & Sutter, 
1974; Schneider et al., 2000; Whelan et al., 2005; Whelan et al., 2009). This research 
is the only one to date to explore diarrhoea, enteral nutrition and aerobic intestinal 
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microflora relationships in critically ill patients. Research examining the role of 
intestinal microflora and ETF-associated diarrhoea has yielded conflicting results for 
more than 40 years. This research also has the potential to enhance awareness of 
diarrhoea characteristics and risk factors in the development of diarrhoea in critically 
ill patients. More importantly, this research has the potential to provide information 
needed to identify interventions for future research, and thereby create clinical 
practice changes to improve the intestinal health of critically ill patients. 
1.5 Structure of the thesis 
This thesis comprises seven chapters. Chapter One contains the background and 
significance of the research including the research problem, aims and objectives and 
the thesis structure. 
Chapter Two introduces the conceptual framework that guides this research. 
Underpinning the conceptual framework is a discussion of literature concerning 
diarrhoea, enteral nutrition and aerobic intestinal microflora relationships in critically 
ill patients. A review of the key constructs associated with diarrhoea in critically ill 
patients, that is, the ICU environment, the critical illness experience, patient 
characteristics (age, gender, ICU LOS, severity of illness), ICU treatments (ETF and 
medications), clinical indicators (hypoalbuminaemia, hyperglycaemia, elevated 
WCC and elevated INR) and aerobic intestinal microflora is also presented in 
Chapter Two. 
Chapter Three introduces the methods used in this research which is comprised of 
two studies. The design, research questions, variables of interest, sampling measures 
and procedures, data management, statistical analytical approaches and ethical 
considerations are also provided for the two studies in Chapter Three. 
Chapters Four and Five present the results of Study One and Study Two, 
respectively. In Chapter Six, a critical discussion of the findings of Study One and 
Study Two as they relate to the research questions and the conceptual framework is 
provided. In the final chapter, Chapter Seven, the strengths and limitations of this 
research and future research opportunities that arise from the findings of Study One 
and Study Two are described. 
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1.6 Summary 
This chapter introduced the background of this research and highlighted the 
importance of research in the area of diarrhoea, enteral nutrition and aerobic 
intestinal microflora relationships in critically ill patients. The implications of 
diarrhoea in critically ill patients and the inconsistent research approaches to 
understanding this complex problem demand more focused research. A 
comprehensive understanding of the relationships between diarrhoea, enteral 
nutrition and aerobic intestinal microflora has the potential to facilitate the 
development of more effective strategies for minimising the complications associated 
with this problem in critically ill patients. The aims and objectives and the research 
plan were briefly outlined in this chapter, and the structure of the thesis was 
described. Chapter Two begins with the conceptual framework that guides this 
research and continues with an examination of literature relating of the key 
constructs in the framework, including diarrhoea, enteral nutrition and aerobic 
intestinal microflora relationships in critically ill patients. 
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CHAPTER TWO: LITERATURE REVIEW—DIARRHOEA, 
ENTERAL NUTRITION AND INTESTINAL MICROFLORA 
RELATIONSHIPS IN CRITICAL ILLNESS 
2.1 Introduction 
In the previous chapter the background and significance of this research were 
introduced. This chapter will begin with a critical discussion of the conceptual 
framework for this study. The framework is based upon current evidence and 
theories surrounding: (a) the critically ill patient with diarrhoea; (b) the ICU 
environment; and (c) the critical illness experience. The critical illness experience 
comprises patient characteristics (age, gender, ICU LOS, severity of illness); ICU 
treatments, include enteral nutrition (time to ETF commencement; duration, delivery, 
preparation and administration of ETF, ETF formula, bowel care), medications 
(aperients, prokinetics, hydrogen-2[H2] receptor antagonists, proton pump inhibitors 
[PPI], sedation, neuromuscular blockade, antibiotics) and clinical indicators 
associated with critical illness (hypoalbuminaemia, hyperglycaemia, elevated WCC, 
elevated INR); and diarrhoea, enteral nutrition and aerobic intestinal microflora 
relationships in the critically ill patient. An overall summary of the literature review 
that informs the conceptual framework will be provided to conclude this chapter. 
2.2 Literature search strategies 
A comprehensive search of databases holding information related to diarrhoea, 
enteral nutrition, aerobic intestinal microflora and critical illness was conducted. 
Databases searched were (in alphabetical order): CINHAL; Cochrane Library 
(including Cochrane Central Register of Controlled Trials, Cochrane database of 
systematic reviews [CDSR], Cochrane Methodology Register); Current Contents 
Connect (via Web of Knowledge); Drug Database (via Informit); Dynamed (via 
EBSCOHost); EBSCOHost; Embase; Evidence-Based Medicine Guidelines; Health 
Collection (via Informit); Journals at Ovid Full Text (via OvidSP); Medline (via 
EBSCOHost); National Theses Database; OldMedline (via NLM Gateway); 
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ProQuest Health & Medical Complete; PubMed; ProQuest; ScienceDirect; The 
Joanna Briggs Institute for Evidence Based Nursing and Midwifery; Web of Science. 
Within these databases relevant information contained within journals, books, 
handbooks and abstracts were searched. Literature searches were limited by language 
(English) and date (1980–2012) and the search terms used the fields of title, abstract, 
key words, references and author. Mono and combination search terms were used 
and joined by Boolean connectors and Mesh terms. The Boolean operators included 
and, or, not and within. Proximity searching and Wildcard characters were used. 
Singular, regular plural and irregular plural tense were also used in the search terms. 
Table 2.1 outlines the search term descriptors used in this study (in alphabetical 
order). 
Table 2.1 
Search Term Descriptors 
Alphabetical listing of search terms 
aperient   histamine-2 receptor 
antagonist   
inotropes  opioid   
aperients   glycaemic control   inotropic  opioids  
bowel care   enteral tube-feeding  intensive care unit  pharmacology  
bowel management   enteral tube formula  ICU  pharmacological   
bowel regimen   faecal output   intestinal microflora  pharmacotherapy  
complication   feed intolerance  intestinal microbial 
flora  
prokinetic  
complications   formula  mechanical 
ventilation  
prokinetics  
critical illness   gastric residual 
volume 
midazolam   propofol  
critically ill   hyperglycaemia  morphine  proton pump 
inhibitor  
critically ill patients 
diarrhoea   
hypoglycaemia  neuromuscular 
blocker  
sedation  
electrolytes   inotrope  normal flora  vasopressor 
enteral nutrition   microflora   
9 
Key authors who published regularly in the research fields of diarrhoea, enteral 
nutrition and intestinal microflora were also searched using the above search 
descriptors. The key words and reference lists of papers of interest were also 
examined. 
2.3 Conceptual framework 
Knowledge drawn from the nursing, medical, nutritional and microbiological 
paradigms informs the conceptual framework underpinning this study (see Figure 2.1 
page 10). The framework is founded on empirical constructs, particularly the 
relationships between the critically ill patient, diarrhoea, enteral nutrition and aerobic 
intestinal microflora. The conceptual framework is presented as a visual 
representation of key risk factors associated with diarrhoea, enteral nutrition and 
aerobic intestinal microflora relationships in the critically ill patient (Figure 2.1, page 
10). The framework is presented prior to the review of the literature to guide the 
discussion of the key constructs of relevance to this research. 
The key construct in this study, the ICU patient with diarrhoea, is presented at the 
centre of the framework. Relationships between key components of the conceptual 
framework are represented by linking arrows. The framework shows that intestinal 
microflora dysbiosis is influenced by the ICU environment, the critical illness 
experience and patient characteristics. This research aims to explore the relationships 
between these variables to facilitate a deeper understanding of diarrhoea risk factors 
in critically ill patients. The three components of the conceptual framework will be 
discussed in sections 2.4 to 2.6 (see pp. 11 to 20). 
The conceptual framework is composed of three main elements: the ICU patient with 
diarrhoea, the ICU environment and the critical illness experience. The elements of 
the critical illness experience are represented as three groups of circles (patient 
characteristics, ICU treatments—ETF and medications and clinical indicators) and 
comprise eight tri-coloured circles. 
Overarching the conceptual framework is the intensive care environment, 
represented by the outermost circle. The ICU environment encompasses the patient’s 
critical illness experience and associated cares within the ICU. The ICU environment 
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is a highly specialised and technological environment that meets the special care 
needs of its patients through constant monitoring and highly complex interventions. 
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Figure 2.1. Conceptual framework. 
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Encompassed within the ICU environment is the patient’s critical illness experience, 
representing the patient’s responses to critical illness and the patient’s responses to 
nursing and medical care interventions. The critical illness experience includes a 
wide range of diarrhoea risk factors, indicated by the eight tri-coloured circles of the 
conceptual framework. The risk factors were identified from a review of empirical 
evidence regarding the impact of the ICU environment on the patient’s physiological 
functioning. Embodied within the conceptual framework is the concept that diarrhoea 
in critically ill patients is associated with patient characteristics (green circle), ICU 
treatments including ETF (from commencement to administration), GIT-associated 
medications (pink circles) and clinical indicators including aerobic intestinal 
microflora (purple circles). 
2.4 The ICU patient with diarrhoea 
The critically ill patient with diarrhoea is the primary focus of this study (see Figure 
2.1, page 10). Diarrhoea is a common complication associated with critical illness 
(Flynn Makic & Carlson, 2009; Halmos, Muir, Barrett, Deng, Shepherd, & Gibson, 
2010; Thorson et al., 2008). The reported prevalence rates for diarrhoea vary widely, 
ranging from between 2% and 95%, with the majority of studies reporting diarrhoea 
prevalence rates between 50% and 75% (DeMao et al., 1998; Lee & Auyeung, 2003; 
Martin, 2007; Whelan et al., 2001; Whelan et al., 2003, Whelan, Judd, Preedy et al., 
2004; Whelan et al., 2009). Reports have indicated that diarrhoea in critical illness is 
associated with splanchnic hypoperfusion, medications (antibiotics, stool softeners, 
intestinal promotility medications, inotropes), acute physiological changes associated 
with critical illness (hypoalbuminaemia, hyperglycaemia, infection), the osmolality 
and fibre content of ETF formulae, microbial contamination of ETF formulae, 
malnutrition and intestinal microflora changes associated with critical illness (Garey 
et al., 2006; Halmos et al., 2010; Martin, 2007). These reported relationships 
between diarrhoea and associated risk factors are depicted within the conceptual 
framework as the ICU environment and the patients’ critical illness experience (see 
Figure 2.1, page 10). 
Diarrhoea occurs in response to intestinal dysfunction which has been associated 
with a failure of gut mechanisms including impairment in digestion, secretion, 
peristalsis, gut immune systems and infection (Hall, 2011). The implications of 
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increased faecal output and diarrhoea are extensive (Whelan Judd, & Taylor, 2004; 
Whelan et al., 2009). Untreated, diarrhoea is a major contributor to death by 
dehydration and electrolyte imbalance (Hall, 2011). As diarrhoeal disease progresses, 
patients become critically ill and suffer significant mortality. Worldwide, morbidity 
and mortality associated with diarrhoeal diseases is estimated to claim 1.4–2.5 
million lives (Hall, 2011). Diarrhoea may not be directly associated with mortality in 
critical illness, however it may be distressing for the patient, the patient’s family and 
health care staff. It can also impede the delivery of enteral nutrition and contribute to 
peri-anal skin breakdown, contaminate wounds, contribute to fluid and electrolyte 
imbalance and acid–base and haemodynamic instability. Diarrhoea also increases 
nursing workloads and potentially increases the patient’s ICU and hospital LOS 
(Martin, 2007). Although iatrogenic aetiologies have been associated with diarrhoea, 
the mechanisms of diarrhoea have been inadequately explored (Halmos et al., 2010; 
Martin, 2007). Multiple factors associated with critical illness increase the patient’s 
risk of developing diarrhoea (see Figure 2.1, page 10). Sections 2.5 and 2.6 will 
outline the risk factors for diarrhoea in ICU patients (see pp. 18 and 20). Specifically, 
as outlined in the study’s conceptual framework (see Figure 2.1, page 10), issues 
associated with the intensive care environment, the critical illness experience and 
other diarrhoea risk factors including ETF, medications, clinical indicators and 
aerobic intestinal microflora will be examined. The review of diarrhoea is 
encompassed throughout the remainder of Chapter Two and will now be discussed. 
2.4.1 Defining diarrhoea 
The absence of a standardised definition of diarrhoea and a validated and reliable 
diarrhoea measurement tool in the critical care setting is a major barrier to 
understanding the relationships in this field (Whelan, Judd, & Taylor et al., 2004, 
Whelan, Judd, Preedy et al., 2004). In clinical practice, health professionals (nurses, 
doctors, dieticians) often do not agree on the defining characteristics of diarrhoea 
(Majid, Emery, & Whelan, 2012). More specifically, there are differing views 
regarding the subjectivity of stool frequency, consistency and the number/volume of 
stools per 24 hours or combinations of these characteristics that would determine 
whether a patient was considered to have diarrhoea or not (Lee & Auyeung, 2003; 
Majid, Emery, & Whelan, 2012; Martin, 2007; Sabol & Carlson, 2007; Thomas et 
al., 2003; Whelan et al., 2003). For example, among several definitions of diarrhoea, 
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the most commonly used is the evacuation of three or more watery stools 
(Bittencourt et al., 2012). However, this definition does not include the volume of 
diarrhoea stools. A more comprehensive definition would incorporate the elements of 
stool frequency, consistency and volume using a faecal stool measurement tool, such 
as the Bristol Stool Form Scale. A more comprehensive definition would also 
incorporate the presence of more than 200 mL of bowel motions each day with stools 
classified as five, six or seven on the Bristol Stool Form Scale (Bishop, Young, 
Goldsmith, Buldock, Chin, & Bellomo, 2010). 
Little progress has been made over the past 20 years to refine a single standardised 
definition of diarrhoea (Bliss, Guenter, & Settle, 1992; Eisenberg, 2002; Majid et al., 
2012; Whelan, Judd & Taylor, 2003). As many as 33 unique definitions of diarrhoea 
have been cited in the literature (Lebak et al., 2003; Majid et al., 2012). The primary 
constructs in defining diarrhoea are: (a) stool frequency; (b) descriptors of stool 
consistency; (c) stool weight; and (d) combinations of frequency, consistency and 
weight (Eisenberg, 2002; Lebak et al., 2003; Majid et al., 2012; Martin, 2007; 
Pancorbo-Hidalgo et al., 2001). Research to advance understanding of the factors 
contributing to diarrhoea requires careful definition and measurement of the problem. 
Studies examining diarrhoea over the past 20 years display significant variation with 
regard to the descriptors used to define diarrhoea. Stool frequency has been variably 
defined as three to four stools per day (Halmos et al., 2010; McClave et al., 1999; 
Pesola et al., 1990). Stool consistency has been defined using multiple descriptors 
including liquid, semi-liquid or loose stools, with or without the use of a faecal 
containment device and with or without the use of a timeframe quantifier (Herlick et 
al., 2000; McPeake, Gilmore, & MacIntosh, 2011). Further, stool consistency has 
been defined diagrammatically using faecal stool measurement tools such as the 
Bristol Stool Form Scale and the Kings College Stool Chart (McPeake et al., 2011). 
Consistent with many descriptors of diarrhoea is a timeframe quantifier, that is, the 
number and/or volume or weight of diarrhoea stools in a 24-hour time frame (Bishop 
et al., 2010; Halmos et al., 2010; Heimburger et al., 1994; McClave et al., 1999; 
McPeake et al., 2011; Nguyen, Ching et al., 2008; Pesola et al., 1990). In 
comparison, some definitions do not use a timeframe quantifier to define diarrhoea 
(DeMeo et al., 1998; Herlick et al., 2000). Other definitions used a volume 
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quantifier, such as a stool volume >200g of stool/day or >3 liquid stools/day 
(Heimburger et al., 1994). More recent studies incorporate multiple stool descriptors 
including combinations of stool frequency, consistency and volume with or without a 
faecal stool measurement tool (Bishop et al., 2010; Nguyen, Ching et al., 2008). 
Monitoring faecal frequency is a simple task; however, monitoring faecal weight and 
consistency in ETF, critically ill patients is more challenging and requires subjective 
assessment by clinicians (Horn & Chaboyer, 2003; Ledbetter, 2006). Due to the 
complexities of critical illness, critically ill patients rarely defecate using a toilet, 
commode or bedpan, thereby making it challenging to measure, weigh and quantify 
stool output and diarrhoea. Critically ill patients are frequently incontinent of faecal 
output and this incontinence often occurs on their bed linen. There is little evidence 
to determine the accuracy of nurses’ ability to identify, measure and quantify normal 
faecal stool or diarrhoea volume (Ledbetter, 2006). 
2.4.2 Tools to quantify diarrhoea 
Debate surrounds the methods that are used to visually validate and measure 
diarrhoea characteristics across different patient cohorts (Whelan, Judd, Preedy, et 
al., 2004). Seven faecal stool output measurement tools have been identified in the 
literature and are outlined in Table 2.2. Tools measuring diarrhoea have evolved 
from verbal descriptors only through to pictorial and verbal descriptors of diarrhoea 
(see Table 2.2). Five tools measured diarrhoea using diarrhoea descriptors with text 
only (Benya et al., 1991; Davies et al., 1986; Hart & Dobb, 1988; O’Donnell et al., 
1990; Walike & Walike, 1977). The inclusion of graphical descriptors of diarrhoea 
characteristics in more recent studies has facilitated the visualisation of diarrhoea 
descriptors (Guenter & Sweed, 1998; Lewis & Heaton, 1997; Whelan et al., 2003). 
Pictorial representations of diarrhoea scoring systems are routinely used in health 
care as a convenient method of assessing and combining clinical variables into one 
quantifiable value. Although reliability and validity testing of pictorial diarrhoea 
descriptors have indicated that both the Bristol Stool Form Scale (Lewis & Heaton, 
1997) and the King’s College Stool Chart (Whelan et al., 2003) reliably validate the 
estimation of diarrhoea, the Bristol Stool Form Scale is more widely used both 
within the clinical and community health care settings. In addition, reliability of the 
Bristol Stool Form Scale has been evaluated in a test–retest study to translate and 
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culturally adapt the Bristol Stool Form Scale from the English language to Spanish 
(Pares et al., 2009). Test–retest assessment of the Bristol Stool Form Scale found an 
interrater agreement of 84.4% (Kappa index 0.82, CI 0.67–0.96). Concordance 
between nurses, physicians and patients was the highest with stool type 7 (91.5%), 
stool type 4 (90.9%) and stool type 6 (80.3%). In addition, agreement between 
nurses, physicians and patients was lowest with stool type 1 (67.9%) and stool type 5 
(43.8%). 
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Table 2.2  
Tools to Quantify Diarrhoea 
Tool Author/date Design Participants Outcome 
11-point categorical stool consistency 
evaluation tool based on stool 
descriptions and pictures 
Walike & 
Walike 
(1977) 
Double-blind, randomised 
cross-over trial comparing 
enteral tube formula with 
and without fibre 
20 patients, 4 lost to 
follow-up. Lactose or 
non-lactose ETF 
formula administered 
for 9–20 days 
Increased stool frequency, decreased stool 
consistency, increased flatulence and 
abdominal distension was observed in the 
lactose versus non-lactose ETF diet. 
8-point categorical scale. Stool 
consistency ranged from loose, 
watery, runny to fragmented 
segments. Stool type 1 = diarrhoea 
and stool type 7 = constipation 
Davies et al., 
(1986) 
Prospective, observational 
study 
51 healthy adults 
(omnivores, vegans, 
vegetarians) who 
consumed an oral 
fibre diet 
Participants who consumed a vegan diet had a 
greater frequency of defecation than 
omnivores and vegetarians. This was in part 
associated with the higher mean (47 g versus 
23 g and 37 g respectively) dietary fibre 
content. 
Semiquantitative tool to measure 
diarrhoea severity based on stool 
volume and consistency. Volume of 
++ estimated to correlate to stool 
volume 200–250 mL. 
Hart & Dobb 
(1988) 
Prospective, placebo-
controlled trial to examine 
the effect of a faecal 
bulking agent (fibre) or 
placebo on diarrhoea 
occurrence 
ETF critically ill 
patients 
Faecal output calculated every 24 hours. 
Scores for all bowel activity were summed to 
provide a daily diarrhoea score. Patients were 
reported to have had diarrhoea if daily 
diarrhoea scores were ≥ 12. Validation and 
reliability have not been examined. 
7-point categorical scale to measure 
the stools’ cohesion or surface 
cracking and to understand 
gastrointestinal transit time. Type 1 
stool resembles constipation and stool 
types 6 and 7 resemble diarrhoea 
O’Donnell et 
al. (1990) 
Prospective observational 
study 
30 patients diagnosed 
with irritable bowel 
syndrome 
Diarrhoea characteristics (type, time, the 
feeling of defecation) identified by study 
participants for 6 consecutive bowel motions. 
Inconsistent results observed between whole of 
gut transit time (WGTT), stool frequency, 
consistency and volume. Tool developed to 
become the Bristol Stool Form Scale. 
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Table 2.2 (continued) 
Tool  Author/date Design Participants Outcome 
Validation of the 7-point Bristol 
Stool Form Scale. Stool 
identification based on stool 
descriptions and pictures 
Lewis & 
Heaton (1997) 
Prospective, randomised 
controlled trial 
66 healthy female 
volunteers who 
consumed an 
omnivorous diet 
WGTT correlated with stool frequency (r = 
0.35, p = .005), stool output (r = -0.41, p = 
.001) and stool consistency (r = -0.54, p < 
.001). WGTT was decreased, however, stool 
frequency, consistency and volume increased 
(all were p < .001) following consumption of 
Senna. Inverse relationships observed with 
consumption of Loperamide. 
10-point categorical stool 
consistency evaluation tool based on 
stool descriptions and pictures 
Guenter & 
Sweed (1998) 
Secondary analysis using 
an observational design to 
validate Walike and 
Walikes’ (1977) diarrhoea 
findings 
20 patients, four lost 
to follow-up. Lactose 
or non-lactose ETF 
formula administered 
for 9–20 days 
Stool consistency ratings validated by stools’ 
water content. Significant increase in stool 
liquidity observed in 9 of 11 patients in the 
lactose-containing ETF formula. 
Kings College Stool Chart applying 
the principles of stool consistency, 
weight and frequency and was based 
on stool descriptions and pictures. 
Diarrhoea is classified by daily 
faecal score ≥ 15 
Whelan et al. 
(2003) 
Questionnaire. Reliability 
of the tool clinically 
evaluated on 47 ETF 
patients who were 
recruited from the ICU, 
stroke, surgical and 
orthopaedic wards in 
eight hospitals 
58 health 
professionals: 
gastroenterologists, 
stroke nurses, ICU 
nurses, dietician. 
Measures diarrhoea using four categories 
(stool consistency, frequency, weight, 
combination of descriptors) previously 
validated by Bliss et al. (1999) to gain daily 
score. 10 cm scale added to chart following 
review of questionnaire. Statistical significance 
found for faecal frequency, consistency, 
diarrhoea scores and incidence (p < .05). Near 
perfect agreement found with interrater 
reliability for faecal consistency (95% 
agreement, k = 0.91) and considerable 
agreement found for faecal weight (83%, k = 
0.75). 
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The wide range of faecal output measurement tools enable clinicians to identify and 
measure diarrhoea using the faecal stools’ characteristics, that is, stool consistency, 
frequency and weight (or volume). Inconsistent use of validated faecal stool 
measurement tools will continue to challenge the definition, identification and 
quantification of diarrhoea in the ICU context. Further research is required to 
validate faecal stool measurement tools in the ICU setting. 
A pragmatic but rudimentary definition of diarrhoea incorporates the verbal 
diarrhoea descriptors of stool frequency, consistency and weight only. A robust 
definition of diarrhoea combines both verbal and pictorial diarrhoea descriptors, for 
example, ‘the abnormal passage of loose or liquid stools more than three times daily 
and/or a volume of stool greater than 200 g/day’ (Bishop et al., 2010; Dorman et al., 
2004; Sabol & Carlson, 2007; Thomas et al., 2003, p. 2). This definition incorporates 
diarrhoea descriptors including stool weight, volume, frequency and consistency. 
2.5 The ICU environment 
Defining critical illness is complex. Historically, critical illness was defined as “the 
presence of actual and/or potential life-threatening health problems. The needs of the 
critically ill patient require continuous observation and intervention to restore and 
prevent complications” (Australian Society of Critical Care Nurses [ASCCN], 1986, 
pp. 3). Today, definitions of critical illness incorporate the complexity of the 
patients’ illness, severity of organ dysfunction and risk of imminent death (Adhikari, 
Fowler, Bhagwanjee, & Rubenfeld, 2010). Geographically, critically ill patient 
management can occur in general wards in hospitals; however, the vast majority of 
critically ill patients are managed and cared for in a designated ICU (Adhikari, 
Fowler, Bhagwanjee, & Rubenfeld, 2010). 
In Australia, there are various types of ICUs that cater for adult, paediatric and 
neonatal patients. The highly specialised ICUs of today provide a setting where 
critically ill patients are treated, managed and cared for in the one expert 
environment by specialist nursing, medical and allied health care services (Wiles & 
Daffurn, 2002). The ICU of the twenty-first century provides a venue for monitoring, 
recording and analysis of physiological functioning and, where necessary, the 
support and altering of human body systems. Today, the ICU is defined as: 
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a designated ward of a hospital which is specially staffed and equipped to 
provide observation, care and treatment to patients with actual or potential 
life-threatening illnesses, injuries or complications, from which recovery is 
possible. The ICU provides special expertise and facilities for the support of 
vital functions and utilises the skills of medical, nursing and other staff 
trained and experienced in the management of these problems. (The 
Australian Council on Healthcare Standards [ACHS], 2005) 
Further to the ACHS (2005), ICUs are defined in accordance with the College of 
Intensive Care Medicine of Australia and New Zealand Minimum Standards for 
Intensive Care Units (College of Intensive Care Medicine, 2010) and include Level I, 
II and III ICUs. A Level III ICU is defined as: 
A separate self-contained, tertiary referral unit of a hospital for intensive care 
patients. The Level III ICU provides comprehensive critical care including 
complex multi-system life support for an indefinite period of time. In 
addition, the Level III ICU demonstrates a commitment to academic 
education and research. In addition, there should be on average, 
approximately 300 ventilated patients admitted per annum to a Level III ICU. 
(College of Intensive Care Medicine, 2010, pp. 1–3) 
By comparison, a Level II ICU provides similar cares to those of a Level III ICU; 
however, the Level II ICU experiences fewer patient admissions and admits 
approximately 200 patients annually. Patients admitted to a Level I ICU often have 
only single-system organ failure and require less invasive monitoring and treatment 
such as mechanical ventilation and simple cardiovascular monitoring (College of 
Intensive Care Medicine, 2010). 
The role of the ICU environment in relationship to the central construct of this 
research needs to be considered. Causes of diarrhoea are multifaceted, as previously 
identified, but many relate to the ICU environment. In this environment, complex 
critical illnesses are managed by multiple guidelines and policies. A Level III ICU 
admits patients with higher illness acuity, therefore these critically ill patients have a 
greater propensity to be exposed to multiple health care interventions and have an 
increased risk for complications, such as diarrhoea. The ICU environment is the 
context in which care is provided for the patient with diarrhoea, and is therefore 
represented by the overarching descriptor of the ICU environment that embodies the 
conceptual framework. 
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2.6 The critical illness experience 
The framework incorporates complex health care interventions and complications 
associated with critical illness and, in particular, diarrhoea in critical illness. 
Critically ill patient characteristics such as age, gender, ICU LOS and severity of 
illness vary widely. Biannual report data from the Australian and New Zealand 
Intensive Care Society (ANZICS) indicate that the ICU patients’ median age is 65 
years, the median ICU LOS is 1.8 days, the median Acute Physiology and Chronic 
Health Evaluation II (APACHE II) score is 14 and that the majority of patients were 
male (58%) (ANZICS CORE Report, 2011). The majority (approximately 94%) of 
critically ill patients experience an ICU LOS less than 10 days (Williams et al., 
2010). Within the ICU, complex nursing and medical care is provided across various 
acute life-threatening and potentially life-threatening conditions such as multiple 
trauma; cardiac, respiratory, hepatic and renal failure; burns and a diverse array of 
invasive procedures (Bellomo, 2010; Bersten, 2010; Buonocore & Sather, 2009; 
Grealy & Chaboyer, 2012; Johnson & Wilson, 2012; Marshall, 2010; Moreno, 
Singer, & Rhodes, 2010; Peterson, 2010). Table 2.3 shows common patient 
admission diagnoses for adult patients admitted to a Level III ICU in Australia. 
Table 2.3  
Common ICU Admission Patient Diagnoses in Australia 
Body system Reason for ICU admission 
Cardiovascular Cardiac arrest, cardia dysrhythmias, hyper/hypotension 
Respiratory Acute respiratory failure, pneumonia, haemo/pneumothorax 
Gastrointestinal Bowel obstruction, infarction 
Renal Acute renal failure 
Hepatobiliary Solid organ tumours 
Neurological Acute brain injury, cerebrovascular accident, neurovascular tumours 
Immunologic Sepsis 
Other Trauma, burns, shock, solid organ tumours, planned surgery, pre-
existing co-morbidities, e.g. diabetes mellitus, chronic renal failure, 
chronic obstructive pulmonary disease, ischaemic heart disease, 
peripheral vascular disease 
Source: Buonocore & Sather, 2009; Johnson & Wilson, 2012; Marshall, 2010; Moreno, 
Singer, & Rhodes, 2010. 
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Many aspects of the critical illness experience predispose a person to diarrhoea, 
including the reason/s for admission to the ICU, the patient’s pre-existing co-
morbidities, dietary changes (Mitchell, Wilson, & Wade, 2012), the LOS in the ICU 
and the patient’s physiologic and pathophysiological responses to critical illness 
(Marshall, 2010; Rivers et al., 2001). Of note in the critically ill patient, are the often 
unpredictable fluctuations between an improvement and deterioration in health 
leading to an increased ICU LOS. 
Moreover, a significant component of nursing care of the ICU patient is focused on 
interventions associated with ventilation and perfusion and body systems support, 
such as for the respiratory, cardiovascular and renal systems and the GIT. Patients 
requiring admission to a Level III ICU are often exposed to routine treatments that 
can include: intubation, mechanical ventilation and oxygenation; invasive 
cardiovascular support (inotropes and vasopressor therapy); renal replacement 
therapy; intravenous fluid resuscitation (crystalloids, colloids, blood products); and 
nutritional therapy (enteral nutrition, parenteral nutrition) (Bourgoin et al., 2005; 
Marshall, 2010). In addition, patients admitted to a Level III ICU frequently receive 
antibiotic therapy (treatment and prophylactic use), sedation and paralysis (opioids 
and neuromuscular blocker medications), promotion of intestinal motility (aperient 
and prokinetic medications), regulation of gastric acidity (PPI, H2 receptor 
antagonists), glycaemic control (insulin therapy), electrolyte replacement (potassium 
chloride, magnesium), and venous thrombus embolus prophylaxis (subcutaneous 
anticoagulant therapy) (Bourgoin et al., 2005; Marshall, 2010). Other common 
management strategies used to care for the critically ill patient include invasive 
monitoring, peripheral and/or central vein access, arterial catheterisation, urinary 
catheterisation and the insertion of nasogastric and orogastric tubes (Grealy & 
Chaboyer, 2012). Some critically ill patients require more advanced cares including 
the insertion of advanced haemodynamic catheters, intraparenchymal catheters, 
cerebral intraventricular drains, intercostal chest tubes and faecal containment 
devices (Brooks, 2009; Grealy & Chaboyer, 2012; Murgo & Leslie, 2012; Sturgess 
& Morgan, 2010). A consequence of these interventions can be the increased risk of 
developing diarrhoea which will be embedded in Sections 2.6.1 to 2.6.7. 
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2.6.1 Complications associated with critical illness 
The nature of critical illness means that improvements in health are not linear and 
complications often ensue. The magnitude of complications is contingent largely on 
the type and severity of injury/illness, physiological stressors, the severity of organ 
dysfunction, pre-ICU admission co-morbidities, haemodynamic/respiratory/renal and 
nutritional status and ICU LOS (Btaiche et al., 2010). Common acute complications 
observed during an episode of critical illness are presented in Table 2.4. Many of 
these complications often present as emergent and life-threatening, for example, 
hypoxaemia and hypotension if left untreated can result in significant life-threatening 
deterioration. Other complications, such as diarrhoea, can occur more insidiously 
(Table 2.4). 
Table 2.4  
Common Complications Associated with Critical Illness 
Complication Examples of complications 
Electrolyte derangement Hyper/hypo: kalaemia, magnesaemia, phosphataemia, calcaemia 
Infection Ventilator-associated pneumonia 
Sepsis, wound infection, invasive catheter infections 
Respiratory system Hypoxia, hypoxaemia 
Ventilation/perfusion mismatch 
Acute pulmonary oedema 
Acute lung injury, acute respiratory distress syndrome 
Cardiovascular system Hyper/hypotension 
Myocardial infarction, ischaemia, cardiac dysrhythmias 
Gastrointestinal system Diarrhoea, constipation 
Ischaemia-reperfusion injury 
Infarcted bowel, small/large bowel obstruction, ileus 
Enteral tube feed intolerance, delayed gastric emptying 
Hyperglycaemia 
Renal system Acute renal failure, reperfusion injury 
Neurologic system Hypoxic brain injury, cerebrovascular accident 
Psychological Altered circadian rhythms, depression, anxiety, psychoses 
Other Systemic inflammatory response syndrome 
Disseminated intravascular coagulopathy 
Bloodstream catheter-related infections 
Source: Bellomo, 2010; Bersten, 2010; Flynn Makic, & Carlson, 2009; Grealy & Chaboyer, 
2012; Marshall, 2010; Peterson, 2010.  
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The treatment of ICU-related complications is dependent on the cause and symptoms 
of the complication. For example, the treatment of shock and hypotension requires 
the administration of intravenous fluids, blood products, inotropes and vasopressors 
and the supply of adequate concentrations of oxygen (McLuckie, 2010). Diarrhoea is 
a common gastrointestinal complication associated with critical illness and its 
associated complications and treatments. For example, diarrhoea can ensue following 
episodes of hypotension, hypoxaemia, ischaemia–reperfusion injury, intestinal 
inflammation, hypoalbuminaemia, antibiotic administration, the administration of 
other medications (aperients, prokinetics, sedation, neuromuscular blockers), 
enteropathogenic infection and changes to the intestinal microflora (MacLaren, 
Kiser, Fish, & Wischmeyer, 2008; Whelan & Schneider, 2011). 
2.6.2 Critical illness and the gastrointestinal tract 
The gut is often not the primary cause of critical illness, but is an important body 
system to consider with regard to the nursing and medical care of the critically ill 
patient. The human GIT is comprised of many sections, each performing specific 
functions including food digestion, nutrient and water absorption, metabolism and 
immunological protection and the storage of waste products (Marieb, 2010; 
Marshall, 2009; Marshall, Williams, & Gordon, 2012). Normal physiological 
function of the GIT is shown in Table 2.5. 
Lining the GIT are 400–500 species of intestinal microflora bacteria (Furrie, 2006; 
Othman et al., 2008; Prakash, Tomaro-Duchesneau, Saha, & Cantor, 2011) covering 
approximately 2000 cm
2
 of colonic surface area (Payne et al., 2006; Wilson, 2008). 
Two main species of intestinal microflora dominate the GIT. The intestinal gaseous 
environment is an important aspect associated with intestinal bacterial growth and 
intestinal homeostasis. Obligatge aerobic bacteria grow in the presence of oxygen 
whereas obligate anaerobic bacteria grow in the absence of oxygen (Forbes, Sahm, & 
Weissfeld, 2007; Tortora, Funke, & Case, 2010; Winn et al., 2006). Obligate 
anaerobes do not possess the required enzymes to rid themselves of the toxic oxygen 
derivatives. In comparison, facultative anaerobic bacteria may grow in the presence 
or absence of an oxygen rich environment (Forbes, Sahm, & Weissfeld, 2007; 
Tortora, Funke, & Case, 2010; Winn et al., 2006).The dominant genera are anaerobic 
bacteria (Bacteroides, Bifobacterium, Eubacteria, Clostridium, Peptococcus, 
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Peptostreptococcus and Ruminococcus) and the subdominant genera are aerobic 
bacteria (Escherichia, Enterobacter, Enterococcus, Klebsiella, Lactobacillus and 
Proteus) (Guarner & Malagelada, 2003). The composition, concentration and 
quantity of each species within these two genera of intestinal microflora vary 
between individuals in states of health and ill health, for example, in those with 
diarrhoea, those receiving antibiotics, those with a variable dietary intake and the 
actual location of the bacterial species within the gut (Guarner & Malagelada, 2003). 
Table 2.5  
Gastrointestinal Physiological Function 
Body organ Physiological function 
Stomach Gastric acid and pepsin production 
Small intestine Mechanical and chemical digestion of carbohydrates, amino acids, lipids, 
nucleic acids 
Diffusion, facilitated diffusion, osmosis, active transport processes 
90% of nutrient absorption occurs in small intestine 
Large intestine Storage of waste products 
10% nutrient absorption occurs in large intestine 
Immunity and 
protection 
Epithelial shedding restricts bacterial adhesion 
Gut-associated lymphoid tissue facilitates normal GIT microflora and 
protects against food allergy 
Hydrochloric acid increases gastric acidity and destroys pathogenic 
bacteria 
Kupffer cells produced by the liver destroy foreign pathogenic substances 
GIT motility propels bacteria through the intestine 
Mucin production reduces bacterial adhesion to intestinal wall 
Zona occludens reduces bacterial translocation through intestinal wall 
Source: Iapichin et al., 2008; Marieb, 2010; Marshall, 2009; Marshall et al., 2012. 
The intestinal microflora composition of the GIT varies widely depending on the 
organisms’ location in the gut. (Forbes et al., 2007; Tannock, 2005). Many bacteria 
are incapable of colonisation in the stomach due to its high acidity and rapid passage 
of digesta. The intestinal microflora of the distal ileum begins to resemble those of 
the large colon (Enterobacteriaceae, Bacteroides species [spp]) (Engelkirk & 
Burton, 2007; Forbes et al., 2007; Guarner, 2008; McFarlane & Dillon, 2007). The 
intestinal microflora of the large colon consists predominantly of anaerobic bacteria 
25 
(Bacteroides, Clostridium, Peptostreptococcus, Bifidobacterium, Eubacterium) and 
some aerobic bacteria (Escherichia coli [E.coli], other Enterobacteriaceae, 
Enterococci, Streptococci) (Guarner & Malagelada, 2003). In the large intestine, 
anaerobic bacterial colonisation outnumbers aerobic bacterial colonisation by 1000:1 
owing to the oxygen-depleted environment (Engelkirk & Burton, 2007; Forbes et al., 
2007; Guarner, 2008). Approximately 60–80% of stool weight is composed of 
bacteria with the human faecal stool consisting of 10
x11
 to 10
x12
 colony forming 
units/gram (CFU/gram) of stool (Engelkirk & Burton, 2007; Forbes et al., 2007; 
Guarner, 2008). 
In critical illness, gastrointestinal dysfunction is often associated with haemodynamic 
instability (Martin, 2007; Quigley, 2005; Thorson et al., 2008), hypoperfusion and 
impaired oxygenation (Marshall, 2009; Marshall et al., 2012; Putensen, Wrigge, & 
Hering, 2006). Factors contributing to the hypoperfused gut include mechanical 
ventilation (Marshall, 2009; Mutlu et al., 2003; Putensen, Wrigge, & Hering, 2006), 
shock (Powell-Tuck, 2007), recent surgery, circulating catecholamines and cytokines 
(Chapman et al., 2007), admission diagnoses such as multiple trauma and pre-
existing co-morbidities including irritable bowel syndrome (Chapman et al., 2007). 
Intestinal ischaemia resulting from splanchnic hypoperfusion may result in intestinal 
failure. Two key factors contribute to this problem: ineffective digestion and 
ineffective absorption (Kutayli et al., 2005; Marshall, 2009). In certain 
pathophysiological states evident in critical illness, the intestinal homeostatic 
ion/fluid balance is impaired because of compensatory absorptive and/or 
antisecretory mechanisms (McFarlane & Dillon, 2007; Payne et al., 2006). This can 
result in hypo- and hypermotility. Gastrointestinal hypermotility manifests as 
diarrhoea that may or may not impair the intestine’s normal microflora (Gill & 
Guarner, 2004; Weisen et al., 2006). 
Gastrointestinal hypoperfusion and stress-related intestinal mucosal injury can lead 
to a disruption to the intestinal barrier to pathogens, disrupt the chemical control of 
bacterial overgrowth, decrease peristalsis and impair immunological activities 
(Marshall et al., 2012). Consequently, inflammation, ischaemia–reperfusion injury, 
capillary leakage syndrome and hypoalbuminaemia leading to exacerbation of or 
induce intestinal oedema ensues. Intensive care unit-associated interventions 
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contributing to intestinal mucosal vulnerability include the administration of 
vasopressors, medications such as H2 receptor antagonists and the absence of 
intraluminal nutrient delivery (McClave & Heyland, 2009). Enteral nutrition is one 
strategy used to support splanchnic perfusion and prevent mucosal breakdown during 
critical illness (Hammarqvist, 2004) through maintaining intestinal luminal nutrients, 
perfusion; thereby minimising intestinal villi atrophy and bacterial translocation 
(Marshall, Williams, & Gordon, 2012). Clinical practice currently focuses on the 
early prevention and detection of intestinal ischaemia (Cresci & Cue, 2008; Marshall, 
2009). 
The adverse effects of intestinal hypoperfusion in critical illness result in gut 
dysfunction. A number of complications arise from this GIT dysfunction, including 
diarrhoea. Complications associated with gastrointestinal dysfunction were examined 
in 400 ETF critically ill patients and, although causality cannot be assumed, 
gastrointestinal disequilibrium was experienced in nearly 15% of patients (Montejo, 
1999). Other gastrointestinal complications included high gastric residual volumes 
(39%), constipation (15.7%), abdominal distension (13.2%), vomiting (12.2%) and 
gastroesophageal regurgitation (5.5%) (Montejo, 1999). The aetiology of GIT 
dysfunction and its relationship with diarrhoea in critically ill patients remains 
variably reported, although many factors are suggested to contribute to the problem 
as outlined in the conceptual framework for this study. 
2.6.3 ICU treatments: ETF commencement, duration, delivery and formula 
Enteral tube feeding is an established mechanism of nutritional therapy in critically 
ill patients. Nutritional support of the gut via ETF is naturally linked to faecal output. 
One strategy to maintain intestinal homeostasis in the critical care setting is through 
the provision of enteral nutrition. Provision of enteral nutrition therapy and 
nutritional requirements is often hindered by gastrointestinal dysfunction in critically 
ill patients. Enteral feeding involves the provision of nutritional supplementation 
using the gut (Guenter, 2010). It is a common method of nutritional therapy in 
critically ill patients who have an intact GIT and who are unlikely to consume a full 
oral diet within 48–72 hours of ICU admission (Btaiche et al., 2010; Kreymann et al., 
2006; Whelan et al., 2009). The route, method and duration of nutritional delivery in 
critical illness are frequently guided by the patient’s presenting diagnosis and 
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physiological responses to treatment (Doig & Simpson, 2006; Jeejeebhoy, 2005; 
Skipper, 2012). 
A number of enteral nutrition clinical practice guidelines exist to guide clinicians in 
consistently implementing evidence-based practice (Btaiche et al., 2010). All 
international enteral nutrition clinical practice guidelines were developed by 
consensus panels of experts who reviewed various levels of evidence (Majid et al., 
2011). Through these guidelines, Canada (Heyland et al., 2003), England (National 
Health Service, National Institute for Health and Clinical Excellence [NICE], 2006), 
Europe (The European Society for Clinical Nutrition and Metabolism [ESPEN], 
Kreymann et al., 2006), the United States of America (American Society for 
Parenteral and Enteral Nutrition [A.S.P.E.N.]) (McClave et al., 2009) and Australia 
(Martin et al., 2004) have endorsed standardised clinical approaches to enteral 
feeding of critically ill patients. These guidelines include recommendations relating 
to time to commencement of ETF, monitoring ETF tolerance, dosing of enteral 
nutrition and selection of the appropriate enteral feed formula (Heyland et al., 2003; 
Kreymann et al., 2006; McClave et al., 2009). Furthermore, one internationally 
endorsed guideline makes recommendations regarding the prescribing, preparation 
and maintenance of ETF (Bankhead et al., 2009). These key areas will now be 
discussed. 
2.6.3.1 Time to ETF commencement 
The early commencement of enteral nutrition within 24–48 hours of ICU admission 
has become the gold standard timing to initiate nutritional therapy in the 
haemodynamically stable patient (Artinian, Kreyman, & DiGiovine, 2006; Bernard 
et al., 2004; de Aguilar-Nascimento, Bicudo-Salomao & Portari-Filho, 2012; Hegazi 
& Wischmeyer, 2011; Heyland et al., 2003; Kreymann et al., 2006; McClave et al., 
2009; Peters, Moran, & Phillips-Hughes, 2005). Guidelines recommend that enteral 
nutrition should be commenced within 24–48 hours of admission to the ICU if the 
GIT is functional and if the patient is likely to be ETF for more than two days 
(Heyland et al., 2003; Jacobs et al., 2004; Kreymann et al., 2006; 2009; Martin et al., 
2004; Martindale et al., 2009; McClave et al., NICE, 2006). 
Intensive care units implement enteral nutrition clinical practice guidelines with 
variability (Doig et al., 2008; Judges, Beverly, Rio, & Goff, 2012). Approximately 
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40–60% of eligible patients will remain unfed for at least 48 hours following 
admission to the ICU (Doig et al., 2008; Doig et al., 2009; Jain et al., 2006). In a 
cross-sectional survey of nutrition support practices, only 58% of nutritional 
requirements were met in those critically ill patients who received nutritional 
therapy; however, the impact of delayed feeding and diarrhoea were not examined 
(Doig et al., 2008). 
A delay in commencing enteral feeding can result in underfeeding and malnutrition 
(Cahill, Murch, Cook, & Heyland, 2012). Hypermetabolism is reported to peak at 
three to five days and subside at approximately seven to 10 days following the 
hypermetabolic stress response often observed in critically ill patients. Early enteral 
feeding is suggested to ameliorate intestinal hypoperfusion and latent secondary 
complications, such as diarrhoea, during and following the hypermetabolic stress 
response (Artinian et al., 2006; Penniman, 2010; Singer et al., 2009; Skipper, 2012). 
Multiple barriers exist with regard to the timely implementation of enteral nutrition 
in the critical care setting. Brantely (2009) proposes that some of these barriers 
include the clarity of the guideline itself, institutional policies, the clinician’s 
determination to change practice and the patients’ clinical status. Other barriers 
include the numerous and complex enteral nutrition clinical practice guidelines, 
resource constraints, staff experience, workloads and administrative issues (Brantley, 
2009; Heyland et al., 2003a). In a multicentre cross-sectional survey, 138 nurses 
were surveyed to identify barriers to feeding critically ill patients. Barriers identified 
included that nutrition is less valued than other elements of patient care in the 
haemodynamically stable patient (50%, range 47–65%), insufficient equipment 
(50%, range 27–70%), enteral formula not available on the ward (48%, range 27–
70%), ICU medical staff were not approached and requested to withhold enteral 
nutrition (38%, range 27–58%) and delays in initiating motility agents in those 
patients who are not tolerating enteral nutrition (38%, range 29–65%) (Cahill, 
Murch, Cook, & Heyland, 2012). 
A meta-analysis of 15 randomised controlled trials (RCTs) examined the efficacy of 
early (<36 hours) versus late (>36 hours) ETF on minimising infectious and 
noninfectious complications, LOS and mortality in critically ill patients (Marik & 
Zaloga, 2001). A lower risk of infection (RR 0.45; 95% CI 0.3–0.66; p = .0006) and 
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a reduced length of hospital stay (mean 2.2 days; 95% CI 0.81–3.653 days; p = .004) 
were identified when patients had enteral nutrition commenced early in their critical 
illness experience. However, there were no statistically significant differences in the 
effectiveness of early ETF and noninfectious complications and mortality. Diarrhoea 
was not measured as an outcome of noninfectious complications. 
Doig et al. (2008) further examined whether evidence-based feeding guidelines 
improved feeding practices and reduced mortality using a cluster RCT across 27 
ICUs and 1118 critically ill patients. The results showed that those patients who were 
ETF earlier achieved caloric goals more often than the control patients (mean days to 
ETF commencement 0.75 versus 1.37 respectively, p < .001). No statistically 
significant differences were found between the two groups regarding mortality (p = 
.75) and ICU LOS (p = .97). This study suggests that the development of nutritional 
therapy guidelines recommend the early initiation of ETF. 
Similar findings were confirmed in another meta-analysis that compared standard 
enteral feeding formula with clinically meaningful, patient-oriented outcomes in 
critically ill patients (Doig et al., 2009). Standard enteral formula was identified as 
any ETF formula that was not supplemented with immune-enhancing ingredients 
such as glutamine and arginine. Six RCTs with 234 participants were analysed for 
primary treatment effects including mortality, quality of life and physical function. 
Secondary treatment effects were also examined and included 
vomiting/regurgitation, pneumonia, bacteraemia, sepsis and multiple organ failure. 
The early commencement of ETF was associated with a significant reduction in 
mortality (odds ratio [OR] = 0.34, 95% confidence intervals [CI] 0.14–0.85) and 
pneumonia (OR = 0.31, 95% CI 0.12–0.78). No statistically significant findings were 
observed with regard to secondary treatment effects. Although the Doig et al. (2009) 
study found that the early commencement of ETF was associated with an overall 
reduction in mortality, the relationships between diarrhoea and mortality, quality of 
life and physical function were not examined. 
The findings identified in the Marik and Zaloga (2001) and the Doig et al. (2008; 
2009) studies confirm the premise that the early commencement of enteral nutritional 
therapy (within 24–48 hours) attenuates the hypermetabolic response and reduces 
septic and nonseptic complications in critically ill patients. Furthermore, these 
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studies support internationally endorsed ETF clinical practice guidelines to 
implement nutritional therapy within 24–48 hours of ICU admission. These studies 
do not, however, examine issues associated with the relationship between diarrhoea, 
ETF and aerobic intestinal microflora (see Figure 2.1, page 10). 
2.6.3.2 Duration of ETF 
The relationship between diarrhoea and the duration of ETF in critically ill patients 
has been examined in diverse ways. Halmos, Muir, Barrett, Deng, Shephard and 
Gibson (2010) conducted a medical chart audit of 160 patient medical records (ICU, 
stroke ward, other wards) to identify factors associated with diarrhoea in patients 
who received ETF. The results showed that the majority of patients experienced 
diarrhoea (61%) and that the LOS (p = .026) and the duration of ETF (p = .021) were 
significantly associated with the patient developing diarrhoea. In these results, longer 
LOS and duration of ETF were associated with participants developing diarrhoea and 
this would be plausible as patients who are admitted to the ward or the ICU and who 
are ETF for a longer period of time are more likely to be observed for a longer period 
of time and therefore more likely to develop diarrhoea. Limitations such as exposure 
misclassification (diarrhoea) and missing data have been associated with 
retrospective chart audit methodology and these factors impede accuracy of data 
analysis and generalisation of findings (Oleckno, 2008). Further analyses controlling 
for the duration of ETF and/or the LOS and/or the period of data observation is 
required to in assessing interventions aimed at managing diarrhoea. 
Current ETF clinical practice guidelines do not address the duration of ETF and the 
relationship(s) with ETF-associated complications, such as diarrhoea (Heyland et al., 
2003b; Jacobs et al., 2004; Kreymann et al., 2006; Martin et al., 2004; Martindale et 
al., 2009; McClave et al., 2009; NICE, 2006). Further research is required to validate 
the Halmos et al. (2010) findings and this is represented in the conceptual framework 
as the dotted line between the patient with diarrhoea and ICU treatments (ETF 
duration) (see Figure 2.1, page 10). 
2.6.3.3 Methods of ETF delivery 
The standard methods for enterally feeding critically ill patients is via the continuous, 
intermittent and bolus methods (Heyland et al., 2003b; Jacobs et al., 2004; Kreymann 
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et al., 2006; Martin et al., 2004; Martindale et al., 2009; McClave et al., 2009; NICE, 
2006) with the continuous infusion of enteral nutrition being the most common 
method (Skipper, 2012). There is however, some variability in the current 
recommendations regarding the most appropriate method (continuous, intermittent or 
bolus) of ETF administration (Heyland et al., 2003b; Jacobs et al., 2004; Kreymann 
et al., 2006; Martin et al., 2004; Martindale et al., 2009; McClave et al., 2009; NICE, 
2006). Each method of nutritional therapy is accompanied by specific benefits and 
risks (see Table 2.6). Contemporary evidence suggests that administering enteral 
nutrition via the gastric route is the most appropriate and safe method of ETF unless 
there are contraindications. The ETF clinical practice guidelines do not provide 
evidence regarding the relationship between the site of ETF (gastric versus small 
bowel), the method of ETF (continuous, intermittent or bolus) and diarrhoea 
(Heyland et al., 2003b Jacobs et al., 2004; Kreymann et al., 2006; Martin et al., 2004; 
Martindale et al., 2009; McClave et al., 2009; NICE, 2006). 
Table 2.6  
Benefits and Risks Associated with Enteral Nutrition Delivery 
Method of 
supplementation 
Indications Benefits Risks  
Continuous Critical illness 
Small bowel feeding 
Intolerance to bolus 
or intermittent feeds 
Pump assisted 
Reduces risk of 
metabolic abnormalities 
Minimises risk of high 
GRV and aspiration 
Routinely infused 
over 24 hours/day 
Restricts ambulation 
Higher equipment 
costs 
Intermittent Non-critically ill 
patients, community 
and home care, 
rehabilitation 
Less expensive than 
continuous due to 
equipment costs 
Feed over shorter period 
of time (15–30 minutes) 
Flexibility of feeding 
regimen 
Increased risk of GIT 
intolerance due to 
higher GRV, nausea, 
vomiting, aspiration, 
diarrhoea, abdominal 
distension 
May require caloric 
or protein-based 
formula 
Bolus Non-critically ill 
patients, community 
and home care 
Larger volumes over 
shorter periods of time, 
that is, 240–400mL 
over15–30 minutes and 
every 4–6 hours 
Less expensive, less 
equipment costs, easy to 
administrater 
Risk of GIT 
intolerance due to 
higher GRV 
Increased risk of 
aspiration, nausea, 
vomiting, diarrhoea, 
abdominal distension 
Source: Bankhead et al., 2009; Hark, Ashton, & Deen, 2012; Skipper, 2012 
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Continuous ETF administered by a peristaltic mechanical infusion device has been 
suggested to reduce the risk of aspiration (Williams & Leslie, 2004). Continuously 
infused ETF instils smaller volumes of formula into the stomach. This has been 
theorised to reduce the risk of gastric intolerance, gastric residual volumes (GRV) 
and potential for aspiration. In comparison, intermittent and bolus ETF are suggested 
to minimise gastric colonisation by enabling gastric pH to return to prefeed or 
‘normal’ levels (Williams & Leslie, 2004). The continuous feeding method is 
recommended as it facilitates nutrient delivery, averts malnutrition and minimises 
GIT complications in critically ill patients (ESICM Systematic Review Group, 2011; 
Williams & Leslie, 2004). 
While dated, a number of studies have compared continuous with intermittent ETF 
(Ciocon, Galindo-Ciocon, Tiessen, & Galinda, 1992; Hiebert et al., 1981; Kocan & 
Hickisch, 1986; MacLeod et al., 2007). MacLeod et al. (2007) examined intermittent 
versus continuous gastric feeding in 164 critically ill and mechanically ventilated 
trauma patients. Study endpoints were attainment of nutritional goals within seven 
days, time to initiation of ETF, the occurrence of diarrhoea, ventilator-associated 
pneumonia within 14 days and the severity of illness. The time to ETF 
commencement was measured as the number of days following ICU admission to the 
commencement of ETF. The occurrence of diarrhoea was measured as the patient 
experienced (n = 5, 6.5%) or did not experience an event of diarrhoea. In total, 139 
patients reached nutritional goals within seven days. Intermittently fed patients were 
more likely to reach their nutritional goals by day seven and demonstrated a higher 
probability of maintaining nutritional goals (χ2 = 6.01, p = .01) compared to the 
continuously fed group. Statistically significant associations between ETF methods 
of delivery and the occurrence and duration of diarrhoea were not reported. 
In another dated study (Serpa, Kimura, Faintuch, & Ceconello, 2003), continuous 
and bolus ETF in critical illness were compared to examine benefits and associated 
complications (frequency of abdominal distension, pulmonary aspiration) in ETF 
critically ill patients (Serpa et al., 2003). In total, 28 consecutive ICU patients were 
randomised to bolus or continuous ETF over 24 hours. Complications experienced 
by both groups include diarrhoea (14.3%), high GRV (46%), abdominal distension 
(28.6%), pulmonary aspiration (3.6%) and gastric tube displacement (25%). 
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Nutritional goals were not met across both groups in 93% (n = 26) of participants. 
Diarrhoea was experienced, but the difference between groups was not statistically 
significant in four patients who received bolus feeds on days two and three and in 
only one patient who was continuously fed and on day one only. The different 
findings to that of the MacLeod et al. (2007) and Serpa et al. (2003) studies suggests 
that further observational studies and RCTs are required to examine the relationship 
between the method of feed delivery and diarrhoea in critically ill patients. 
2.6.3.4 ETF formula 
No one specific nutritional formula will suit the physiological and metabolic needs of 
all critically ill patients (Hegazi & Wischmeyer, 2011). There is in excess of 100 
enteral formulae commercially available, including standard formula (Jevity, Jevity 
Plus), elemental and specialised formulae (renal, for example, Nepro) (Dieticians 
Association of Australia, 2011; Dudrick & Palesty, 2011). There is no consensus 
regarding the most suitable formula to administer, the appropriate rate and the 
appropriate method of formula delivery (Brantley, 2009). 
Enteral feed formula is composed of proportions of protein (1.5g/kg/day), 
carbohydrate (30–70%) and fat (10–30%) that is suggested to resemble a typical 
western diet (Dudrick & Palesty, 2011; Elamin & Camporesi, 2009; Skipper, 2012). 
The effect of variable ratios of enteral feed proponents and gastrointestinal function 
in critical illness remains relatively unexamined. Furthermore, there are no data on 
the effect of increasing the proportion of daily fat intake in the form of enteral feeds 
and lipid-based sedation such as Propofol on gastrointestinal function in critical 
illness (Elamin & Camporesi, 2009; Nguyen, Chapman, Fraser, Bryant, Burgstad et 
al., 2007). Propofol has been associated with less delayed gastric emptying compared 
with morphine and midazolam sedation in critically ill patients (Nguyen, Chapman, 
Fraser, Bryant, Burgstad et al., 2007); however, it remains uncertain as to whether 
the lipid-soluable content of propofol or the sedative effects of propofol on the gut 
contribut in any manner to diarrhoea. Fibre is often added to enteral feed formulae to 
combat the common side effect of ETF-associated diarrhoea (Klosterbuer, Roughead, 
& Slavin, 2011). 
Specialised formulae are available to patients who are ETF in the ICU. Within these 
formulae, it is largely the osmolality of the feed that has the impact on the gut, 
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namely diarrhoea. Enteral feed formulae are classified according to their osmolality, 
that is, the number of water particles per kilogram of water (Skipper, 2012). Human 
serum is approximately 300 milliosmoles/kg (mOsm/kg) of water, therefore a 
formula with an osmolality of 300–500 mOsm/kg has similar concentrations of 
solutes in the blood (Skipper, 2012). Formulae are classified as hypo- (<300 mOsm), 
iso- (300–500 mOsm) or hyperosmolar (>500 mOsm) (Dieticians Association of 
Australia, 2011; Skipper, 2012). In theory, isotonic solutions infused into the 
stomach optimise feed absorption (Dieticians Association of Australia, 2011). In 
comparison, hypoosmolar solutions delay gastric emptying while hyperosmolar 
formulae increase gastric emptying (Dieticians Association of Australia, 2011; 
Skipper, 2012). Distal colonic function is suppressed during the administration of 
hyperosmolar formula, which results in reduced water absorption and the rapid 
transit of colonic contents. This leads to the development of diarrhoea. Seminal 
intestinal perfusion studies demonstrate abnormal colonic responses to ETF as 
depicted by the ascending colon’s rapid secretion of fluid and the development of 
diarrhoea (Bowling, Raimundo, Grimble, & Silk, 1993; Whelan et al., 2001). These 
perfusion studies suggest that the administration of short-chain fatty acid, acetate, 
propionate and butyrate into the caecum reverses the abnormal secretion of intestinal 
fluid leading to diarrhoea (Bowling et al., 1993; Whelan et al., 2001). 
Special considerations when choosing the appropriate formulae for ICU patients 
includes the osmolality, nutritional completeness, fluid content of the feed 
(approximately 70–80%), the need for specialty formulae and the method of ETF 
(Dieticians Association of Australia, 2011). Calorie-dense formulae are most 
practically used for those patients who require bolus or overnight feeding (Malone, 
2005). Variable agreement exists within international guidelines regarding the 
appropriate formula with which to initiate ETF. Three of the five guidelines 
recommend commencing ETF with a protein-based formula that is free of immune-
enhancing elements (Heyland et al., 2003b; Kreymann et al., 2003; Martindale et al., 
2009; McClave et al., 2009). Bankhead et al. (2009) recommend starting ETF with a 
formula that is specific to the patient’s needs, while Martin et al. (2004) make no 
recommendations with regard to the initial ETF formula. No ETF guidelines make 
reference to the relationships between the type ETF formula (osmolality, fibre 
content, volume) and diarrhoea. 
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2.6.4 ICU treatments: ETF care and maintenance, a pathway to microbial 
contamination and bowel care 
Enteral formulae provide an ideal environment for opportunistic microorganism 
growth, potentially resulting in intestinal microflora disequilibrium. Specific care and 
maintenance strategies informed by the literature and local health care facility 
policies are directed at the routine management of the ETF patient. These ETF care 
and maintenance strategies and bowel care strategies are now examined regarding the 
relationships between diarrhoea and ETF formula, associated equipment and the 
feeding tube. 
2.6.4.1 ETF care and maintenance 
Enteral feeding is infrequently regarded as a source of infection in the specialised 
critical care setting. Pathogenic colonisation of enteral formula, ETF administration 
sets and associated equipment may potentially modulate the intestinal microflora 
leading to disequilibrium of intestinal bacteria homeostasis and diarrhoea. Enteral 
nutrition formula, administration sets and associated equipment present opportunistic 
portals of entry for contamination through poor equipment hygiene and variable daily 
management practices (Barrett, Shephard, & Gibson, 2009; Best, 2008; Mathus-
Vliegen, Bredius, & Binnekade, 2006). Strategies are proposed to improve the 
nursing management of ETF formula and associated equipment to thereby minimise 
bacterial contamination that may result in intestinal microflora imbalance and 
diarrhoea in critically ill patients (see Table 2.7). 
Improvements in the microbiological safety of ETF systems have occurred over the 
past two decades (Mathus-Vliegen et al., 2006). These improvements include ready-
to-use liquid formulae, closed feeding systems with drip chambers in the delivery 
sets, collapsible plastic feeding bottles/bags, use of positive pressure mechanical 
infusion devices to administer feeds (Lau & Girard, 2011; Mathus-Vliegen et al., 
2006; Williams & Leslie, 2005), improvements in the nutritional value of the 
formula (Skipper, 2012) and improvements with mechanical infusion pumps 
(Tepaske et al., 2006). Despite such improvements retrograde feeding set 
contamination from health care professionals’ contaminated hands often remains 
overlooked as a cause of infection and diarrhoea in the ICU (Lloyd & Powell-Tuck. 
2004). This occurs via contamination of the ETF set distal to the formula source 
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resulting in ETF formula contamination; for example, contamination of the Y-port 
during medication administration, feed set misconnection and routine daily use (Best, 
2008; Lau & Girard, 2011). Infection and diarrhoea may ensue as enteral formulae 
provide an ideal environment for bacterial growth (Barrett et al., 2009; Lau & Girard, 
2011).   
Table 2.7  
Strategies to Minimise Contamination of Enteral Feeding Tubes 
Procedure Purpose 
Aseptic technique Appropriate hand hygiene prior to/upon completion of preparing 
administration sets and changing of feed containers. 
Use of non-sterile gloves to prepare administration sets is 
controversial with mixed results. 
Equipment hygiene Day-to-day cleaning of ETF-associated equipment including feed 
pumps and prior to storage. 
ETF administration 
sets and establishing 
feeding 
Label administration sets with patient’s name, date, time the 
formula was opened. 
Dispose of administration sets between intermittent feeding. 
Use single use administration sets/syringes to minimise human 
contact and contamination. 
Flush feeding tubes regularly with tap water to prevent blockage 
and clear feeding tube luminal adherence of aspirated gastric 
contents. 
ETF formula 
management 
Store formula as per manufacturer’s recommendations to avoid 
fluctuations in temperature beyond 5–25°C. 
Use smaller containers for bolus feeds to restrict the length of time 
container is exposed to environmental contamination. 
Refrigerate opened and unused formula for ≤24 hours. 
Avoid decanting/reconstituting ETF. 
Use only sterile containers, syringes, feed sets. 
Replace ETF container every 24 hours. 
Avoid mixing additives into formula to reduce feed contamination 
and coagulation. 
Administer medications via a designated injection port and avoid 
mixing directly with ETF formula. 
Daily ETF 
management 
Implement asepsis to prepare equipment and access feed sets. 
Change feed containers/administration sets every 24 hours. 
Use only single use, designated syringes for medication 
administration and tube aspiration. 
Frequently flush feed tube with tap water and aspirate GRV. 
Regular assessment of bowel function. 
Regular administration of medications. 
Source: Bankhead et al., 2009; Best, 2008; Fletcher, 2010; Irish Clinical Resource Efficiency 
Support Team, 2004; Lau & Girard, 2011; Manchester NHS, 2010; Marshall & West, 2004; 
Mathus-Vliegen, Bredius, & Binnekade, 2006; NICE, 2003. 
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Feed tube site contamination was examined in an RCT of 37 ICU patients who 
received ETF via a glass bottle (with a sterile elastomer cap that was spiked by a 
feeding administration set) or plastic Pack feed system (a triple foil laminated 
collapsible bag without an air inlet) (Mathus-Vliegen et al., 2006). Bacteria were 
cultured in three of 112 glass bottles with one bottle suspended for more than eight 
hours and two of the 95 Pack systems. Contamination at the Y-port of the 
administration sets increased to 48%. Exogenous contamination of ETF feed sets was 
less likely to occur compared with endogenous contamination from retrograde flow. 
Two strategies proposed to minimise the retrograde feed set contamination were the 
positive pressure exerted by the feeding pump and effective health care worker hand 
hygiene (Mathus-Vliegen et al., 2006). The significance of retrograde feed set 
contamination and diarrhoea was not measured in the Mathus-Vliegen et al. (2006) 
study. However, glass bottle enteral nutritional formulae are used less frequently in 
clinical practice. 
International clinical practice guidelines recommend specific preparation and 
maintenance practices be implemented with the provision of enteral nutrition 
(Bankhead et al., 2009). These guidelines aim to minimise the risk of harm, such as 
feed contamination and infection among patients who receive ETF. Specific 
recommendations include appropriate shelf-life of the enteral formulae and 
administration sets, refrigeration of the feed immediately it is opened, disposal of 
unused feed at 24 hours following opening, changing administration sets every 24 
hours and labelling ETF formulae and administration sets with the patients’ name 
and date and time of opening to minimise the hanging time (Bankhead et al., 2009; 
Best, 2008; Lloyd & Powell-Tuck, 2004). The relationship between these guidelines 
and diarrhoea in critically ill patients was not reported. 
Two methods of ETF preparation are routinely used in ICUs and include ready-to-
hang packs and decanting of feed into flexi-containers (Skipper, 2012). 
Contamination of ETF formulae has been demonstrated in the decanting of formula 
into a flexi-container in adult patients (Beattie & Anderton, 2001; Best, 2008). 
Microbiological risks were examined in the assemblage and running of four enteral 
feeding systems using prefilled nutrient containers and decanting ETF into flexi-
containers in a simulated ward environment (Beattie & Anderton, 2001). Equipment 
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was prepared with hands encased in disposable gloves, or deliberately contaminated 
with a test organism, or contaminated hands deliberately touching the nutrient 
container top and administration set connector. No feed contamination was found 
when ready-to-hang feed systems were used. However, formulae contamination was 
found at 24 hours when feed was decanted from bottles, suggesting poor hygiene at 
the lip of the can. There is a clinically significant relationship between feed system 
contamination and preparation and maintenance techniques, however, the 
relationships between diarrhoea and the variables were not examined. 
Feed intolerance has been reported in 43–63% of ETF patients, with high GRV 
occurring in 30–51% of this patient population (MacLaren et al., 2008; McClave et 
al., 2004). The transient cessation of the ETF often accompanies clinical 
management of feed intolerance. Patients who experience feed intolerance are more 
likely to encounter diarrhoea, more abdominal distension, nausea, vomiting, poor 
nutrition, increased lengths of ICU and hospital stays and higher mortality rates 
(Chan, 2010; MacLaren et al., 2008). 
The use of GRV has become a barrier to effective nutrient delivery and potentially 
increases the risk to critically ill patients (Hurt & McClave, 2010). Intensive care 
nurses routinely aspirate GRV every two to four hours (Skipper, 2012). The practice 
and frequency of GRV remains contentiously reported in the literature over the past 
20 years (Marshall & West, 2006; McClave et al., 1992; McClave et al., 2005). 
Practices surrounding GRV include the aspiration and/or the return of aspirated 
gastric contents and feed to the patient, versus the discarding of aspirated gastric 
contents. The reinfusion of aspirated gastric contents remains controversial. 
However, the discarding of aspirated feed and gastric contents may result in the 
underdelivery of nutritional requirements and the depletion of electrolytes (Williams 
& Leslie, 2004). 
The practice of returning or discarding GRV and patient-associated complications 
was examined in a small RCT (n = 10) (Booker et al., 2000). No significant 
differences were observed between the two groups regarding acquiring aspiration 
pneumonia, electrolyte abnormalities and delays in feeding and tube replacements. 
These findings may be associated with the small sample size. Similar findings were 
observed in a larger RCT that also examined the returning (n = 63) or the discarding 
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of (n = 62) GRV (Juve-Udine et al., 2009). Delayed gastric emptying was 
significantly lower in the reinfused GRV group. Both the Booker et al. (2000) and 
Juve-Udine et al. (2009) studies examined similar ETF intolerance endpoints 
including diarrhoea, abdominal distension and nausea and vomiting. No statistically 
significant differences were found between the two groups in both studies (Booker et 
al., 2000; Juve-Udine et al., 2009). Consequently, it is recommended that GRVs less 
than 500 mL are reinfused. The noteworthy limitation of the Booker et al. (2000) and 
Juve-Udine et al. (2009) studies was that contamination of the ETF feed and 
retrograde contamination of the administration sets were not measured. 
Regular flushing of the feeding tube with cool boiled water, sterile water or tap water 
is recommended to maintain tube patency and to irrigate potentially harmful bacteria 
that may result from regular aspiration (Beattie & Anderton, 2001; Kenny & 
Goodman, 2010; NHMRC, 2010; NICE, 2003). Evidence supporting the routine 
flushing of feeding tubes remains limited. Practice is often guided by the clinician’s 
experience or the health care facility’s local policy. Iatrogenic relationships between 
diarrhoea and ETF have variably been associated with the time to commencement of 
ETF following ICU admission, the method of ETF delivery, the osmolality and fibre 
content of ETF formula and the preparation and maintenance of ETF formula and 
systems. 
2.6.4.2 Bowel care 
Effective bowel care is suggested to prevent and/or reduce the incidence of diarrhoea 
in critically ill patients. Bowel care is an important aspect of the critically ill patient’s 
nursing care. It is often overlooked, however, and considered less important than the 
primary concern of patient care being to stabilise haemodynamic and oxygenation 
parameters (Dorman et al., 2004). Effective bowel care is reported to reduce 
secondary complications such as abdominal distension, vomiting, dehydration, faecal 
overflow, restlessness, confusion, malaise and obstruction and perforation of the gut 
(Dorman et al., 2004). 
Bowel care protocols include assessment of the abdomen, nasogastric tube drainage, 
tolerance to ETF, frequency of feeding tube aspirations, regularity of feeding tube 
administration set changes, regularity of bowel opening—including a description of 
stools, use of rectal tubes, use of pro and anti-motility medications, co-administration 
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of antibiotics, fluid balance and documentation (Dorman et al., 2004; McPeake, 
Gilmour, & McIntosh, 2011). Specific regimens to manage bowel care in the ETF 
critically ill patient are not a common management strategy within international 
nutritional therapy clinical guidelines (Bankhead et al., 2009; Heyland et al., 2003b; 
Kreymann et al., 2006; McClave et al., 2009). Only one guideline specifically 
explored strategies to manage ETF-associated diarrhoea; however, it did not 
precisely identify a bowel care protocol (Doig et al., 2004). Currently, there is 
insufficient evidence that has examined clinical guidelines and algorithms that 
promote effective bowel care in the critically ill (McPeake et al., 2011). No enteral 
nutrition guideline addresses bowel care regarding the commencement and 
maintenance of ETF in critically ill patients (Bankhead et al., 2009; Heyland et al., 
2003b; Kreymann et al., 2006; Martin et al., 2004; Martindale et al., 2009; McClave 
et al., 2009). The diversity in bowel care algorithms between ICUs may be founded 
on the individual health care professional’s clinical experience, past clinical practices 
and local health care facility policy that is often informed by clinical experts. 
Using a chart audit Ferrie and East (2007) prospectively examined diarrhoea 
incidence and the introduction of a bowel care algorithm in 650 critically ill patients 
who experienced either diarrhoea or constipation and who had an ICU LOS more 
than three days. Diarrhoea was defined as three or more loose bowel motions, or four 
or more bowel motions of any consistency, or more than 300 mL stool on at least two 
consecutive days. Diarrhoea incidence was significantly less following the 
implementation of the bowel care algorithm (36% pre versus 23% post algorithm 
introduction, p = 0.002) and also occurred on 8% fewer ICU days (p = 0.0001). 
Although the Ferrie and East (2007) study did not specify the elements of the bowel 
care algorithm, the authors recommend that a bowel care algorithm is introduced 
owing to the reduction in diarrhoea incidence. 
Likewise, McPeake et al. (2011) examined the implementation of a bowel 
management protocol that incorporated a daily review of bowel activity, the 
administration of intestinal promotility medications to facilitate bowel activity and a 
review of bowel activity documentation. The Bristol Stool Form Scale was used to 
identify diarrhoea characteristics. Following the implementation of the bowel care 
algorithm, the number of days that diarrhoea was experienced reduced by 15.8% (p = 
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.18), constipation incidence decreased by 20.7% (p = .13) and the number of days 
that bowel care documentation occurred on increased by 13% (p = .0003). Although 
the findings of this study did not reach statistical significance regarding diarrhoea 
management, the bowel care algorithm appeared to be a useful tool to manage bowel 
care of the critically ill patient more effectively. 
2.6.5 ICU treatments: medications 
Many essential medications administered during critical illness have the potential to 
affect gastric emptying, gastrointestinal motility, gut function and diarrhoea. These 
medications include high osmolar medications, such as, aperients (coloxyl, senna, 
lactulose and sorbitol, suppositories), prokinetics (metoclopramide, erythromycin 
and rarely cisapride), H2-receptor antagonists, PPI, antibiotics and sedation, opioids 
and neuromuscular-blocking medications (Marshall & West, 2004; MacLaren et al., 
2008; Schmidt & Martindale, 2003) (see Figure 2.1, page 10). 
2.6.5.1 Aperient and prokinetic medications 
Decreased intestinal motility and constipation are often managed by using aperients 
and laxatives. These medications either bulk and/or lubricate the stool, stimulate 
intestinal peristalsis or provide an intestinal osmotic effect. Consequently, aperients 
and laxatives may induce secretory or osmotic diarrhoea in some critically ill patients 
(Toney & Agrawal, 2008). 
An estimated 22% of critically ill patients will receive prokinetic medications for 
gastrointestinal hypomotility and feed intolerance (Heyland et al., 2003b; Heyland et 
al., 2004). Prokinetics commonly used to promote gastrointestinal motility include 
metoclopramide and erythromycin and are often prescribed as either single or 
combination rescue treatments (Nguyen, Chapman, Fraser, Bryant, Burgstad et al., 
2007). Short-term administration of prokinetic medications is well established, but 
the translation of short-term use into clinical practice remains inconclusive and 
subject to the clinician’s experience and local health care facility policy. The 
effectiveness of single prokinetic medication treatment for GIT dysmotility has been 
demonstrated to decline after two to three days (MacLaren et al., 2008; Taylor, 
Manara, & Brown, 2010). In comparison, combination rescue prokinetic treatment 
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has been associated with a longer duration of effect of up to six days (Nguyen, 
Chapman, Fraser, Bryant, Burgstad et al., 2007). 
Metoclopramide is suggested to stimulate gastric and duodenal motility. Short-term 
use of metoclopramide 10 mg four times daily has been associated with a reduction 
in feed intolerance and increased duodenal motility (MacLaren et al., 2008). 
Prolonged administration of metoclopramide beyond three days has been associated 
with a significant decline in feeding tolerance (Nguyen, Chapman, Fraser, Bryant, 
Burgstad et al., 2007) and Rhoney et al. (2002) theorised that metoclopramide is 
ineffective when administered to brain injured patients. 
Erythromycin has been associated with high antral, pyloric and duodenal 
contractions (Fraser & Bryant, 2010). This results in accelerated gastric emptying 
and intestinal motility leading to increased feeding tolerance and increased faecal 
output (MacLaren et al., 2008). Placebo-controlled RCTs have demonstrated that 
low-dose erythromycin (3–7 mg/kg/day) is associated with increased gastric 
emptying and success of feeding tolerance in critically ill patients (Berne et al., 2002; 
Reignier et al., 2002). Similar to metoclopramide, the effectiveness of erythromycin 
is reduced with prolonged use of more than seven days (Nguyen, Chapman, Fraser, 
Bryant, et al., 2007; Nguyen, Ching, Fraser, Chapman, & Holloway, 2007). 
Erythromycin treatment for intestinal hypomotility is not without complications. 
Clostridium difficile-related diarrhoea was examined in patients who received 
erythromycin-based prokinetic therapy for feed intolerance in a mixed ICU (Nguyen, 
Ching et al., 2008). Diarrhoea was defined as three or more loose, liquid stools with 
an estimated stool volume equal to or greater than 250 mL/day. Participants received 
erythromycin (n = 53), metoclopramide (n = 37) or combination therapy (n = 90). 
Diarrhoea occurred in 72 (40%) patients and at 9.9 (± 0.8) days following the 
commencement of therapy. No patients returned a positive stool culture for 
Clostridium difficile. Diarrhoea was more prevalent with combination therapy (49%) 
compared to monotherapy (metoclopramide 32%, erythromycin 30%) and the mean 
duration of diarrhoea was 3.6 (± 1.2) days. Other diarrhoea risk factors identified 
included patients with respiratory failure and who required ventilation with higher 
positive end expiratory pressures, significant burns, antibiotics or higher feed 
volumes (Nguyen, Ching et al., 2008). 
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2.6.5.2 Stress ulcer prophylaxis medications 
It is suggested that stress-related mucosal damage results from gastrointestinal 
ischaemia and that 75–100% of all critically ill patients experience this outcome 
(Brett, 2005; Fennerty, 2002). Stress ulcer prophylaxis focuses on maintaining 
gastric >pH 4. The medications used within such prophylaxis efforts may contribute 
to diarrhoea. Several agents such as Histamine-2 (H2) receptor antagonists and PPIs 
are routinely used to treat stress-related mucosal damage in critically ill patients. 
Histamine-2 receptor antagonists act by incompletely suppressing gastric acid 
secretion (Duerksen, 2003) resulting in enteropathogenic bacterial organism survival 
and overgrowth and the potential to develop diarrhoea (Marshall & West, 2004; 
Thomas, 2001; Whelan et al., 2001). In comparison, PPIs have been demonstrated to 
be superior acid suppressant medications compared to H2 receptor antagonists 
(Sesler, 2007) through the sustained suppression of gastric acid as the PPI 
irreversibly binds to the proton pump (Brett, 2005; Duerksen, 2003). This 
consequently blocks parietal cell receptor sites of acid secretion. Prospective RCTs 
have demonstrated that intravenous or enteral administration of PPIs increases 
gastric acid pH to at least four (Laterre & Horsmans, 2001; Morris, Karlstadt, 
Blatcher, & Field, 2001) and this may result in the development of diarrhoea. 
A meta-analysis conducted by Lin et al. (2010) examined the efficacy and safety of 
PPIs compared to H2 receptor antagonists for stress-related upper GIT bleeding 
prophylaxis. The pooled risk for stress-related upper GIT bleeding was -0.04 (95% 
CI, -0.09–0.01; p = .08). No difference was identified between PPI and H2 receptor 
antagonists and the risk of pneumonia and ICU-related mortality. Consistent with 
earlier research, the meta-analysis did not find strong evidence supporting the 
efficacious use of PPIs over H2 receptor antagonists for the prevention of stress-
related upper GIT bleeding prophylaxis. Although Lin et al. (2010) examined the 
relationship between PPIs, H2 receptor antagonists and pneumonia, the study did not 
examine associated diarrhoea risk factors. 
In the Nguyen, Ching et al., (2008) study that examined Clostridium difficile-related 
diarrhoea in patients who received erythromycin-based prokinetic therapy the use of 
acid suppression was not associated with diarrhoea incidence. This is in contrast to 
an earlier study examining diarrhoea incidence associated with the administration of 
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H2 receptor antagonists and PPI medications (Cunningham, Dale, & Undy, 
2003).This disparity may result from reduced gastric colonisation secondary to the 
prokinetics effects of increased gastric emptying and intestinal transit time.  
2.6.5.3 Antibiotic medications 
Diarrhoea is commonly associated with the use of antibiotics. Antibiotic-associated 
diarrhoea prevalence rates vary between 5–25% (Cote & Buchman, 2006) with the 
majority of antibiotic-associated diarrhoea being nonspecific in nature (Toney & 
Agrawal, 2008). This type of diarrhoea results from a disruption in the intestinal 
microfloras’ normal ecosystem, which may lead to either osmotic or secretory 
diarrhoea (Barbut & Meynard, 2002; Marshall & West, 2004; Meier et al., 2003; 
Toney & Agrawal, 2008; Whelan et al., 2001). This disruption to the intestinal 
microflora homeostasis enables overgrowth of exogenous organisms and gives rise to 
diarrhoea. Antibiotics commonly associated with diarrhoea usually have a greater 
impact on anaerobic organisms such as Clostridium Perfringens, Staphylococcus 
Aureus, Candida spp, Klebsiella Oxytoca and Salmonella spp. Some antibiotics, such 
as erythromycin, do not affect the intestinal microbial ecosystem; however, they 
stimulate motilin receptors that leads to increased intestinal motility (Toney & 
Agrawal, 2008). Antibiotics most commonly studied in relation to diarrhoea include 
Clindaymin (10–25%), oral Ampicillin (5–10%) and Amoxicillin-Clavulanate (10–
25%) (Toney & Agrawal, 2008). Simple antibiotic-associated diarrhoea is often 
dose-dependent, occurs in 70–80% of patients and generally resolves within days of 
discontinuing the offending antibiotic (Toney & Agrawal, 2008). 
2.6.5.4 Sedation, opiates and neuromuscular blockade medications 
Most patients admitted to the ICU receive sedation, opiates and, at times, 
neuromuscular-blocking medications (Cullis & Macnaughton, 2006). Routine 
administration of these medications occurs using continuous infusion to relieve 
discomfort and distress (Cullis & Macnaughton, 2006), provide sedation (Tamion et 
al., 2003) and to facilitate effective mechanical ventilation (Nguyen, Chapman et al., 
2008; Ritz et al., 2001). Many sedative agents are known to impair upper GIT 
motility. Medications commonly used for sedation include mono-sedation of 
propofol and combination sedation of morphine and midazolam (Nguyen, Chapman 
et al., 2008). In addition, many critically ill patients who receive sedation, opiates 
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and neuromuscular-blocking medications also receive prokinetics, PPI and H2 
receptor antagonists to promote gastrointestinal motility. The fluctuation between 
intestinal hypo and hypermotility may lead to diarrhoea (Herbert & Holzer, 2008). 
Morphine and midazolam have demonstrated gastric motility inhibitory effects in 
animal studies and healthy and critically ill human studies (Hammas, Hvarfner, 
Thorn, & Wattwil, 1998; Inada, Asia, Yamada, & Shingu, 2002). The effects of 
combination sedation, morphine and midazolam (n = 20) compared with mono-
sedation, propofol only (n = 16) were examined in medical and surgical mechanically 
ventilated and ETF patients. Patients who received combination sedation were 
sedated longer (median 153 minutes; IQR 72–434 minutes) and had greater gastric 
retention (p < .01). Glycaemic control was similar between the two groups. There are 
two significant limitations of the Nguyen, Chapman et al. (2008) study. The 
implications of prokinetics, PPI and H2 antagonists on gastrointestinal motility were 
not examined, nor was the relationship between sedation and diarrhoea. Currently, 
there is insufficient evidence examining gastrointestinal dysmotility, sedation, 
opiates, prokinetics, PPI and H2 receptor antagonists’ medication administration and 
diarrhoea relationships in critically ill patients. 
The relationship between neuromuscular blockade medications and gastrointestinal 
motility remains somewhat controversial. In clinical practice health care 
professionals often witness the cessation of ETF in the presence of neuromuscular-
blocking medications and, in particular, when the medication is being continuously 
infused (Tamion et al., 2003). Tamion et al. (2003) found no consistent relationship 
between gastric emptying and intestinal motility when patients received 
neuromuscular-blocking medications. The Tamion et al. (2003) RCT examined 
gastrointestinal function in 20 ETF patients who received a neuromuscular-blocking 
medication (cisatracurium). Participants were randomly selected to receive an opioid 
sedation infusion (fentanyl and midazolam) at time point one and the same sedation 
and cisatracurium at time point two. Enteral feeding was withheld when the GRV 
exceeded 200 mL. Although the mean GRV value was not reported, the study 
suggested that the mean GRV was not statistically different between the two groups 
(Tamion et al., 2003). Although this study reported that GRVs were higher at time 
point two, the relationship with ETF interruptions and diarrhoea were not examined. 
46 
Data regarding aperient, prokinetic, H2 receptor antagonist, PPI, antibiotics and 
sedation, opioids and neuromuscular-blocking medications suggest inconsistent 
relationships exist between the use of these medications with critically ill patients 
and the development of diarrhoea. The administration of stress ulcer prophylaxis and 
other medications for the treatment and management of the critically ill patient is 
essential. However, these medications are not without complications and diarrhoea is 
a common occurrence. In summary, these relationships will be examined in this 
study using the conceptual framework (see Figure 2.1, page 10). 
2.6.6 Clinical indicators associated with critical illness 
Many critically ill patients experience altered physiological responses, particularly 
during episodes of ETF (Whelan & Schneider, 2011). The prevalence of 
physiological changes associated with critical illness is difficult to measure due to 
the heterogeneity of critical illness. Relationships between gastrointestinal 
dysfunction (diarrhoea) and physiological responses to critical illness 
(hypoalbuminaemia, hyperglycaemia, elevated WCC and elevated INR) remain 
minimally examined within the literature. 
2.6.6.1 Hypoalbuminaemia 
Albumin is an independent prognostic clinical marker of morbidity and mortality in 
critically ill patients (Falcao & Japiassu, 2011). Hypoalbuminaemia is commonly 
defined as a serum albumin level less than 35 g/dL (Marshall & Boyle, 2007; 
Nguyen, Chapman, Fraser, Bryant, Burgstad et al., 2007; Whelan et al., 2009) and 
this condition occurs commonly in critically ill patients (Dubois et al., 2006; Falcao 
& Japiassu, 2011). The convention of serum albumin reporting is g/dL rather than 
mmoL (Marshall & Boyle, 2007; Nguyen, Chapman, Fraser, Bryant, Burgstad et al., 
2007; Whelan et al., 2009). It is not uncommon for intravenous albumin to be 
administered for the management of hypoalbuminaemia and hypotension during a 
critical illness experience. Studies have demonstrated that hypoalbuminaemia is 
associated with a reduction in colloidal osmotic pressure that leads to intestinal 
mucosal oedema (Marshall & West, 2004; Whelan et al., 2001). The mucosal 
oedema causes secretion of fluid into the intestine in the ETF patient and hence, 
diarrhoea. Approximately 40% of albumin is distributed in the intravascular space 
while 60% is distributed in the extravascular space (Boldt, 2010). The high capacity 
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for albumin to bind with water and the vascular distribution of albumin might explain 
the relationship between diarrhoea and hypoalbuminaemia in critically ill patients 
(Boldt, 2010). Nguyen, Chapman, Fraser, Bryant, Burgstad et al. (2007) examined 
prokinetics and feed intolerance in 75 mechanically ventilated patients. Secondary 
outcome measures examined hypoalbuminaemia, diarrhoea and severity of illness 
(APACHE II score). The results showed that hypoalbuminaemia and severity of 
illness were significantly associated with gastrointestinal dysmotility and that 
diarrhoea was experienced by 40% of patients. The Nguyen, Chapman, Fraser, 
Bryant, Burgstad et al. study (2007) did not examine specific relationships between 
hypoalbuminaemia and diarrhoea. However, hypoalbuminaemia (serum albumin <35 
g/L) was experienced by 95% of participants in an observational study that examined 
intestinal microflora and short-chain fatty acid changes in ETF patients (Whelan et 
al., 2009). Two (10%) hypoalbuminaemic patients had a serum albumin <20 g/L; 
however, hypoalbuminaemia was not associated with patients developing diarrhoea 
(β = 0.146, p = .698) (Whelan et al., 2009). Gastrointestinal complications associated 
with the administration of albumin include increased oncotic pressure and this may 
result in decreased intestinal water absorption leading to diarrhoea (Weisen et al., 
2006). The question of whether to administer albumin in hypoalbuminaemic patients 
for the purpose of managing diarrhoea in ETF critically ill remains unanswered. 
2.6.6.2 Hyperglycaemia 
Hyperglycaemia has been reported as blood glucose levels exceeding 180 mg/dL 
(>10 mmoL/L) (Cook et al., 2009) and a blood glucose level persistently sustained at 
140–180 mg/dL (7.7–10 mmoL/L) (American Association of Clinical 
Endocrinologists and American Diabetes Association, 2009). The relationships 
between hyperglycaemia and morbidity and mortality, infection, cardiac 
complications, haemodynamic and electromyocardial disturbances and acute renal 
failure have been well established (Burkett, Keijzers, & Lind, 2009; Hsu, 2012; 
Schmeltz, 2011). Brealey and Singer (2009) suggest that hyperglycaemia in critical 
illness is associated with peripheral and hepatic insulin resistance, enhanced hepatic 
and renal glucose production and higher glucose loading from nutritional therapy and 
intravenous infusions. 
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During critical illness hyperglycaemia is often present. Although there are few 
studies that have examined the prevalence of stress hyperglycaemia in critically ill 
patients, one study reported that 38% of patients admitted to a general hospital 
developed stress hyperglycaemia with 16% of participants having had no previous 
history of diabetes mellitus (Cortsjens et al., 2006). The reported prevalence of 
stress-related hyperglycaemia in critical illness is, however, much higher with 
approximately 75% of all patients, including diabetics, having blood glucose levels 
>6.1 mmoL/L at ICU admission and 12% of all patients having blood glucose levels 
>11.1 mmoL/L during their critical illness experience (Hsu, 2012; van den Berghe et 
al., 2001). Similarly, hyperglycaemia (defined as blood glucose >180 mg/dL [10 
mmoL/L]) was experienced in 46% of ICU patients and 31.7% of non-ICU patients 
in a study that examined more than 12 million blood glucose levels in 126 American 
hospitals (Cook et al., 2009). Furthermore, hyperglycaemia has been associated with 
increased infection coupled with morbidity and mortality (Krinsley, 2004, 2004; van 
den Berghe et al., 2001; van den Berghez et al., 2003). Elevated blood glucose has 
been demonstrated to exhibit a pro-inflammatory effect, which is a prominent trigger 
in gastrointestinal function (Kellow et al., 1999). 
In critically ill patients, studies have examined the relationships between 
hyperglycaemia, mortality and morbidity, infection, ETF and gastric tolerance 
(Nguyen, Ching et al., 2007). While hyperglycaemia has been reported to relax the 
proximal stomach, impair gastric motility and gastric emptying in healthy and 
diabetic patients, the relationship between hyperglycaemia, gastric motor function 
and diarrhoea in critically ill patients is less clear and warrants further investigation. 
2.6.6.3 Elevated WCC 
The primary role of white blood cells is to provide the body with protection against 
infection. The relationship between elevated WCC and critical illness often reflects 
an infective process. Critically ill patients who experience an elevated WCC are 
often commenced on broad and narrow spectrum antibiotics to treat the causative 
infective agent. The relationship between elevated WCC, diarrhoea, ETF and aerobic 
intestinal microflora in critically ill patients remains unknown. The majority of 
contemporary evidence examines antibiotic administration, diarrhoea and intestinal 
microflora relationships rather that the underlying physiological changes to the 
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infection, that is, elevated WCC. Currently, there are no epidemiological studies that 
have examined elevated WCC, diarrhoea, enteral nutrition and aerobic intestinal 
microflora relationships in the critically ill ICU patient. 
2.6.6.4 Elevated INR 
The relationship between diarrhoea, elevated INR, ETF and aerobic intestinal 
microflora in critically ill patients also remains unknown and no research to date has 
examined these relationships. Critically ill patients often experience abnormal 
physiological responses including hypotension, hypoxaemia, elevated WCC and 
elevated INR following a critical injury or illness. Critically ill patients are 
considered at high risk for physiological changes including elevated INR; however, 
high quality epidemiological studies examining the relationships between elevated 
INR, diarrhoea, enteral nutrition and aerobic intestinal microflora have not been 
undertaken. 
2.6.7 Aerobic intestinal microflora in critical illness 
Physiological responses experienced during critical illness are not limited to those 
previously discussed and include changes in the intestinal microflora. Responses to 
critical illness can alter the defence mechanisms of the GIT resulting in intestinal 
microflora dysbiosis and the patient subsequently developing diarrhoea. The 
bacterial community found in the colon plays a significant role in health and ill 
health states. Enteropathogenic bacteria and colonic water secretion have previously 
been associated with diarrhoea in patients receiving enteral nutrition. Certain species 
of intestinal microflora are responsible for attachment to the intestinal wall to prevent 
translocation, infection and abnormal water secretion that may lead to the 
development of diarrhoea. Intestinal preventative bacteria have been reported to 
decline and disappear within four to six hours of a stressful event, for example, when 
pancreatitis is induced in an animal model (Leveau et al., 1996). The absence of 
these bacteria results in pathogenic bacterial overgrowth, translocation and diarrhoea, 
particularly in the presence of reduced splanchnic blood flow, a hypoperfused gut 
and vasopressor support (Bengmark, 2005; Leveau et al., 1996). 
The relationship between the pathogenesis of diarrhoea, ETF and intestinal 
microflora has been studied in healthy persons and ETF patients (Whelan et al., 
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2004). In a study by Schneider et al. (2000), non-critically ill participants who were 
ETF were found to have higher concentrations of aerobic bacteria and lower 
concentrations of anaerobic bacteria compared with healthy participants (p < .01). 
This prospective observational study examined the relationship between faecal 
bacteria (aerobic and anaerobic intestinal microflora) and short-chain fatty acids in 
eight patients who received long-term standard polymeric ETF, five patients who 
received total parenteral nutrition and 10 healthy individuals. Nutrition was the only 
variable associated with changes in faecal microflora. The results did not show a 
relationship between aerobic bacteria and diarrhoea in ETF participants. However, 
the authors inferred that changes in aerobic and anaerobic bacteria might be 
associated with diarrhoea in participants who received enteral nutrition, and also 
those participants who received antibiotics. 
Whelan et al. (2005) examined the effects of enteral formula, with and without a 
prebiotic (fructoologosaccarhide) and fibre on the faecal microflora of 10 healthy 
participants. Participants consumed a ‘normal’ diet for 14 days followed by ETF for 
a six-week washout phase and then were ETF for a further 14 days. The study 
showed a significant reduction in faecal bacteria and short-chain fatty acid 
concentrations in both formulae, however, concentrations were higher in the 
fructoologosaccarhide and fibre group. Furthermore, stool frequency was higher in 
the fructoologosaccarhide and fibre group compared with the standard formula group 
(p = .019). The reduction in faecal bacteria is suggested to reduce colonic bacterial 
colonisation, while a reduction in short-chain fatty acid concentrations may impede 
colonocytes ability to absorb water. Although the Whelan et al. (2005) results show 
intestinal microflora changes in healthy individuals, these findings may not apply to 
critically ill patients. Enteral tube-feeding is recommended in critically ill patients 
within 48 hours of admission to the ICU and there is no ‘wash out phase’ to observe 
individual patient responses to enteral nutrition, as was noted in the Whelan et al. 
(2005) study. The microflora of a formed stool in a healthy ETF patient may not be 
representative of diarrhoea observed in critically ill ETF patients. 
In another observational study, Whelan et al. (2009) examined intestinal microflora 
and short-chain fatty acid changes in 20 medical and surgical non-critically ill 
patients who were ETF for 14 days. The study compared the intestinal microflora of 
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those patients who did and did not develop diarrhoea. Diarrhoea was identified using 
the King’s College Stool Chart. Results demonstrated little change in intestinal 
microflora during ETF; however, significant individual variation was noted between 
faecal samples. These results support similar findings of Whelan et al.’s (2005) 
previous study. Patients who developed diarrhoea (n = 10, 50%) had significantly 
higher concentrations of clostridia (p = .026) and lower concentrations (p = .069) and 
proportions (p = .029) of bifidobacteria. This difference in bifidobacteria proportions 
was also observed between patients who did and did not develop diarrhoea (median 
0.4%, p = .035).  
Of note, Whelan and colleagues (2009) excluded critically ill patients because of the 
complexities associated with the administration of multiple antibiotics in this patient 
cohort. Antibiotic administration is routine management and is a reality of clinical 
practice associated with the care of critically ill patients. Furthermore, hospital 
admission baseline data of faecal counts were not obtained, making it impossible to 
compare faecal microflora without preintervention/observation baseline data. The 
Whelan et al. (2009) study identified relationships between diarrhoea, ETF and 
intestinal microflora in hospitalised patients. There is, however, a gap in current 
knowledge as to whether this relationship exists in critically ill, ETF patients who are 
cared for in ICUs. 
A few RCT and observational studies have investigated the relationships between 
diarrhoea, ETF, intestinal microflora and specific disease states such as systemic 
inflammatory response (SIRS) and infection, inflammatory bowel disease, cancer 
and pancreatitis (Shannon, 2004; Shimizu et al., 2006). Shimizu et al. (2006) assert 
that intestinal microflora is significantly altered in critically ill patients with severe 
SIRS. The study showed that in 25 critically ill ICU patients with severe SIRS, 
anaerobic bacterial counts were significantly lower compared with 14 healthy 
volunteers (p < .05). Participants who received antibiotics displayed fewer faecal 
bacterial counts than those participants who did not receive antibiotics (n = 19 versus 
n = 6 respectively, p < .05). Although anaerobic faecal counts were higher in the ETF 
patients (n = 11) statistical significance was not attained. However, participants who 
experienced diarrhoea displayed significantly fewer anaerobic intestinal microflora 
compared with those participants who did not experience diarrhoea (n = 9 versus n = 
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16 respectively, p < .05). The Shimizu et al. (2006) study reported significantly 
altered intestinal microflora in critically ill patients with severe SIRS. However, there 
remains a gap in knowledge with regard to diarrhoea, ETF and aerobic intestinal 
microflora relationships in critically ill patients. 
2.7 Summary 
There are a myriad of contributing factors associated with diarrhoea in the critically 
ill patient, depicted within the conceptual framework (see Figure 2.1, page 10). 
Factors known to be associated with diarrhoea in critically ill patients include a range 
of characteristics of the ICU environment, ICU treatments (enteral nutrition, 
medications and clinical indicators) and aerobic intestinal microflora (see Figure 2.1, 
page 10). However, significant limitations are evident within historic and 
contemporary research regarding these diarrhoea relationships. Disequilibrium 
within the intestinal microflora and the relationships between diarrhoea and enteral 
nutrition have previously been explored in healthy individuals only. To date, no 
research has examined the relationships between diarrhoea, enteral nutrition and 
aerobic intestinal microflora in the critically ill patient (see Figure 2.1, page 10). 
There is a clinical need to explore the relationships between these variables and 
diarrhoea so that the complexities of ICU-associated diarrhoea can be better 
understood and that nursing care can be directed to managing this common problem. 
In Chapter Three the methodological considerations for the conduct of this two-phase 
study will be discussed. 
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CHAPTER THREE: METHODOLOGY 
3.1 Introduction 
This research comprised two studies. Study One used a retrospective, repeated 
measures, observational cohort design to examine diarrhoea and risk factors 
associated with diarrhoea in a single-setting ICU. Study Two built on the findings of 
Study One by examining the relationships between diarrhoea, enteral nutrition and 
aerobic intestinal microflora in the same ICU (see Figure 2.1, page 10). This chapter 
presents the methods used for Studies One and Two. In this chapter Study One and 
Study Two will be discussed collectively and where points differ between studies the 
methods will be presented separately. The aims and research questions and 
hypotheses are presented prior to the discussion of the study design. Areas discussed 
include the research design, study setting, the study’s sample size, data collection 
procedures and the data collection instruments. Data management strategies and the 
analytical plan are also presented. Ethical considerations for this research are 
described. 
3.2 Study aims and research questions 
The aim of Study One was to examine the incidence of, and factors associated with, 
diarrhoea in critically ill patients who were ETF in a single-setting ICU. In addition, 
Study Two examined the relationships between diarrhoea, enteral nutrition and 
aerobic intestinal microflora in emergency admission, critically ill adult ICU 
patients. 
Consistent with the aims of this study, the following questions and hypotheses 
guided both Study One and Study Two. 
Question 1: What is the period prevalence of diarrhoea in ETF patients in the ICU? 
Question 2: Is there a relationship between the number of events of diarrhoea and 
the duration of diarrhoea in ETF critically ill patients? 
Hypothesis 1: No relationship will be observed between the number of events 
of diarrhoea and the duration of diarrhoea. 
54 
Question 3: Are clinical indicators such as hypoalbuminaemia, hyperglycaemia, 
elevated WCC, elevated INR and infection associated with diarrhoea? 
Hypothesis 2: Diarrhoea is not associated with hypoalbuminaemia, 
hyperglycaemia, elevated WCC, elevated INR and infection. 
Question 4: Is diarrhoea in ETF patients associated with: 
 the type of ETF formulae? 
 the time to commencement of ETF following ICU admission? 
 the duration of ETF? 
 gender, age, ICU LOS and APACHE II scores? 
 the duration of aperient, prokinetic, sedation, neuromuscular blockade, H2 
antagonist, PPI and antibiotic medication administration? 
Hypothesis 3: Diarrhoea in ETF patients: 
 will not be associated with the type of enteral feeding formulae; 
 will not be associated with the time to commencement of ETF following ICU 
admission; 
 the duration of ETF; 
 will demonstrate no relationship with gender, age and APACHE II scores; 
and 
 will demonstrate no relationship with the duration of aperient, prokinetic, 
sedation, neuromuscular blockade, H2 antagonist, PPI and antibiotic 
medication administration. 
The following additional research questions and hypotheses were addressed in Study 
Two. 
Question 5: What is the identity and semiquantitative counts of aerobic intestinal 
microflora of: 
 emergently admitted ICU patients? 
 patients enrolled into Study Two who are discharged from the ICU? 
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Question 6: Does the baseline aerobic intestinal microflora change during ICU 
admission? 
Hypothesis 4: The identity and semiquantitative counts of aerobic intestinal 
microflora of acutely admitted, critically ill patients as collected from rectal 
swabs will remain unchanged between admission to and discharge from the 
ICU. 
Question 7: Does a relationship exist between aerobic intestinal microflora and: 
 enteral nutrition and diarrhoea in emergency admission, critically ill, adult 
patients? 
 the timing of enteral nutrition commencement? 
Hypothesis 5: There is no difference in the aerobic intestinal microflora of 
critically ill patients who: 
 are enterally tube fed and experience diarrhoea, and 
 commence ETF at <24 hours and >24 hours following admission to the ICU. 
Question 8: Are the differences in aerobic intestinal microflora of ETF critically ill 
patients who develop and those who do not develop diarrhoea associated with: 
 age? 
 pre-admission diet? 
 APACHE II and SOFA scores? 
 antibiotic therapy? 
 clinical indicators (the occurrence and duration of hypoalbuminaemia, 
hyperglycaemia, elevated WCC, elevated INR and infection)? 
 Study ICU LOS? 
Hypothesis 6: The aerobic intestinal microflora of ETF critically ill patients 
who develop and those who do not develop diarrhoea will demonstrate no 
relationship with: 
 age, 
 pre-admission diet, 
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 APACHE II and SOFA scores, 
 antibiotic therapy, 
 clinical indicators (the occurrence and duration of hypoalbuminaemia, 
hyperglycaemia, elevated WCC, elevated INR and infection), and 
 Study ICU LOS. 
3.3 Study design 
To answer the research questions, a two-study research approach that involved the 
collection of data from one to 14 days following ICU admission was used to 
understand the variables of interest and to capture the complexity of relationships 
that exist between them (Kumar, 2011; Polit & Beck, 2012). Quantitative research 
seeks to examine phenomena about a specific researchable problem (Burns & Grove, 
2005; Muijs, 2011). The current research design applies a quantitative, realist and 
positivist approach (Burns & Grove, 2005; Muijs, 2011). This research is founded on 
control, rigour and objectivity to test objective and measurable hypotheses (Burns & 
Grove, 2005). Muijs (2011) proposes that the quantitative, realist and positivist 
methodological approach is founded on the concept of human nature, and therefore 
the researcher requires objectivity and detachment from the research questions. 
Objective enquiry about the world’s physical problems, such as diarrhoea and 
associated risk factors, is facilitated through the use of a reliable and measurable data 
collection tool. In the context of this study, the data collection tool collected data 
about the ICU environment, ICU treatments including ETF (time to commencement, 
duration, delivery, formula, preparation, administration, bowel care), medications 
(aperients, prokinetics, H2 antagonists, PPI, sedation, neuromuscular blockers, 
antibiotics), clinical indicators associated with critical illness (hypoalbuminaemia, 
hyperglycaemia, elevated WCC, elevated INR, infection) and diarrhoea, enteral 
nutrition and aerobic intestinal microflora relationships (see Figure 2.1, page 10). 
The two-study approach used in this research includes a retrospective, repeated 
measures, observational cohort design (Study One) and a prospective, repeated 
measures, correlation, cohort design (Study Two). The quantitative descriptive 
design used in Study One enabled the researcher to build knowledge about, and 
synthesise detailed descriptions of, the patients’ illness situations and specifically 
diarrhoea and associated diarrhoea risk factors in critically ill patients (Brown, 2012). 
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The quantitative design used in Study Two examined diarrhoea, enteral nutrition and 
aerobic intestinal microflora relationships in a prospective sample of patients 
admitted to the ICU. 
3.3.1 Study One 
The research questions for Study One were answered using a cohort approach to 
retrospectively audit patients’ charts for diarrhoea and associated diarrhoea risk 
factors. Study One engaged a Level I retrospective, repeated measures, correlation 
cohort design (Bent, 2003). According to Bent (2003), Level I research design uses 
an exploratory descriptive design to enable the researcher to identify and describe 
occurrences, experiences or concepts that are relevant and important to informing 
nursing practice. In the context of Study One, these phenomena comprise diarrhoea 
and associated diarrhoea risk factors including patient characteristics, ICU treatments 
(ETF and medications) and clinical indicators (see Figure 2.1, page 10). 
Study One was a pilot study to examine the feasibility of  obtaining data that could 
be examined within a larger scale study, that is, Study Two (Leon, Davis, & 
Kraemer, 2011). The retrospective cohort design facilitated an understanding of the 
relationships between the variables of interest—diarrhoea, the ICU environment, 
ICU treatments (ETF and medications) and clinical indicators associated with critical 
illness (see Figure 2.1, page 10) (Kumar, 2011). The design of Study One did not 
examine a treatment effect, therefore the one group of patients—specifically 
emergency admission, critically ill adult patients who were ETF—were examined 
through retrospective chart audit (Field, 2009; Polit & Beck, 2008). 
The systematic and scientific investigation of patients’ medical records through chart 
audit is an important methodological approach used in health care research. Study 
One used existing data initially recorded for reasons other than research, namely 
patient medical records (Gearing, Mian, Barber, & Ickowicz, 2006; Hess, 2004). A 
particularly useful aspect of the retrospective study design is that it can be used as a 
pilot study to inform prospective research designs, such as that used in Study Two 
(Hess, 2004). As such, chart audits are particularly useful to examine inpatient care 
(Gearing et al., 2006). Three main advantages of retrospective designs include that it 
is a relatively inexpensive approach to access readily available and existing data, it 
contains multiple elements of prospective design and it facilitates the generation and 
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refinement of hypotheses that will be tested using a prospective design (Gearing et 
al., 2006; Hess, 2004). 
3.3.2 Study Two 
Study Two used a prospective, repeated measures, correlation, cohort design. This 
approach involved the observation of natural worldly events, specifically, the human 
aerobic intestinal microflora in ETF, critically ill patients, without directly interfering 
with them (Cormack, 2003; Field, 2009; Funk, 2003; Polit & Beck, 2008). As the 
research did not examine the effect of a treatment on patients, the design used in 
Study Two comprised one group of participants, those emergency admission 
critically ill adult patients who were ETF. 
This study involved what Bent (2003) described as a Level II correlation cohort 
methodological approach to examine relationships between two or more variables in 
the environment in which these variables exist and where the researcher does nothing 
to change the order or outcome of these variables. In Bent’s (2003) categorisation of 
levels of research, a Level II research design employs an analytic approach to 
examining relationships and differences between occurrences, experiences or 
concepts that are relevant and important to informing nursing practice. The 
significant difference between Level I and Level II research designs is that the Level 
II design examines occurrences, experiences or concepts as they exist free from 
interference or manipulation by the researcher (Bent, 2003). 
3.4 Study setting 
The research setting for both studies was the ICU of a major metropolitan teaching 
and tertiary referral hospital in Australia that had a 710 tertiary referral bed capacity. 
The ICU offers Level III intensive care services in two units, one a 10-bed elective 
postoperative unit and the other a 15-bed general ICU specialising in trauma 
management, solid organ transplantation and spinal cord injuries. The two ICUs are 
technically separated from each other; however, they are co-located side-by-side and 
are staffed by the same staff roster and staff rotations. Referrals to the ICU are taken 
from throughout Queensland, the Northern Territory, northern New South Wales and 
neighbouring Pacific nations. The research site offers Level III ICU services 
including comprehensive multisystem life support for indefinite periods of time and 
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academic education and research services. During 2006, the research site’s ICU 
admitted approximately 2254 patients. Of these patients, 901 patients were 
nonelective, emergency admission patients and 1353 patients were elective 
postoperative admission patients. The ICU admitted approximately 75 emergency 
admission patients each month. The median ICU LOS for emergency admission 
patients in 2006 was 2.2 days (range 1–81 days) and the mean APACHE II score was 
13 (range 0–42). The research site is reflective of general Level III ICU patient 
demographics and therefore an appropriate site for the conduct of this research 
(Centre for Outcome and Resource Evaluation Database, 2008). 
3.5 Sample 
3.5.1 Population 
The population for Study One comprised all emergency admission, critically ill adult 
patients admitted to the ICU between January 2007 and May 2007. The population 
for Study Two comprised all emergency admission, critically ill adult patients 
admitted to the ICU for the period between September 2008 and November 2009. 
3.5.2 Inclusion criteria 
Critically ill patients who met the following inclusion criteria were screened for 
eligibility for both Study One and Study Two: 
 emergency admission, adult ICU patients who had not been an inpatient of a 
ward or another hospital as aerobic intestinal microflora dysbiosis was likely 
to occur early following a critical injury or illness; 
 enterally tube fed during their ICU admission; and 
 aged 18 years and older. 
In addition to the above three inclusion criteria, Study One had the following specific 
criterion: 
 Patient’s length of stay in the ICU was ≥5 days as ETF-associated diarrhoea 
often occurs at seven to 10 days following the commencement of enteral 
nutrition (Bowling, 2010). 
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In addition to the Study One criteria, Study Two had the following specific criteria: 
 The patient or the substitute decision-maker spoke English as they were 
required to provide consent. 
 Patients were expected to remain in the ICU for ≥2 days. This is different to 
Study One as it is postulated that aerobic intestinal microflora dysbiosis was 
likely to occur early following a critical injury or illness (Hayakawa et al., 
2011). 
3.5.3 Exclusion criteria 
Participants were excluded from Study One and Study Two if they: 
 were immunocompromised or had received a solid organ transplant, 
chemotherapy or radiation therapy for the treatment of cancer or experienced 
fulminant hepatic failure—these patients were potentially at an increased risk 
of aerobic intestinal microflora imbalance; 
 were admitted for the management of burns (due to the small numbers of 
patients admitted to this research setting) as the nurtional needs and 
physiological changes associated with burn injury may present a different risk 
pattern; and 
 were elective postoperative patients, as these patients often have an ICU 
length of stay less than 48 hours, were not routinely ETF and were not 
previously exposed to acute care and ICU care treatments which may have 
contributed to altering aerobic intestinal microflora homeostasis. 
In addition, Study Two participants were also excluded if they met any of the 
following criteria: 
 Trauma patients with severe perianal trauma as the collection of a rectal swab 
may be potentially harmful to the patient. 
 Patient and/or substitute decision-maker refusal or inability to contact the 
patient’s substitute decision-maker within 48 hours of patient admission to 
the ICU. 
 Patient was enrolled in another study. 
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3.5.4 Sampling method 
Study One used nonprobability, retrospective convenience sampling to audit a 
consecutive sample of patient records. Study One’s sample was drawn from the 50 
admissions immediately preceding May 2007. Study Two’s sampling method used 
nonprobability, convenience sequential sampling during the study recruitment period 
between September 2008 and November 2009. 
3.5.5 Sample size 
3.5.5.1 Study One 
A sample of 50 participants was recruited. This was deemed to be a reasonable 
sample size for a pilot study for multiple reasons (Hertzog, 2008; Kraemer, Mintz, 
Noda, Tinklenberg, & Yesavage, 2006; Loscalzo, 2009). First, wide variation in the 
reported diarrhoea incidence, from 2 to 95%, is evident (Majid, Emery & Whelan, 
2012; Whelan et al., 2009; Whelan & Schneider, 2011), making it difficult to 
calculate a sample size for this study setting (Julious, 2005). Second, a pilot study 
was required to determine the incidence rate of diarrhoea at the research site because 
of the wide incidence figures of diarrhoea reported in the literature (Majid et al., 
2012; Whelan et al., 2009; Whelan & Schneider, 2011). Further, the diarrhoea 
incidence rate identified from the pilot study (Study One) was used to inform the 
sample size calculation for Study Two. Third, a sample of 50 participants was 
representative of six months of patient admissions at the ICU at the research site. 
Sample sizes of between 10–30 participants in exploratory survey research (Isaac & 
Michael, 1995) and a minimum of 12 subjects per group in medical pilot studies 
(Julious, 2005) have been previously proposed as sufficient to explore the variables 
of interest in pilot studies (Johanson & Brooks, 2010). 
3.5.5.2 Study Two 
In Study One, 78% of patients who were audited experienced at least one event of 
diarrhoea, therefore, the expected proportion of diarrhoea was determined from this 
baseline data (Brase & Brase, 2003; Field, 2009; Whelan et al., 2009). The sample 
size for Study Two was calculated using data on diarrhoea incidence observed in 
Study One. A power calculation using the Statistical Package for the Social Sciences 
(SPSS) software indicated that a total sample size of 320 participants was required to 
detect a moderate effect size (β = 0.1, 90%), using an alpha (α) .05 and variability of 
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0.1 to detect a minimal meaningful difference in diarrhoea and aerobic intestinal 
microflora of 10% in Study Two. These levels of type I and type II error are widely 
used within current health care literature and research standards (Brase & Brase, 
2003; Field, 2009; Polit, 2010a, 2010b). 
3.6 Variables 
This section will present the primary and secondary outcomes measures, including 
operational definitions used for Study One and Study Two. 
3.6.1 Primary outcomes 
Two primary outcome measures were used in this research. In Study One, the 
primary outcome measure was diarrhoea. For the purpose of this study, diarrhoea 
was defined as ‘the abnormal passage of loose or liquid stools more than three times 
daily and/or a volume of stool greater than 200 g/day during the patient’s ICU 
admission’ (Thomas et al., 2003, p. 2). This definition was applied retrospectively for 
the purpose of data collection as no validated diarrhoea measurement tool was used 
in the ICU at the time Study One was conducted. Diarrhoea was recorded 
subjectively by nursing staff within the patients’ electronic medical records. Faecal 
volume was recorded by nurses as small (<100 mL), medium (100–200 mL) and 
large (≥200 mL). Stool consistency was recorded as formed, semiformed, loose, 
watery, or the patient had a bowel management system in situ. The researcher then 
cross-referenced chart records of faecal volume and consistency using the Bristol 
Stool Form Chart (Dorman et al., 2004).  
For Study Two, diarrhoea was identified by RNs using the Bristol Stool Form Chart. 
The variable was dichotomous, that is, the study participant either had or did not 
have diarrhoea. This dichotomous variable was also scored and analysed as a 
continuous variable by recording the daily number of events of loose or liquid stools 
and the number of days (or the duration of diarrhoea) where a single event or 
multiple events of diarrhoea was experienced by the critically ill patient. As the 
interrelationship between the number of events of diarrhoea and time potentially 
confounds the findings of this research, the incidence rate of diarrhoea will be used 
to examine diarrhoea over a time period (Kirkwood & Sterne, 2006; Oleckno, 2008). 
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Definitions used to guide this research during the data collection period include: 
 Diarrhoea: diarrhoea was either experienced or not experienced by the 
participant. 
 Diarrhoea event: one event of diarrhoea experienced by a participant. 
 Number of events of diarrhoea: the total number of events of diarrhoea 
experienced by a study participant. 
 Diarrhoea duration: the number of days a participant experienced an event of 
diarrhoea. 
 Diarrhoea incidence rate: the number of new occurrences of diarrhoea 
occurring during a specified period of time divided by the total participant 
observation days. 
In Study Two, the primary outcome measure was colonisation by aerobic intestinal 
microflora. Faecal microflora colonisation was defined as aerobic bacterial 
colonisation (absent, scant, 1+, 2+, 3+) defined at the genus level—Lactose 
fermenters, non-Lactose fermenters, Pseudomonas species (sp), Streptococci sp, 
Staphylococci sp, Enterococci sp, multi resistant Staphylococcus aureus, 
Vancomycin resistant Enterococcus, and Candida. Faecal aerobic intestinal 
microflora were colonised from rectal swabs that were collected on admission to and 
discharge from the ICU, and second daily faecal specimens if diarrhoea developed. 
Aerobic intestinal microflora changes were examined over time by comparing the 
normal faecal flora of rectal swabs collected at admission to and discharge from the 
ICU in comparison to those normal faecal flora collected from a rectal swab and 
faecal specimen. The clinical value of comparing two rectal swabs is that there is a 
possibility that some skin cells could be collected on the swab, for example, 
Coagulase Negative Staphylococcus. In addition, diarrhoea was unlikely to occur on 
admission to and discharge from the ICU; therefore, collection of aerobic intestinal 
microflora by rectal swab was an appropriate method of investigating aerobic 
intestinal microflora changes over time by collection of a rectal swab at two different 
time points. The inadvertent contamination of rectal swabs with residential and 
opportunistic bacteria is likely to skew the findings. It is unlikely that these bacteria 
would be collected with the collection of a faecal specimen. Aerobic intestinal 
bacteria colonisation was scored as a categorical variable, that is, the aerobic 
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intestinal microflora were measured semiquantitatively and recorded as absent, scant, 
1+, 2+ and 3+ (Winn et al., 2006). The variable was also scored dichotomously 
(faecal microflora did or did not change) and categorically (increase, decrease or no 
change) during the patient’s critical illness. 
3.6.2 Secondary outcomes 
There were no secondary outcome measures in Study One. In Study Two, the 
secondary outcome measure was diarrhoea. This was defined, scored and measured 
as per the criteria used in Study One. 
3.6.3 Independent variables 
The following variables have been previously associated with, yet variably attributed 
to, the development of diarrhoea in ETF critically ill patients (Garey et al., 2006; 
Halmos et al., 2010; Lopez-Herce, 2009; Martin, 2007). The following relationships 
were examined in both Study One and Study Two: 
Demographic variables: These variables describe the study sample and enable 
generalisation to the broader ICU population. Demographic variables included: 
 Age: defined in whole years as at the patient’s most recent birthday and was 
scored continuously as whole years. 
 Gender: defined as either male or female and was scored as a dichotomous 
variable. 
 Pre-hospital diet: identified as the predominant diet the patient consumed 
prior to admission to the ICU. Pre-hospital diet was recorded categorically 
and as western, vegetarian, fast food or other diet and as a categorical 
variable. 
 Co-morbidities: defined as the co-morbid illnesses that the participant 
presented with on admission to the ICU. 
Diarrhoea has previously been associated with age (Luft et al., 2008), gender, diet 
(Mitchell, Wilson, & Wade, 2012) and co-morbidities such as irritable bowel 
syndrome (Thorson et al., 2008). It is also presumed that ethnicity often influences 
diet intake (Finegold, Attebery, & Sutter, 1974). For these reasons, the demographic 
data of age, gender, ethnicity, pre-hospital diet and co-morbidities have been 
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considered as having potential relationships between aerobic intestinal microflora 
changes and the development of diarrhoea in critically ill, ETF patients. 
Hospital length of stay: Hospital LOS was defined as the period of time the 
participant was admitted to the hospital as an inpatient (Harris, Nagy, & Vardaxis, 
2010). Hospital LOS was calculated by subtracting the date and time of hospital 
admission from the data and time of hospital discharge. Patients who are more 
acutely and critically ill require more intensive therapy to recover from their illness 
or injury and are more likely to experience physiological complications. 
Consequently, critical illness is more likely to be associated with the number of 
events, duration of diarrhoea and the incidence rate of diarrhoea (Luft et al., 2008; 
Shimizu et al., 2006; Whelan et al., 2009). Hospital LOS was recorded as a 
continuous variable. 
Actual ICU length of stay: Intensive care unit LOS was defined as the period of 
time the participant was admitted to the ICU as an inpatient (Harris et al., 2010). The 
actual ICU LOS was calculated by subtracting the date and time of ICU admission 
from the data and time of ICU discharge. Consistent with the hospital LOS, patients 
who are admitted to the ICU are more acutely and critically ill in comparison to ward 
patients. Critically ill patients require more intensive treatment to facilitate recovery 
from their injury/illness. As such, these patients are more likely to experience 
physiological complications, potentially contributing to the number of events, 
duration of diarrhoea and the incidence rate of diarrhoea (Luft et al., 2008; Shimizu 
et al., 2006; Whelan et al., 2009). Actual intensive care unit LOS was recorded as a 
continuous variable. 
Study ICU length of stay: As would be expected true ICU LOS (as defined above) 
would demonstrate a wide range of patient admission days. This potentially 
confounds analyses with data collected during a defined period. Therefore, for 
analyses, ICU LOS during the data collection (one to 14 days) was used and this 
variable was scored as a continuous variable. 
APACHE II score at ICU admission: APACHE II scores provide an estimate of 
ICU mortality based on a number of laboratory values and patient physiological 
signs that take into account the patient’s acute and chronic disease states (Owen et 
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al., 2010). Scores calculated using the APACHE II predictors of ICU mortality have 
been recorded to range between 0 and 71, with higher scores corresponding to more 
severe disease states and a higher risk of mortality. The severity of patient illness has 
been variably associated with diarrhoea in critically ill, ETF patients. It was 
appropriate to consider the patient’s severity of illness as an associated risk factor 
between diarrhoea, enteral nutrition and aerobic intestinal microflora based on the 
wide variation in the findings in recent research (Thorson et al., 2008). The 
APACHE II scores were scored as a continuous variable, while APACHE II and ICU 
admission diagnoses were scored as dichotomous variables. 
ETF type and duration: Enteral tube feeding (ETF) was defined as the study 
participant receiving enteral nutrition via the nasogastric or orogastric routes during 
their critical illness experience in the ICU. The variable was dichotomous, that is, the 
study participant either was or was not ETF. The variable was also analysed as a 
continuous variable by recording the number of days that the study participant 
received ETF. Enteral nutrition type was identified as the enteral nutrition formula 
administered to participants and included standard formulae including Jevity, Jevity 
Plus and Nepro (see Appendices 3 and 4). Enteral feeding was delivered using a 
constant flow Patrol feeding pump (Tyco Industries). The duration of ETF was 
defined as the number of days that the participant received enteral nutrition during 
the data collection period. The osmolality and fibre content of ETF formulae have 
been variably associated with diarrhoea in critically ill patients (Eisenberg, 2002; 
Thorson et al., 2008). Diarrhoea may be associated with the site of gastric feeding 
(gastric or jejunal), the variable validation of specific ETF formulae, incongruous 
methods of ETF (bolus, continuous or intermittent) and variable preparation 
techniques used to prepare the ETF administration sets. Variables associated with 
ETF type and duration include: 
 Enteral nutrition: defined as the patient received or did not receive ETF and 
was scored as a dichotomous variable. 
 ETF formula: identified as the enteral nutritional formula administered to 
patients and was scored as categorical variables; Jevity Plus, Jevity, Nova 
Source or Nepro and other. 
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 ETF rate of administration: defined as the rate of administration of ETF 
formulae and was scored continuously as the volume of ETF formula 
administered at four hour intervals. 
 Gastric residual volumes: identified as nasogastric or orogastric tube 
aspirates collected as categorical variables every four hours and scored as a 
continuous variable; the volume of gastric contents aspirated at four-hourly 
intervals. 
Time to commencement of ETF in the ICU: The time to commencement of ETF 
was defined as the period of time from admission to the ICU to when the participant 
was commenced on enteral nutrition. The time to commencement of ETF in the ICU 
was calculated by subtracting the ETF start date and time from the date and time of 
ICU admission. International clinical practice guidelines recommend that critically ill 
patients be commenced on enteral nutrition within 24–48 hours of admission to the 
ICU (Heyland et al., 2003b; Kreymann et al., 2006; Martin et al., 2004; McClave et 
al., 2009; NICE, 2006). Enteral tube-feeding commencement and cessation were 
scored continuously as the date and time of commencement and cessation of enteral 
nutrition. Enteral tube feeding commencement was measured in two ways which 
included 1) ETF commenced within 24 hours of ICU admission and this was scored 
as a dichotomous variable; and 2) the exact time (in hours) to ETF commencement, 
which was scored as a continuous variable. 
Bowel activity: Bowel activity was defined as the participant passing or not passing 
a bowel motion during the data collection period of their ICU admission. The date 
and time of the initial bowel activity was noted. The time to bowel activity was 
identified as the period of time between the participant’s admission to the ICU and 
the passing of their first bowel motion during the data collection period of their 
critical illness experience. A delay to initial bowel activity has been associated with 
diarrhoea in critically ill patients (Flynn, Makic, & Carlson, 2009; Thorson et al., 
2008; Whelan et al., 2009). The time to initial bowel activity was calculated by 
subtracting the date and time of initial bowel activity from the date and time of ICU 
admission. The frequency, number, consistency and volume of stools was also 
collected. Bowel activity was scored as a dichotomous variable and as bowels 
opened or did not open. Bowel activity was also scored continuously as the number 
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of events, the consistency and the volume of faecal stool. The time delay from ICU 
admission to initial bowel activity was scored continuously as the time measured in 
hours from ICU admission until the study participant’s bowels opened. 
Bowel regimen: The bowel regimen was defined as practices implemented to 
manage the participants’ bowel activity during their critical illness. Bowel care of 
critically ill ETF patients requires daily review of the patient’s bowel function and 
the adjuvant administration of gastrointestinal promotility medications. The research 
site used an evidence-based bowel care regimen (see Appendix 5). Currently, there is 
a paucity of evidence regarding bowel care regimens, diarrhoea and enteral nutrition 
in critically ill patients (Bankhead et al., 2009; Doig et al., 2004; Heyland et al., 
2003a, 2003b; Kreymann et al., 2006; McClave et al., 2009). A causal relationship 
between promotility and prokinetic medications and diarrhoea has been previously 
identified (Dorman et al., 2004; McPeake et al., 2011). For each medication, the drug 
name, dose, frequency and duration were recorded. Medications were scored as 
dichotomous variables, that is, the medication was administered or not administered 
to study participants. Medications were also scored continuously as the number of 
days over which study participants received the medications. 
Medications: The following variables describe the aperients, prokinetics, stress ulcer 
prophylaxis, sedation, neuromuscular blockade and antibiotic medications 
administered to the study sample and include: 
 Aperients: defined as the administration of laxative medications for the 
purpose of softening and loosening stools to prevent and treat constipation. 
 Aperient combinations: identified as the patient having received more than 
one aperient for the purpose of softening and loosening stools to prevent and 
treat constipation. 
 Prokinetics: medications administered to participants for the purpose of 
stimulating gastrointestinal motility to prevent and/or treat constipation. 
 Prokinetic combinations: identified as the patient having received more than 
one prokinetic medication for the purpose of stimulating gastrointestinal 
motility to prevent and/or treat constipation. 
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 Stress ulcer prophylaxis: defined as H2 receptor antagonists or PPI 
medications administered to participants for the purpose of treating and/or 
preventing stress ulcer mucosal damage. 
 Sedation: defined as the administration of opioid and nonopioid medications 
for the purpose of medically inducing a state of depressed consciousness with 
or without participant rousability. 
 Neuromuscular blockade medications: defined as medications administered 
for the purpose of muscle paralysis to facilitate medical and nursing cares. 
 Antibiotics: medications administered to study participants for the treatment 
of an active infection or the prophylactic treatment of infection. 
 Antibiotic combinations: identified as the patient having received more than 
one antibiotic medication for the treatment of an active infection or the 
prophylactic treatment of infection. 
The drug, dose, frequency and duration of all of the above medications were 
recorded. These variables were recorded dichotomously as the study participant 
received or did not receive these medications during the data collection period of 
their critical illness experience. Further, these variables were also scored and 
analysed as continuous variables as the number of days over which the study 
participant received these medications during the data collection period of their 
critical illness experience. Sedation, neuromuscular blockade medications and some 
antibiotics have been causally associated as a diarrhoea risk factor in critical illness 
(Landzinsky et al., 2008; Martin, 2007). 
Clinical indicators (hypoalbuminaemia, hyperglycaemia, elevated WCC, 
elevated INR): These variables describe clinical indicators experienced by the study 
participants and enable generalisation to the broader ICU population. Normal 
reference ranges were used to define these serum values. These variables included: 
 Hypoalbuminaemia: defined as the serum albumin less than 30g/L. 
Hypoalbuminaemia has been demonstrated to be associated with a reduction 
in colloidal osmotic pressure resulting in intestinal mucosal oedema and 
diarrhoea (Marshall & West, 2004; Whelan et al., 2001). 
 Hyperglycaemia: defined as the serum glucose levels greater than 8.0mmol/L. 
Similar to hypoalbuminaemia, hyperglycaemia is often present during critical 
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illness. The relationship between hyperglycaemia, gastric motor function and 
diarrhoea in critically ill patients remains unclear. 
 Elevated WCC: defined as the serum WCC greater than 4.0–11.0 x 109/L. The 
majority of evidence examines antibiotic administration, diarrhoea and 
intestinal microflora relationships rather than elevated WCC, therefore, the 
relationship between elevated WCC, diarrhoea, ETF and aerobic intestinal 
microflora in critically ill patients remains unknown. 
 Elevated INR: defined as the serum INR values greater than 0.9–1.2. Changes 
in INR values occur in response to inflammation and organ system disruption 
and are serum markers routinely investigated at the research site. No research 
to date has examined the relationships between diarrhoea, enteral nutrition, 
aerobic intestinal microflora and critical illness. 
Clinical indicators were scored as the participant having experienced an occurrence 
of a clinical indicator or not. Further, the duration of clinical indicators were scored 
as the number of days on which a participant experienced at least one event of a 
clinical indicator. All serum blood assay values were recorded as continuous 
variables. Invasive catheters or lines of various types are a common source of 
infection in critical illness and were recorded as dichotomous variables, that is, the 
study participant did or did not have an invasive catheter in situ and the catheter was 
or was not replaced or removed. Microbial investigations were recorded as 
dichotomous variables, that is, the study participant did or did not have the collection 
of a microbial investigation. These variables were also score semiquantitatively 
(continuously) as absent, scant, 1+, 2+ and 3+ (Winn et al., 2006). 
Infection screen (blood culture, sputum sample, urine tests): Participants who 
developed a new febrile illness were investigated for the development of a clinical 
infection. Infection was identified as elevated WCC (> 4.0–11.0 109/L), temperature 
(≥38.5˚C or ≤32.0˚C), an INR (>0.9–1.2 IU) and the co-administration of antibiotics. 
Patients who experience an infection are more likely to receive antibiotics, have 
higher severity of illness scores and are more likely to experience a longer ICU 
admission (Beyersmann et al., 2006; Garnacho-Montero et al., 2003). For this reason 
infection may be associated with the critically ill ETF patient developing diarrhoea 
and experiencing an imbalance in their aerobic intestinal microflora (Ukleja, 2010). 
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At the time this research was conducted, the research site routinely collected the 
following specimens when a study participant was suspected of developing an 
infection: 
 Blood cultures: defined as a microbiological culture of blood to examine the 
presence of bacteria or fungi and were scored semiquantitatively at the genus 
level as absent, scant, 1+, 2+ and 3+ (Winn et al., 2006). 
 Sputum specimen: defined as sputum collected to examine for the presence of 
bacteria or fungi within the respiratory tract as the causative agent for an 
infection and were scored semiquantitatively at the genus level as absent, 
scant, 1+, 2+ and 3+ (Winn et al., 2006). 
 Urine specimen: defined as urine collected to examine for the presence of 
bacteria or fungi within the urinary system as the causative agent for an 
infection and were scored semiquantitatively at the genus level as absent, 
scant, 1+, 2+ and 3+ (Winn et al., 2006). 
Multiresistant organism surveillance: Multiresistant organisms are bacteria 
resistant to the effects of multiple antibiotics (Centre for Healthcare Related Infection 
Surveillance and Protection [CHRISP], 2008). Surveillance of multiresistant 
organisms is necessary to monitor multiresistant infection in ‘at risk’ populations, 
such as critically ill ICU patients. Routine multiresistant organism screening at the 
research site was conducted twice weekly and included nose, groin and rectal swabs 
and urine and sputum specimens. Multiresistant organism colonisation was identified 
at the genus level and scored semiquantitatively at the genus level as absent, scant, 
1+, 2+ and 3+ (Winn et al., 2006). 
3.7 Data collection instrument 
A study specific data collection instrument containing eight key sections was 
developed by the researcher for Study One (see Appendix 1). Section A contains 25 
items addressing the patient’s demographic data ranging from date of birth, hospital 
and ICU admission and discharge dates, some clinical background data and 
APACHE II scores and diagnoses. Section B contains 11 items addressing enteral 
nutrition data. Section C addresses rates of enteral nutrition delivery and GRV, 
which were collected four-hourly and on a daily basis on days one to 14. Section D 
contains eight items addressing the patient’s bowel activity and medication 
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administration. Sections E and F addressed items associated with the patient’s 
clinical indices, including daily arterial blood gases and blood tests. Section G 
collected information associated with invasive lines and Section H collected 
information pertaining to the patient’s microbial investigations. Sections D to H 
collected data on a daily basis. 
The Bristol Stool Form Scale is a validated 7-point faecal score that describes faecal 
stools and assesses and combines faecal stool characteristics into one quantifiable 
value (see Table 3.1) (Lewis & Heaton, 1997; O’Donnell et al., 1990; Pares et al., 
2009). This faecal stool measurement tool is widely used within the clinical 
healthcare setting and also by individuals in the community setting; thereby, making 
this tool suitable for both research and clinical use and therefore, this study. 
Table 3.1  
Bristol Stool Form Scoring Scale 
Score Description 
1 Separate hard lumps like nuts 
2 Sausage shaped but lumpy 
3 Like a sausage or snake but with cracks on its surface 
4 Like a sausage or snake, smooth and soft 
5 Soft blobs with clear cut edges 
6 Fluffy pieces with ragged edges, a mushy stool 
7 Watery, no solid pieces 
Source: O’Donnell et al., (1990) 
The instrument for Study Two (see Appendix 2) was the same as Study One with the 
addition of three sections (I, J and K) and minor changes to Sections A and D. 
Section A contained 23 items addressing demographic data. Section D included 
items covering medication administration (H2 receptor antagonists and PPI 
medications) and was collected daily. These medications alter gastric motor function, 
thereby contribute to diarrhoea (MacLaren, Fish, & Wischmeyer, 2008; Toney & 
Agrawal, 2008). Sections I, J and K contained items addressing the microbiology 
results of rectal swabs and faecal specimens. 
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3.8 Study procedures 
3.8.1 General study procedures 
Departmental managers gave approval for this research to be undertaken. Following 
ethical approval, access to medical records for Study One was negotiated directly 
with the Department of Medical Records. In Study Two, the researcher negotiated a 
study protocol commencement date with the Nurse Unit Manager, the Director of 
Intensive Care Medicine and the Director of Microbiology at the study site. 
For both Study One and Study Two, all patients who met the inclusion criteria were 
recorded on a screening log (see Appendix 6) and then on an enrolment log and 
assigned a study number if no exclusion criteria were identified (see Appendices 7 
and 8). For Study Two, informed consent was obtained from either the patient or the 
patients’ substitute decision-maker prior to assignment of a study number and 
recording of enrolment on the enrolment log. The ICU’s APACHE II database was 
used to screen for eligible patients, that is, patients whose ICU LOS was greater than 
five days for Study One and two days for Study Two. Patients excluded from 
recruitment eligibility were recorded as ineligible using the exclusion criteria coding 
located on the screening logs (see Appendix 6). Data were collected as per the study 
protocol for eligibility. 
Study One and Study Two procedures will now be reported separately. 
3.8.1.1 Study One 
In Study One, data were collected retrospectively and at one point in time via chart 
audit following the patient’s discharge from the ICU, therefore it was not appropriate 
to educate nurses regarding the use of a faecal output measurement tool. Data were 
collected using a data collection tool (see Appendix 1) for each day of the patient’s 
ICU admission to a maximum of 14 days into the patient’s critical illness experience 
or discharge from the ICU, whichever occurred first. Patient information outlined in 
Sections 3.6 and 3.7 (pp. 62 and 71) were collected from the electronic patient 
information systems including CareVue (real-time electronic charting management 
system), Hospital-Based Corporate Information System (HBCIS) (patient 
demographic data management system) and AUSLAB (clinical laboratory interface 
system). Laboratory data including routine blood tests and multiresistant organism 
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surveillance were collected from the primary laboratory information management 
system (AUSLAB). All data were collected by the researcher. Missing data were 
cross-checked between the patient’s observation chart, medication and fluid balance 
charts, primary laboratory data sources and the patient’s medical record. 
3.8.1.2 Study Two 
Prior to the commencement of Study Two the study protocol was disseminated to 
registered nurses (RNs) in the ICU using the following strategies: 
 All RNs were provided with a staff information sheet outlining the study 
protocol (see Appendix 9). Education sessions during the routine nurse 
education forums were provided and included the study protocol, consent 
process, definition of diarrhoea and the procedures required to collect rectal 
swabs and faecal specimens. The aim of this intense nursing education was to 
ensure compliance with rectal swab and faecal stool identification and 
collection. 
 The study protocol (see Appendix 10), Participant Information Sheet (see 
Appendix 11) and Staff Information Sheets (see Appendix 9) were circulated 
on the ICU’s intranet. 
 The study protocol (see Appendix 10), associated study protocol procedures 
(see Appendix 9) and participant recruitment updates were presented at 
routine nursing staff meetings, circulated in the ICU monthly newsletter and 
emailed to staff monthly. 
 Patients recruited into the study were identified on the nursing staff handover 
form to facilitate continuity of the study’s protocol after normal business 
hours. 
 All new RNs who commenced working in the ICU following the 
commencement of the study protocol for Study Two were educated regarding 
the study and the study’s procedures during their orientation to the ICU. 
 Potential participants were discussed with the ICU medical consultants on a 
daily basis prior to approaching the patient or the patient’s substitute 
decision-maker. This was to minimise the potential for dual consent of 
potential participants into this study and other clinical trials occurring within 
the ICU. 
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Patients were informed and recruited to the study by the researcher and the site’s 
research nurse and clinical trials coordinator. The site’s research nurse and clinical 
trials coordinator were educated regarding the study protocol and method for consent 
and provided with a resource folder containing the study protocol, staff information 
sheets, staff education tools and Participant Information Sheet and Consent Forms. 
Daily telephone contact was made with the site’s research nurse and clinical trials 
coordinator when the researcher was located off-campus from the research site. 
Education of laboratory staff at the research site was also conducted. Specimen 
processing procedures were established in consultation with the Director of 
Microbiology and laboratory staff prior to the commencement of Study Two. 
Laboratory staff were contacted daily via email, telephone or personal contact 
regarding participant recruitment and study protocol specimen collection. This 
intense education was to promote homogeneity of clinical practice and specimen 
processing in adherence with the study protocol. All specimens were processed, 
cultured, analysed and reported on by the same two scientists. 
The researcher attended the ICU five to seven days per week between 0900 and 2000 
hours from September 2008 to November 2009 to facilitate continuity of the study 
protocol implementation, undertake participant recruitment and communicate daily 
with the Department of Microbiology regarding the collection of rectal swabs and/or 
faecal specimens according to the study protocol and to collect data. This ensured 
that all potential study participants were screened for eligibility to participate in the 
study, contact was made with the patient or the patient’s substitute decision-maker 
and regular communication was maintained with the ICU nursing and medical staff 
and the Department of Microbiology staff. 
Following commencement of Study Two, the researcher, or the study site’s research 
nurse or clinical trials coordinator, screened all ICU patients daily for study protocol 
eligibility. Patient eligibility was screened using the ICU’s daily patient 
admission/discharge diary and CareVue or ICIP. The daily diary is a one day-to-a-
page yearly diary where all patient admissions and discharges into and out of the 
ICU are recorded. The patient’s name, medical record number, admission date/time, 
location prior to ICU admission and discharge date/time and location are recorded in 
the daily diary. Eligible patients were then screened for exclusion criteria. Patients 
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excluded from recruitment eligibility were recorded as ineligible using the exclusion 
criteria coding located on the screening los (see Appendix 6). A new screening log 
was maintained each calendar month. Screening logs were password protected to 
maintain patient confidentiality. Patients were not de-identified on the screening log 
due to password encryption. 
The RN caring for the potential study participant was then approached and informed 
that the patient met the study’s inclusion criteria. The RN was asked to discuss the 
study with the patient and/or the patient’s substitute decision-maker at a suitable 
time. If additional information was requested or a willingness to participate in the 
study was demonstrated, the RN was asked to page the researcher, the research nurse 
or the clinical trials coordinator to discuss consent with either the patient or the 
patient’s substitute decision-maker. The researcher, research nurse or the clinical 
trials coordinator introduced themselves to the patient and/or the patient’s substitute 
decision-maker and discussed the Participant Information Sheet (see Appendix 11) 
prior to consent being provided. Where possible, Study Two was discussed with the 
patient. 
Following patient consent, an entry was made in the patient’s electronic medical 
record noting consent to participate in the study, the name of the person providing 
consent and the relationship to the patient of the third party providing consent to 
participate in the study. The patient or the patient’s substitute decision-maker was 
provided a copy of the Participant Information and Consent and Withdrawal forms. 
The patient’s routine daily care list was updated so that nursing staff were aware of 
the study requirements for the shift. In addition, a note was entered onto the ICU 
nursing handover form to inform staff that the patient was participating in the study. 
The RN caring for the patient was informed of the patient’s consent into the study 
and the study protocol requirements. Following consent, the patient’s participant 
study number was recorded in a password-protected enrolment log (see Appendix 8) 
to ensure patient confidentiality. To facilitate continuity of specimen processing and 
culturing techniques the laboratory staff in the Department of Microbiology were 
notified daily of any newly consented study participants and additional specimens 
collected during the previous 24 hours. 
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Data were collected daily up to day 14 of the patient’s ICU admission or to discharge 
from the ICU, whichever occurred first. All study participants received routine ICU 
cares (see Appendix 10): the collection of sociodemographic data, the provision of 
enteral nutrition ICU treatments, including monitoring tolerance to ETF through 
regular aspiration of GRVs and monitoring of bowel activity and diarrhoea, the 
provision of ICU medication treatments (GIT promotility medications, sedation, 
antibiotics and other medications) and the collection of routine clinical indices and 
other investigations (routine blood tests, invasive catheters, microbial investigations 
and multiresistant organism screening). In addition, study participants had a rectal 
swab collected within 48 hours of ICU admission and following informed consent, 
second daily faecal tests to a maximum of 14 days into the patient’s ICU admission if 
diarrhoea developed and a rectal swab was collected prior to the patient’s discharge 
from the ICU (see Appendix 10). Data were collected only by the researcher. Patient 
information outlined in Sections 3.6 and 3.7 (see pp. 62 and 71) were collected from 
the electronic patient information systems including CareVue and/or ICIP, HBCIS 
and AUSLAB. The data collection tool was piloted on the first five patients for 
relevant diarrhoea risk factors. No changes to the data collection tool were required. 
The bowel care regimen used at the research site incorporates the elements of 
intestinal motility and feed tolerance, including promotility medications (see 
Appendix 5). Critically ill patients who commenced ETF in the research site’s ICU 
were routinely prescribed a bowel care regimen to promote gastrointestinal motility, 
feed tolerance and thereby promote intestinal motility homeostasis (see Appendix 5). 
Nutritional assessment of individual patients by RNs, dieticians or screening tools 
was not routinely undertaken at the research site’s ICU. Rather, nutritional 
requirements were met via a standardised enteral nutrition feeding protocol that was 
adapted from the Australia and New Zealand Intensive Care Society (ANZICS) 
evidence-based ICU feeding algorithm (see Appendix 4). 
A study protocol pack was placed at the study participant’s bedside. Each protocol 
pack consisted of: (a) a single cotton tip admission to ICU rectal swab, pathology 
request form and specimen collection bag; (b) a faecal specimen container, pathology 
request form and specimen collection bag; (c) a single cotton tip discharge from ICU 
rectal swab, pathology request form and specimen collection bag; and (d) a study 
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protocol check list. The RN caring for the study participant was requested to collect 
the admission to ICU rectal swab upon the patient’s next repositioning with the 
patient lying in the left lateral position and to also inform the patient of the collection 
of this swab prior to this procedure. The swab was then labelled as per the ICU’s 
usual specimen labelling procedures and forwarded to the Department of 
Microbiology for processing. 
Study participants were observed for signs of diarrhoea each shift by the RN caring 
for the participant. A faecal specimen was collected every two days to a maximum of 
14 days into the participant’s ICU admission if diarrhoea developed. All specimens 
were labelled as per the ICU’s usual specimen labelling procedures and forwarded to 
the Department of Microbiology for processing. 
Study participants were screened daily for potential discharge from the ICU. If the 
participant was to be discharged from the ICU, the RN caring for the participant was 
approached to collect the rectal swab prior to this event. The RN was requested to 
collect the rectal swab with the patient lying in the left lateral position and also to 
inform the patient of the collection of this swab prior this procedure. The swab was 
labelled as per the ICU’s usual specimen labelling procedures and forwarded to the 
Department of Microbiology for processing. 
3.8.2 Laboratory procedures 
Continuity of specimen plating and interpretation of specimen results for the Study 
Two rectal swabs and faecal specimens was managed by the allocation of one senior 
and one junior scientist by the Director of the Department of Microbiology at the 
research site. 
The following procedures were used in the Department of Microbiology at the study 
site for the microbiological processing, analysis and interpretation of rectal swabs 
and faecal specimens for Study Two: 
 Upon receipt of rectal swabs to the Department of Microbiology, the rectal 
swab was inoculated in trypticase soy broth (TSB). 
 One drop of the inoculated broth was placed onto the following agar plates to 
identify normal faecal flora at the genus level: 
 Horse blood agar plate (HBA) 
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 Colistin nalidixic agar plate (CNA) 
 MacConkey plate (MAC) 
 MacConkey plate with gentamicin tablet (MACG) 
 Xylose lysine desoxycholape (XLD) (salmonella, shigella) 
 VRE was cultured on a VRE agar half plate 
 MRSA was cultured on a MRSA Chromagar half plate 
 Candida was cultured on a Candida Chromagar half plate 
 Chromagar Orientation. 
 1 mL of inoculated TSB was placed into a microfuge tube and placed in a 
–80 ˚C freezer. 
 The first 10 rectal swabs had the remainder of the TSB frozen at –80 ˚C. This 
was to validate that freezing did not compromise the samples. 
 Normal faecal flora was semiquantified, that is, absent (no colonisation), 
scant (very little colonisation), 1+ (small colonisation), 2+ (moderate 
colonisation) and 3+ (large or heavy colonisation). A modified Bartlett’s 
grading system was used for semiquantitative counts of normal faecal flora 
(Winn et al., 2006). 
 Normal faecal flora was visually identified at the genus level. Normal faecal 
flora were cultured as: 
 Lactose fermenters (LF) 
 Non-lactose fermenters (NLF) 
 Pseudomonas sp. (NLF) 
 Streptococci (beta or alpha haemolysis) 
 Staphylococci (aureus or coagulase negative) 
 Enterococcus sp. 
 Multiresistant organisms were cultured on multiresistant Staphylococcus 
aureus (MRSA) Chromagar plate, a MacConkey gentamicin agar plate and a 
Vancomycin resistant Enterococcus (VRE) agar plate. 
 Yeasts were cultured on a Candida Chromagar plate and identified visually. 
The procedure for reporting study specimens was as follows: 
Normal faecal flora 3+ (LF ?E.coli, LF ?Klebsiella sp, 2+ Enterococcus sp and 2+ 
coagulase negative Staphylococci). 
80 
A large number of specimens were expected to be generated from Study Two. Prior 
to the commencement of Study Two, the researcher liaised with the Director of the 
Department of Microbiology at the research site regarding the impact of these 
specimens on staff workloads. To manage this situation, the reliability and validity of 
freezing and thawing specimens was tested using the culturing techniques listed 
above. The first five participants had their admission and discharge rectal swabs 
tested, then frozen at −80 ˚C, thawed and retested. The study’s microbiological 
culturing procedures presented above were used in this test–retest validity test. If 
little or no change to bacterial strain virology was identified, then all rectal swabs 
were to be frozen at −80 ˚C. The specimen culture plates were interpreted by the 
microbiology staff appointed to this study. The results of this analysis were 
communicated with the Director of the Department of Microbiology. General 
agreement was that there was little difference between the two culturing methods, 
therefore, the freezing/thawing culturing approach was adopted by Study Two. 
3.9 Data management 
For Study One and Study Two all data were collected by the researcher to maintain 
consistency and minimise interrater error. Data were entered, summarised and 
analysed using the SPSS version 18 (v18). All data were also entered by the 
researcher to minimise potential data entry error. Data cleaning processes were 
followed to identify extreme or outlier information, duplicates or unfeasible data. All 
data were manually reviewed for error, missing or erroneous data and checked by 
running descriptive checks using SPSS. These were then cross-checked against the 
raw field data collection tool and the patients’ medical record. 
3.10 Data analysis 
3.10.1 Statistical assumptions 
The underlying a priori statistical assumptions were examined before performing 
statistical analysis. Statistical significance was reported at the widely used 
convention p ≤ .05 (two-tailed) (Field, 2009; Polit & Beck, 2008). 
Normality of the continuous variables distribution scores were tested using the 
Kolmogorov-Smirnov statistic. A Kolmogorov-Smirnov statistic less than p = .05 
indicated normality of data distribution. A p > .05 violated the assumption of 
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normality. This may often be seen spuriously in larger sample sizes of greater than 
30 study participants (Field, 2009; Pallant, 2011). Where tests of normality were 
violated or not met, nonparametric statistical tests were applied. 
3.10.2 Descriptive statistics 
Descriptive statistics were used to describe the samples of the two studies. The 
means and standard deviations for continuous variables and the count and 
percentages for dichotomous or categorical (nominal) data were calculated. Data 
described using descriptive statistics include patient demographic data; bowel 
function characteristics (the incident rate of diarrhoea); as well as ICU treatments 
that included ETF (formula, duration of ETF), medications (the number of events 
and the duration of intestinal promotility medications, sedation, neuromuscular 
blockade, antibiotic and other medications) and aerobic intestinal microflora strains 
and counts. Frequencies of all variables were scrutinised to determine the distribution 
of the data. 
3.10.3 Univariate and bivariate statistics 
Relationships between categorical independent variables and categorical dependent 
variables were explored using the chi-square test for independence. Relationships 
between continuous variables were examined using correlation statistics. The 
assumptions underlying the statistical techniques used to examine continuous 
variables include variables that must be measured at the interval or ratio level except 
when there is one dichotomous (two values) independent variable and one 
continuous variable (Field, 2009; Pallant, 2011; Polit & Beck, 2008). Where the 
underlying assumptions of parametric analyses were violated or not met, then an 
alternative nonparametric test such as the Spearman’s Rho correlation coefficient, 
Mann–Whitney U test, chi-square test for independence, Kruskal-Wallis test or the 
Wilcoxon Signed Rank test were used (Field, 2009; Pallant, 2011; Polit & Beck, 
2008). 
Univariate and bivariate correlations were assessed using the Pearson product–
moment correlation statistic to describe the strength and direction of the relationship 
between the two variables. The assumptions underlying this statistical test include 
that the variables are measured at the continuous level; however, a dichotomous 
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variable consisting of only two values may be incorporated into correlation statistics 
(Pallant, 2011). Further, the observations must be independent of one another, the 
distributions scores must be normally distributed, linear relationships between the 
two variables are paramount and the homoscedasticity of variables must be equal 
(Field, 2009; Pallant, 2011; Polit & Beck, 2008). General relationships between 
demographic variables and other key variables (diarrhoea, ETF and clinical 
indicators) were assessed using the Pearson’s product–moment correlation 
coefficient for normally distributed continuous variables and the Spearman’s Rho 
correlation coefficient for continuous variables not normally distributed. 
The mean differences of normally distributed continuous data and two different 
groups were analysed using an independent sample t test. This test examines the 
probability that the two scores originated from the same population. The assumptions 
underlying the independent sample t test include that the dependent variable must be 
measured at the interval or ratio level (continuous variable), each observation or 
measurement must be independent of each other and the samples are obtained from 
populations of equal variance (Field, 2009; Pallant, 2011). The Mann–Whitney U 
test was used to examine the relationships between continuous variables that were 
not normally distributed (the incident rate of diarrhoea and the duration of ETF) and 
a range of dichotomous variables associated with diarrhoea (gender, time to ETF 
commencement, common medications and clinical indicators) (Field, 2009; Pallant, 
2011; Polit & Beck, 2008). 
A one-way between-groups ANOVA test was used to test the significance of 
difference in means scores of the dependent continuous variable across one 
categorical group consisting of three or more categories. The assumptions underlying 
this statistical test include that the independent variable is measured at the interval or 
ratio level (continuous variable), observations are to be independent of one another, 
distribution scores are normally distributed and the variability of scores between the 
groups is similar (Field, 2009; Pallant, 2011; Polit & Beck, 2008). The Kruskal–
Wallis test was used for continuous variables that were not normally distributed, for 
example the the incidence rate of diarrhoea and the ETF formulae. 
Repeated measures data were collected on the same participants at different time 
points in this study. Repeated measures data were analysed using the paired samples 
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t test for normally distributed continuous variables. The paired samples t test 
examined the data for a statistically significant difference in the mean scores between 
Time 1 and Time 2 (Field, 2009; Pallant, 2011). In this study, these two time points 
were (a) the rectal swab collected at admission to and discharge from the ICU, (b) 
rectal swab collected at ICU admission with the first three faecal samples, (c) the 
first faecal sample and faecal samples two and three, and (d) the first three faecal 
samples and the rectal swab collected at discharge from the ICU. The assumptions 
underlying the paired samples t test include the dependent variable must be measured 
at the interval or ratio level (continuous variable), each observation or measurement 
must be independent of each other and the samples are obtained from populations of 
equal variance (Field, 2009; Pallant, 2011). Where data were not normally 
distributed, the Wilcoxon Signed Rank test was used. 
Univariate regression modelling was used to examine the interrelationships between 
common diarrhoea risk factors associated with critical illness in Study One and Two. 
The relationships in univariate regression modelling determined the shared variation 
between the dependent continuous variables (the incident rate of diarrhoea) and 
several key continuous independent variables (duration of ETF, medication 
administration and clinical indicators) (Field, 2009; Pallant, 2011). Variables that 
were found to be statistically significant were then incorporated into forced 
multivariate regression models and generalised estimating equation (GEE) models. 
3.10.4 Multivariate statistics 
Generalised estimating equation (GEE) modelling was used to analyse the within and 
between subject variation across repeated measures in this study. This model 
provides a sound statistical method of capturing variably repeated measures data 
within longitudinal studies that cannot be explained by using a repeated measures 
ANOVA test (Field, 2009; Fitzmaurice, Laird, & Ware, 2004; Pallant, 2011). 
Assumptions underlying the GEE modelling include data that is clustered due to the 
repeated measures of the variable within the same individual, data are not required to 
be normally distributed and data can be measured as either categorical or continuous 
data (Ghisletta & Spini, 2004; Liu et al., 2009). Importantly, GEE modelling enables 
variation within and between data collection time points while considering this data 
available for analysis and not as missing data (Ghisletta & Spini, 2004; Liu et al., 
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2009). The GEE modelling allows for missing data both within and between 
subjects. As stated previously, there were no missing data for each individual patient. 
However, in this study there were a variable number of repeated measures for each 
participant; for example, diarrhoea (the incident rate of diarrhoea), the duration of 
enrolment (two to 14 days or discharge from the ICU, whichever occurred first) 
when rectal swabs were collected, ETF, medication administration and clinical 
indicators. The variability between each individual participant’s data may be 
interpreted in traditional statistical models as missing data which, if included, may 
falsely reject the null hypothesis. 
3.11 Ethical considerations 
Ethics approval was obtained from the university and the ICU research site’s Human 
Research Ethics Committees (HREC) prior to the commencement of Study One and 
Study Two (see Appendices 12, 13 and 14). A number of ethical issues were 
considered for the conduct of this study and these are outlined in the following 
section. 
3.11.1 Consent and participant information 
Ethical approval to conduct this study was granted by the university and the research 
site’s HREC and further written consent was not required to conduct Study One as 
per the NHMRC National Statement on Ethical Conduct in Research Involving 
Humans (1999) section 1.11. 
In Study Two, informed and written consent was obtained from or on behalf of all 
study participants. All patients and/or the patient’s substitute decision-maker were 
informed that they could withdraw participation from Study Two at any point in time 
without fear or threat or comment to the care that the patient and the patient’s 
substitute decision-maker were receiving. Patients and/or the patients’ substitute 
decision-makers were provided the opportunity to discuss the patient’s participation 
in the study with other family members if requested. Written consent was provided 
by the patient or the patient’s substitute decision-maker and witnessed by the 
researcher and one other person who was independent to Study Two. Copies of the 
Participant Information Sheet, signed consent form and withdrawal to participate 
from the study form were provided to the individual who gave written consent (see 
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Appendix 11). No patient or patient’s substitute decision-maker withdrew consent to 
participate in Study Two. 
If a patient retained residual effects of sedative medication, they were informed that 
the substitute decision-maker would be required to provide informed consent. The 
patient was asked if they agreed to the researcher discussing the study protocol with 
their substitute decision-maker who would then provide informed consent. The 
residual effects of sedative medication were guided by expert opinion and the 
patient’s physiological condition. Elements of the patient’s physiological condition 
were considered, including liver and renal function. Impaired liver and/or renal 
function may reduce the clearance times of sedation and therefore increase the 
duration of their residual effects (Skidmore-Roth, 2012). Consequently, these may 
affect the patient’s level of consciousness and ability to provide legally informed 
consent. 
3.11.2 Anonymity and confidentiality 
Study One and Study Two implemented strategies to protect the privacy of 
participants. Participant privacy and data security were maintained by: (a) de-
identification of participant information using a numerical code on the participant’s 
data collection tool; (b) storage of the screening log of participants in a locked filing 
cupboard at the research site; (c) access to participant information only being 
available to the researcher; (d) password protection of study-associated electronic 
screening and enrolment logs, with only the researcher and the research site’s 
research nurse and clinical trials coordinator being aware of the password code; (e) 
no significant relationship evident between the data and the participant’s welfare; (f) 
absence of commercial exploitation of participant information; and (g) no intent of 
the research to expose participant engagement in illegal activity. 
All data collected for both Study One and Study Two remained de-identified. An 
electronic master copy of the monthly screening logs and enrolment logs was 
maintained using password encryption which was maintained separately from the 
patient data pool. The monthly screening and enrolment logs were accessible only to 
the researcher for Study One and also the research site’s research nurse and clinical 
trials coordinator for Study Two. Only the researcher and the research site’s research 
nurse and clinical trials coordinator were privy to this password. Study participants’ 
86 
signed consent forms for Study Two were stored in a folder separated from data 
collection tools and kept in a locked filing cupboard for the conduct of Study Two. 
Study participants were de-identified to a study participation number on their data 
collection tool for both Study One and Study Two. Data collection tools were and 
will continue to be stored in a locked filing cupboard that is accessible only to the 
researcher for five years following publication of results. Data storage is maintained 
in conjunction with NHMRC data storage guidelines (NHMRC, 2007). Patient data 
was reported in aggregate form only in any publication and conference presentations. 
3.11.3 Risks 
The following risk management strategies were applied in Study Two: 
 Any participant with a known allergy to the enteral nutritional formulae 
administered as routine cares throughout the course of this study was unable 
to participate. 
 Nursing staff were educated to collect the rectal swab on admission to and 
discharge from ICU with the patient positioned in the left lateral position. The 
purpose of positioning the patient in this way is to follow the normal 
anatomical position of the sigmoid colon, therefore, potentially minimising 
rectal and colon trauma. 
 There were no identified risks to study participants regarding the collection of 
faecal specimens. The majority of ICU patients are incontinent of faeces, 
therefore, the collection of faecal specimens occurred in conjunction with the 
study participant’s personal hygiene cares. 
 Nursing staff were advised to use universal precautions for the collection of 
study protocol associated specimens including rectal swabs and faecal 
specimens. 
 In addition to the ongoing support of the researcher and the unit’s clinical 
leaders, counselling support will be available to those individuals who request 
additional support. 
3.12 Summary 
Quantitative examination of diarrhoea and associated relationships, including enteral 
nutrition and aerobic intestinal microflora, has been inadequately conducted in the 
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context of critical illness. The use of a realist and positivist method of enquiry as a 
research framework enabled these phenomena to be explored and observed in their 
natural environment. This chapter has presented the assumptions and methodological 
approaches used to conduct this exploratory research. Presented were the study’s 
research setting, design, sampling framework, procedures and the analytical plan 
used to examine the findings of this study. This was followed by a discussion of the 
ethical considerations of this study including consent, anonymity, confidentiality and 
risks to both study participants and nursing staff. The methodology used in Study 
Two expanded and extended the research protocol and study findings identified from 
Study One, the retrospective clinical chart audit. The paucity of knowledge of 
diarrhoea, enteral nutrition and aerobic intestinal microflora relationships in critically 
ill patients will be answered following the application of the analytical plan outlined 
in this chapter. The next chapter, Chapter Four, will present and describe the results 
of Study One in the context of critical illness and relevant literature. 
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CHAPTER FOUR: STUDY ONE RESULTS: RETROSPECTIVE 
AUDIT 
4.1 Introduction 
This chapter presents the findings of Study One including the sample characteristics 
and the characteristics of the ICU patient with diarrhoea: the occurrence of diarrhoea, 
the number of events and the duration of diarrhoea, the incidence rate of diarrhoea, 
the time to commencement and duration of ETF and the occurrence and duration of 
GIT medication administration. The chapter also presents results of analyses to 
examine associations between diarrhoea, enteral nutrition and selected clinical 
indicators. The results of Study One are presented under the headings of the four 
research questions. This chapter will conclude with a discussion of the key findings 
of Study One. 
4.2 Characteristics of Patients Audited 
Medical records for a sample of 50 patients who met the inclusion criteria were 
audited over five months (May 2006 to January 2007). The flow of patients in Study 
One is described in the modified Consort flow chart (Moher et al., 2010; Schulz, 
Altman, & Moher, 2010) (see Figure 4.1). The 50 patients were admitted to the ICU 
for a total of 644 patient admission days (ranging from 5 to 83 days). Sample 
characteristics of Study One are presented in Tables 4.1 and 4.2 respectively. Just 
over half of participants were male (n = 27, 54%). The higher APACHE II scores 
suggest that patients were acutely and critically ill on admission to the ICU (see 
Table 4.1). 
Due to the low number (less than 10) of patients with some variables (medications 
and clinical indicators), caution is required when interpreting the results of Study 
One. Study One collected data to a maximum range of 14 days; however, patients 
may have received medications and/or experienced clinical indicator derangement 
beyond this time point. Patients who were admitted to the ICU for a longer period of 
time and who were ETF for a longer period of time may have been more likely to 
experience diarrhoea as the patient was monitored over more observation days. The 
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limitations of these study design features need to be considered when interpreting the 
study findings and will be discussed in depth in Chapter Seven.  
 
 
 
 
 
 
 
 
 
Figure 4.1. Modified Consort flow chart of Study One research process. 
 
Table 4.1  
Sample Characteristics of Study One (n = 50) 
Variable 
Number (n) Percent (%) Median Range 
Gender 
 Male 
 Female 
 
27 
23 
 
54 
46 
- - 
Admission by body system disorder   
 Respiratory 8 16 - - 
 Neurologic 15 30 - - 
 Gastrointestinal 1 2 - - 
 Renal 1 2 - - 
 Spinal 2 4 - - 
 Cardiovascular 5 10 - - 
 Multiple trauma 11 22 - - 
 Sepsis 2 4 - - 
 Vascular 4 8   
 Metabolic 1 2   
Age (years) - - 53
*
 19–88* 
Actual ICU LOS (days)
*
 - - 9
*
 5–83* 
APACHE II score
*
 - - 12
*
 1–29* 
Number of observation days per 
patient
*
 
- - 11
*
 5–14* 
Note. - = Statistic not reported since it is not appropriate for this variable; *Data rounded to whole 
numbers for continuously scored variables.  
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Eligibility to participate assessed  
(n = 901) 
Study participants excluded (no ETF, 
ETF >48 hours post ICU admission, 
burns/hepatic failure, inter-hospital 
transfer, ICU LOS <5 days) (n = 851) 
Study participants audited (n = 50) 
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4.2.1 Enteral nutrition 
The characteristics of ETF and the duration of ETF administered to patients 
following admission to the ICU are presented in Table 4.2. All study participants 
received full-strength enteral feed formula. In total, patients were ETF over 449 
patient admission days. 
Table 4.2  
Enteral Nutrition Characteristics of Study One (n = 50) 
Variable Number (n) Percent (%) Median Range 
Enteral nutrition by type 
  
 Jevity Plus 37 74 - - 
 Jevity 6 12 - - 
 Nepro 7 14 - - 
Time to ETF commence following ICU admission 
  
 < 24 hour 29 58 - - 
 24–48 hour 17 34 - - 
 > 48 hour  4 8 - - 
ETF formula changed during ICU admission 
  
 2 x ETF formulae changes 9 18 - - 
 3 x ETF formulae changes 1 2 - - 
 4 x ETF formulae changes 1 2 - - 
 ETF ceased in ICU 27 54 - - 
 Time to start ETF (hour)
* - - 20* 2–86*† 
 ETF duration (days)
* - - 9* 3–14*† 
Note. - = Statistic not reported since it is not appropriate for this variable; *Data rounded to 
whole numbers for continuously scored variables. †Maximum data collection was14 days. 
4.2.2 Medications 
The majority of the sample examined in Study One received aperient, prokinetic, 
sedation, neuromuscular blockade and antibiotic medications (see Table 4.3).  
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Table 4.3  
Medications Administered and Observed Days of Medication Administration (n = 50) 
 Number of Patients who 
received the medication 
Number of observed 
days of medication 
administration 
Medications administered Number (n) Percent (%) Median Range 
Aperients 42 84 9
*
 0–12*† 
 Coloxyl/Senna 39 78 6
*
 0–12*† 
 Bisacodyl supp†† 32 64 0
*
 0–10*† 
 Lactulose 24 48 0
*
 0–9*† 
 Glycerine supp†† 6 12 0
*
 0–3*† 
 Microlax 5 10 - - 
 Other 1 2 - - 
Prokinetics 42 84 7
*
 0–14*† 
 Maxalon 41 82 6
*
 0–14*† 
 Erythromycin 21 42 0
*
 0–10*† 
Sedation and opioids†††     
 Sedation 44 88 11
*
 0–14*† 
 Opioid 48 96 7
*
 0–14*† 
 Morphine 37 74 4
*
 0–14*† 
 Fentanyl 30 60 3
*
 0–14*† 
 Midazloam 44 88 4
*
 0–14*† 
Neuromuscular blocker     
 Vecuronium 31 62 1
*
 0–12*† 
Antibiotic (AB) combinations 46 92 11
*
 0–14*† 
Number of AB     
 One AB 46 92 4
*
 0–13*† 
 Two AB 39 78 3
*
 0–13*† 
 Three AB 25 50 1
*
 0–10*† 
 Four AB 14 28 0
*
 0–7*† 
 Five AB 5 10 - - 
 Six AB 1 2 - - 
 Seven AB 1 2 - - 
Note. - =  Data not reported for small sample size ≤10 patients; *Data rounded to whole 
numbers for continuously scored variables; †Maximum data collection was14 days; †Supp = 
suppository; ††Sedation = medication co-administration, for example, opioid/midazolam, 
morphine/fentanyl. 
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4.2.3 Clinical indicators 
The majority of the sample experienced hyperglycaemia, hypoalbuminaemia, 
elevated WCC, elevated INR and infection (see Table 4.4). Hypoglycaemia and 
multiresistant infection were rare events (10 or less) and no analyses were made 
using these clinical indicators (see Table 4.4). 
Table 4.4  
Clinical Indicators Experienced (n = 50) 
 Number of patients who 
experienced clinical indicators 
Number of observed 
days of clinical 
indicator derangement 
Clinical indicators Number (n) Percent (%) Median Range 
Hypoglycaemia 3 6 - - 
Hyperglycaemia 46 92 4
*
 0–10*† 
Hypoalbuminaemia 47 94 7
*
 0–14*† 
Elevated WCC 47 94 6
*
 0–14*† 
Elevated INR 40 80 3
*
 0–14*† 
Infection 33 66 - - 
Multiresistant infection 5 10 - - 
Note.  - = Data not reported for small sample size ≤10 patients or dichotomous scored 
variable; *Data rounded to whole numbers for continuously scored variables; †Maximum 
data collection was 14 days. 
4.3 Research Question 1 
What is the period prevalence of diarrhoea in ETF patients in the ICU? 
The majority of patients experienced bowel activity during their ICU admission (see 
Table 4.5). The characteristics of the patients’ bowel function and diarrhoea are 
presented in Table 4.5. The period prevalence of diarrhoea in Study One was 78% (n 
= 39). The number of events of diarrhoea per patient ranged from 0 to 8 events each 
day, with the cumulative number of events of diarrhoea per patient ranging from 0 to 
29 events (Mdn = 5). The aggregate number of diarrhoea events was 326, which were 
observed over 120 patient admission days. The cumulative incidence rate of 
diarrhoea was 0.64 events per patient observation day, with the individual patient 
incidence rate of diarrhoea ranging from 0 to 2.90 events per patient observation day 
(see Table 4.5). 
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Table 4.5 
Bowel Activity Characteristics of Study One (n = 50) 
Bowel activity Number 
(n) 
Percent 
(%) 
Median Range 
Bowel activity occurred   - - 
 Males 24/27 89 - - 
 Females 22/23 96 - - 
Time to initial bowel activity (hour)
*
 - - 114
*
 5–206* 
Diarrhoea   - - 
 Males 23/27 85 - - 
 Females 16/23 70 - - 
 Number of diarrhoea events
*
 - - 5
*
 0–29* 
 Diarrhoea duration (days)
*
 - - 2
*
 0–10* 
 Diarrhoea incidence rate per 
 patient observation day
*
 
- - 0.42 0–2.90 
Note. - = Statistic not reported since it is not appropriate for this variable; *Data rounded to 
whole numbers for continuously scored variables (time to initial bowel activity and diarrhoea 
duration). 
Characteristics of the four patients who experienced no bowel activity during their 
ICU admission are presented in Table 4.6. Three patients were male (n = 3) and one 
patient was female (n = 1). Two of the patients who had no bowel activity developed 
a non-multiresistant infection and the other two developed a multiresistant infection 
during the data collection period. All of these patients received antibiotics during the 
data collection period. 
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Table 4.6  
Characteristics of Patients Who Experienced no Bowel Activity during Study One (n = 4) 
Variable Median Range 
Age (years) 46
*
 22–66* 
Actual ICU LOS (days) 6
*
 5–8* 
Time to start ETF (hour) 32
*
 8–36* 
Duration of ETF (days) 6
*
 3–7* 
Duration no bowel activity (hour) 139
*
 122–192* 
Aperients duration (days) 3
*
 0–16* 
Prokinetics duration (days) 2
*
 0–5* 
Antibiotic duration (days) 8
*
 2–16* 
Sedation duration (days) 8
*
 6–13* 
Note.*Data rounded to whole numbers for continuously scored variables. 
4.4 Research Question 2 
Is there a relationship between the number of events of diarrhoea and the duration of 
diarrhoea in ETF critically ill patients? 
Analyses were conducted using the Spearman’s r correlation coefficient to examine 
the association between the number of events of diarrhoea and the duration of 
diarrhoea in ETF critically ill patients. A statistically significant and positive 
correlation was identified between the number of events of diarrhoea and the 
duration of diarrhoea (Spearman’s r = 0.93, p < .001). As would be expected, this 
finding suggests that patients who are observed to experience diarrhoea over a longer 
period of time are also more likely to experience more events of diarrhoea. The 
occurrence of diarrhoea and the incidence rate of diarrhoea will now be examined 
within the context of diarrhoea and associated risk factors. 
4.5 Research Question 3 
Are clinical indicators such as hypoalbuminaemia, hypoglycaemia, elevated WCC, 
elevated INR and infection associated with diarrhoea in this study? 
Bivariate (Chi-squared) analyses were made to determine the association between the 
occurrence of diarrhoea and a range of clinical indicators and are presented in Table 
4.7. There was a statistically significant association between the occurrence of 
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diarrhoea and the occurrence of hypoalbuminaemia and also between the occurrence 
of diarrhoea and the occurrence of an infection (see Table 4.7). Study participants 
who developed hypoalbuminaemia or an infection during their ICU admission were 
more likely to have an event of diarrhoea recorded during that admission. No other 
statistically significant associations were identified in these analyses, suggesting that 
the occurrence of diarrhoea was not associated with the occurrence of the remaining 
clinical indicators including hyperglycaemia, elevated WCC and elevated INR. 
Table 4.7  
Association Between Diarrhoea Occurrence and Clinical Indicator Occurrence (n = 50) 
Clinical indicator occurrence Continuity Correction χ21 p value 
Hyperglycaemia 0.00 1.00 
Hypoalbuminaemia 6.99 0.008* 
Elevated WCC 0.00 1.00 
Elevated INR 1.23 0.27 
Infection 7.34 0.007* 
Note. 
*
Statistical significance at p (two-tailed) < .05. 
Further bivariate analyses to examine the association between the incidence rate of 
diarrhoea and the occurrence of clinical indicators are presented in Table 4.8. There 
was a statistically significant association between the incidence rate of diarrhoea and 
the occurrence of hypoalbuminaemia, and the incidence rate of diarrhoea and the 
occurrence of an infection. In both cases a higher incidence rate of diarrhoea was 
associated with the presence of these clinical indicators (see Table 4.8). No 
significant difference was found between the incidence rate of diarrhoea and the 
occurrence of other clinical indicators including hyperglycaemia, elevated WCC and 
elevated INR. 
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Table 4.8  
Incidence Rate of Diarrhoea by Clinical Indicator Occurrence Associations (n = 50) 
Clinical indicator 
occurrence 
z p value Median incidence 
rate of diarrhoea 
with clinical 
indicator 
Median incidence 
rate of diarrhoea 
without clinical 
indicator 
Hyperglycaemia - 0.43 .67 .43 .30 
Hypoalbuminaemia - 2.40 .02
*
 .43 .00 
Elevated WCC - 0.35 .73 .42 .64 
Elevated INR - 1.90 .06 .50 .13 
Infection - 2.30 .02
*
 .50 .17 
Note. 
*
Statistical significance at p (two-tailed) < 0.05. 
Analyses using GEE modelling were conducted to examine individual clustered 
patient variance between the occurrence of diarrhoea, the occurrence of clinical 
indicators and the duration of ETF (see Table 4.9). A statistically significant 
association was identified between the occurrence of diarrhoea, the occurrence of 
clinical indicators including infection, hyperglycaemia, hypoalbuminaemia and 
elevated WCC and the duration of ETF (see Table 4.9). The GEE analysis identified 
that critically ill patients who were ETF for a longer period of time were more likely 
to experience an occurrence of diarrhoea when an occurrence of these clinical 
indicator derangements were experienced. 
Table 4.9  
Multivariate Associations Between Diarrhoea Occurrence, Clinical Indicator Occurrence 
and Control for ETF Duration (n = 50) 
Clinical indicator 
occurrence 
Estimated 
coefficient 
95% confidence 
interval 
p value 
Infection .07 .04 – .10 < .001* 
Hyperglycaemia  .06 .03 – .09 < .001* 
Hypoalbuminaemia .06 .03 – .09 < .001* 
Elevated WCC  .06 .03 – .09 < .001* 
Note. 
*
Statistical significance at p (two-tailed) < .05. 
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Separate analyses were conducted using the Spearman’s r correlation coefficient to 
examine the association between the incidence rate of diarrhoea and the number of 
days of clinical indicator derangement for a range of clinical indicators (see Table 
4.10). A statistically significant association was observed between the incidence rate 
of diarrhoea and the number of days of hyperglycaemia, hypoalbuminaemia and 
elevated INR with a higher incidence rate of diarrhoea associated with more days of 
clinical indicator derangement (see Table 4.10). These findings might be associated 
with the duration of participant observation. No significant difference was found 
between the incidence rate of diarrhoea and the duration of elevated WCC (see Table 
4.10). 
Table 4.10  
Association Between the Incidence Rate of Diarrhoea and the Number of Days of Clinical 
Indicator Derangement (n = 50) 
Number of days of clinical indicator 
derangement 
Spearman’s r p value 
Hyperglycaemia .29 .04* 
Hypoalbuminaemia .31 .03* 
Elevated WCC .20 .18 
Elevated INR .30 .04* 
Note.
*
Statistical significance at p (two-tailed) < .05. 
4.6 Research Question 4 
Is diarrhoea in ETF patients associated with: 
 The type of ETF formulae? 
Analyses were conducted using the Kruskal-Wallis test to examine the association 
between the incidence rate of diarrhoea and the type of ETF formula (see Table 
4.11). No statistically significant differences were identified between the incidence 
rate of diarrhoea and the three types of ETF formula (see Table 4.11). Although no 
statistically significant result was observed, of particular note was that Nepro 
formulae had a higher median incidence rate of diarrhoea (Mdn = 0.92) when 
compared with the other two formulae of Jevity and Jevity Plus (see Table 4.11). 
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However, the low number of participants receiving Jevity and Nepro formulae 
suggests that these results should be considered with caution. 
Table 4.11  
Incidence Rate of Diarrhoea and ETF Formula (n = 50) 
ETF formula Number of 
participants receiving 
formula 
H(2) p value Median 
diarrhoea 
incidence 
rate 
  3.73 .16  
Jevity Plus 37   .43 
Jevity 6   .25 
Nepro 7   .92 
Note. 
*
Statistical significance at p (two-tailed) < .05; H(2) = two degrees of freedom. 
 The time to commencement of ETF following ICU admission? 
The association between the occurrence of diarrhoea and the time to ETF 
commencement was examined using the Mann-Whitney U test. No statistically 
significant difference was identified between those patients who developed diarrhoea 
and those patients who did not develop diarrhoea and the time to ETF 
commencement (z = -1.07, p = .29). 
Analyses were also conducted using the Mann-Whitney U test to examine the 
association between the incidence rate of diarrhoea and the timing to ETF 
commencement. Due to the low numbers of people who commenced ETF more than 
48 hours following ICU admission, the categories of ETF commenced within 24–48 
hours and more than 48 hours following ICU admission were pooled into ETF 
commenced more than 24 hours following ICU admission. No statistically significant 
difference was observed between the incidence rate of diarrhoea and ETF 
commenced < 24 hours (Mdn = .5, n = 29) and ETF commenced > 24 hours (Mdn = 
.2, n = 21) following ICU admission (z = - 1.34, p = .18). 
Further analyses using the Spearman’s r correlation coefficient were conducted to 
examine the association between the incidence rate of diarrhoea and the time to ETF 
commencement (time in exact hours). No statistically significant difference was 
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observed between the incidence rate of diarrhoea and the time to ETF 
commencement (Spearman’s r = - 0.12, p = .42).  
 The duration of ETF? 
The association between the occurrence of diarrhoea and the duration of ETF were 
examined using the Mann-Whitney U test. A statistically significant difference was 
identified between those patients who developed diarrhoea (Mdn = 11.0, n = 39) and 
those patients who did not develop diarrhoea (Mdn = 6.0, n = 11) and the duration of 
ETF (z = -3.73, p = < .001). 
Analyses were also conducted using the Spearman’s r correlation coefficient to 
examine the association between the incidence rate of diarrhoea and the duration of 
ETF. A statistically significant association (Spearman’s r = 0.39, p = .006) was 
identified, suggesting that those participants who were ETF for a longer period of 
time experienced a higher incidence rate of diarrhoea. 
 Gender, age, Study ICU LOS and APACHE II scores? 
Analyses were conducted to examine the association between the occurrence of 
diarrhoea and gender. The Chi-square test for independence suggested that diarrhoea 
was not associated with gender (Continuity Correction χ2 = 0.97, p = .32). Further, 
the association between the occurrence of diarrhoea and age, Study ICU LOS and 
severity of illness (APACHE II score) were examined using the Mann-Whitney U 
test. There was a statistically significant association between Study ICU LOS and the 
occurrence of diarrhoea (see Table 4.12) suggesting that patients who were admitted 
to the ICU for a longer period of time were more likely to experience an occurrence 
of diarrhoea. Apart from the findings for Study ICU LOS, no significant associations 
were identified between the occurrence of diarrhoea and other demographic or 
clinical variables (see Table 4.12). 
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Table 4.12  
Diarrhoea Occurrence by Age, Study ICU LOS and Severity of Illness (n = 50) 
Diarrhoea 
occurrence 
z p value Median age, Study 
ICU LOS, 
APACHE II score 
with the 
occurrence of 
diarrhoea 
Median age, Study 
ICU LOS, APACHE 
II score without the 
occurrence of 
diarrhoea 
Age (years) - 0.13 .90 53.0 52.0 
Study ICU LOS 
(days) 
- 3.81 < .001
*
 12.0 7.0 
APACHE II score - 0.22 .82 11.0 13.0 
Note. 
*
Statistical significance at p (two-tailed) < 0.05. 
Analyses were also conducted to examine the association between the incidence rate 
of diarrhoea and gender. The Mann-Whitney U test identified that there was no 
association between the incidence rate of diarrhoea and gender (z = - 1.32, p = .19). 
Analyses were also conducted using the Spearman’s r correlation coefficient to 
examine the association between the incidence rate of diarrhoea and age, Study ICU 
LOS and APACHE II scores (see Table 4.13). There was a statistically significant 
association identified between the incidence rate of diarrhoea and the Study ICU 
LOS (Spearman’s r = 0.44, p = < .002) (see Table 4.13) with those patients admitted 
for a longer period more likely to have a higher incidence rate of diarrhoea. No other 
statistically significant associations were identified between the incidence rate of 
diarrhoea and the patient’s age and APACHE II scores. 
Table 4.13  
Association Between the Incidence Rate of Diarrhoea and Age, Study ICU LOS and Severity 
of Illness (n = 50) 
Patient characteristic Spearman’s r p value 
Age (years) .12 .93 
Study ICU LOS (days) .44 .002
*
 
APACHE II score .14 .35 
Note. 
*
Statistical significance at p (two-tailed) < .05. 
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 The duration of aperient, prokinetic, sedation, neuromuscular blockade 
and antibiotic medication administration? 
Analyses were conducted to examine the association between the incidence rate of 
diarrhoea and medication administration (see Table 4.14). The association between 
the incidence rate of diarrhoea and dichotomously scored medications were 
examined using the Mann-Whitney U test (see Table 4.14). In addition, analyses 
using the Spearman’s r correlation coefficient were used to examine the association 
between two continuous variables: the incidence rate of diarrhoea and the duration of 
medication administration (see Table 4.14).  
The significant associations arising from these analyses suggest that patients are 
more likely to experience a higher incidence rate of diarrhoea when the duration of 
antibiotic administration is longer and when combinations of three antibiotics are 
administered to ETF critically ill patients (see Table 4.14). There was also a 
statistically significant association between the incidence rate of diarrhoea and the 
longer duration of antibiotic administration as well as the longer duration of 
combinations of three antibiotics being administered to ETF critically ill patients (see 
Table 4.14). No other statistically significant associations were identified between 
the incidence rate of diarrhoea, the administration of medications and the number of 
days of medication administration during the data collection period. 
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Table 4.14  
Incidence Rate of Diarrhoea by Medications Administered (n = 50) 
 
Number of 
patients 
Medications administered Number of 
days of 
medication 
administration 
   Mann-Whitney U test Spearman’s r 
 (n) (%) z p Median 
incidence rate 
of diarrhoea 
with 
medication 
Median 
incidence rate 
of diarrhoea 
without 
medication 
r p 
Aperients 42 84 - 0.72 .47 0.39 0.50 - 0.95 .51 
Coloxyl/Senna 39 78 - 1.79 .07 0.31 0.77 - 0.22 .88 
Bisacodyl supp 32 64 - 0.35 .72 0.42 0.32 0.01 .96 
Lactulose 24 48 - 0.90 .37 0.59 0.33 0.13 .36 
Glycerine supp 6 12 - - - - - - 
Microlax enema 5 10 - - - - - - 
Other 1 2 - - - - - - 
Prokinetics 42 84 - 1.17 .24 0.36 0.81 0.20 .89 
Metoclopramide 41 82 - 1.54 .12 0.31 0.86 0.12 .90 
Erythromycin 21 42 - 1.62 .11 0.60 0.30 0.25 .09 
Sedation 44 88 - 1.39 .16 0.43 0.10 0.67 .65 
Opioids 48 96 - 0.10 .32 0.43 0.18 0.25 .08 
Morphine 37 74 - 0.98 .33 0.46 0.24 0.04 .77 
Fentanyl 30 60 - 1.01 .31 0.52 0.32 0.24 .09 
Midazolam 44 88 - 1.88 .61 0.46 0.10 0.14 .34 
Neuromuscular blocker         
Vecuronium 31 62 - 0.74 .46 0.43 0.20 0.18 .22 
Antibiotic (AB) 
combinations 
46 92 - 1.30 .20 0.43 0.08 0.36 .01
*
 
Number of AB         
One AB 46 92 - 1.30 .20 0.43 0.08 0.08 .56 
Two AB 39 78 - 1.78 .08 0.50 0.17 0.01 .94 
Three AB 25 50 - 2.22 .03* 0.64 0.29 0.32 .03* 
Four AB 14 28 - 1.82 .07 0.64 0.30 0.23 .12 
Five AB 5 10 - - - - - - 
Six AB 1 2 - - - - - - 
Seven AB 1 2 - - - - - - 
Note.  - = Data not reported for small sample size ≤10 patients; *Statistical significance at p 
(two-tailed) < .05. 
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4.7 Study One Discussion 
The present study was designed to examine diarrhoea incidence and associated 
diarrhoea risk factors in ETF, emergency admission, critically ill adult patients in a 
single-centre ICU. A number of research questions and hypotheses were tested in 
accordance with the aims of Study One. The conceptual framework (see Figure 2.1, 
page 10) underpinning this study will be used to guide the interpretation of results of 
Study One. In this section, the central study construct of diarrhoea in the ICU setting 
and the associations between diarrhoea and ETF will be discussed. This will be 
followed by a discussion of the characteristics of the Study One sample with regard 
to enteral nutrition, medication administration and clinical indicators. The conceptual 
framework (see Figure 2.1, page 10) that underpins this study will be used to guide 
the interpretation of the results. 
4.7.1 Sample Characteristics 
Critically ill patient participants comprised a diverse group in Study One with regard 
to age, gender, presenting diagnoses (respiratory, cardiovascular and multiple 
trauma), actual ICU LOS and severity of illness (APACHE II score, Mdn = 12, range 
1–29) (see Figure 2.1, page 10). The heterogeneity of the critically ill patient cohort 
included in Study One broadly reflects characteristics of those adult patients admitted 
to other Level III tertiary ICUs in Australia (ANZICS CORE Report, 2011; Btaiche 
et al., 2010). The age (Mdn = 53 years, range 19–88 years) of patients included in 
Study One also broadly reflects that of other Australian Level III tertiary ICUs 
(ANZICS CORE Report, 2011; Btaiche et al., 2010). The majority of patients in the 
sample were male (n = 27, 54%) and this is also consistent with the national 
ANZICS dataset (ANZICS CORE Report, 2011). 
Patients were admitted to the ICU for a median of 9 days (range 5–83 days) in Study 
One. It is not surprising that number of patients admitted to the Level III tertiary ICU 
resulted in an overrepresentation of patients who were acutely ill and who had higher 
severity of illness scores compared with either a Level I or Level II ICU. It is not 
uncommon for more acutely ill patients to be admitted to the public sector for the 
management of critical illness, such as trauma and emergency health care, compared 
with the private sector. Therefore, patients admitted to the research setting’s ICU 
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experienced higher severity of illness scores with a diverse array of admission 
diagnoses. 
4.7.2 Diarrhoea and Critical Illness 
Diarrhoea was examined as the period prevalence, the occurrence and the incidence 
rate of diarrhoea in Study One. The period prevalence (78%) in Study One is 
consistent with that reported in other studies: 2% to 95% (Ferrie & East, 2007; 
Whelan, Judd, & Taylor, 2004, Whelan et al., 2009). Two explanations for the high 
incidence of diarrhoea reported in Study One compared to other studies in the field 
are proposed. First, the diarrhoea definition used in Study One differs to diarrhoea 
definitions used in similar research with regard to the quantity, frequency and weight 
of loose or liquid stools (Bliss, 1992; Ferrie & East, 2007; Whelan et al., 2009). 
Contemporary clinical practice applies diarrhoea definitions that use parameters 
including faecal consistency, frequency and volume/weight (Lewis & Heaton, 1997; 
Nguyen, Ching et al., 2008; Thomas et al., 2003; Thorson et al., 2008). Discussion 
continues within the clinical practice and research paradigms with regard to the 
parameters used to define diarrhoea, for example, the number of stools and the 
volume/weight of stools per 24-hour period. Incorporated within these definitions of 
diarrhoea are stool frequency (>3 stools/day, >4 stools per day), stool consistency 
(loose, liquid, watery), stool weight (>200 g/day, >250 g/day, >300 g/day for 2 days) 
and combinations of these diarrhoea characteristics (>2 liquid stools/day, >200 g 
liquid stool/day) (Eisenberg, 2002; Lebak et al., 2003; Martin, 2007; Pancorbo-
Hidalgo et al., 2001). For the purpose of this study, diarrhoea was defined using 
frequently cited diarrhoea defining characteristics as ‘the abnormal passage of loose 
or liquid stools more than three times daily and/or a volume of stool greater than 200 
g/day’ (Thomas et al., 2003). 
The second explanation is that diarrhoea in critically ill patients is indeed associated 
with multiple risk factors such as severity of illness, enteral nutrition (ETF formulae, 
methods of administration), a variety of medications (antibiotics, intestinal 
promotility, sedation and neuromuscular blockade medications) (Bersten, 2010; 
Bourgoin et al., 2005; Figgis & Bihari, 2010; Heaviside & Hayes, 2010; Marshall, 
2010; Rivers et al., 2001) and a derangement of some clinical indicators (Sturgess & 
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Morgan, 2009). Enteral nutrition has previously been identified as a risk factor for 
diarrhoea in critically ill patients (Luft et al., 2008; Thorson et al., 2008). 
To date, there is limited research that has examined the association between the 
number of events of diarrhoea and the duration of diarrhoea and the incidence rate of 
diarrhoea in ETF, emergency admission critically ill adult patients. Current research 
typically focuses on the number of events of diarrhoea and associated diarrhoea risk 
factors and not the incidence rate of diarrhoea that takes into account the number of 
events of diarrhoea over a period of time. Clinically, patients who experience 
frequency of diarrhoea over a longer period of time are at increased risk of secondary 
complications, such as perianal skin breakdown, wound contamination and infection 
(Whelan et al., 2004, 2009) and fluid and electrolyte imbalance (Garey et al., 2006; 
Halmos et al., 2010; Martin, 2007). The current study examined the association 
between the incidence rate of diarrhoea and commonly known diarrhoea risk factors 
in the ETF, emergency admission critically ill adult patient. A positive and 
significant association was observed in this study between the number of events of 
diarrhoea and the duration of diarrhoea, suggesting that patients who experience 
more events of diarrhoea were also more likely to experience diarrhoea for a longer 
timeframe. 
Central to this research is the conceptual framework (see Figure 2.1, page 10) that 
guided Study One. The findings reaffirm the association between the number of 
events of diarrhoea and the duration of diarrhoea in ETF critically ill patients 
identified in the conceptual framework. This association could be explained by the 
number of days of observation. While this study contributes to the ongoing 
development of knowledge of diarrhoea and associated risk factors further research 
with a larger sample size is required to clarify and explore this complex relationship. 
4.7.3 Diarrhoea Risk Factors 
Commonly known diarrhoea risk factors including patient characteristics and ICU 
treatments (ETF, medications and clinical indicators) were associated with the 
occurrence and incidence rate of diarrhoea in Study One. This is evidenced by the 
green circle (patient characteristics) and the pink circles (ETF and medications) in 
the conceptual framework (see Figure 2.1, page 10). 
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4.7.3.1 Patient characteristics 
Both the occurrence and incidence rate of diarrhoea were associated with only one 
commonly known patient characteristic at the group level: the Study ICU LOS. One 
explanation for this association is that patients admitted and/or observed in the ICU 
for a longer period of time are more likely to receive ETF, antibiotics and other 
medications and other ICU treatments over a longer period of time. Consequently, 
the patient’s potential to develop diarrhoea is increased (Halmos et al., 2010). It is 
acknowledged, however, that the longer ICU stay suggests that patients can be 
observed and monitored for a longer period of time, thereby increasing the likelihood 
that diarrhoea will be observed. 
It is important to note that there are some differences between findings from Study 
One and the literature with regard to the association between diarrhoea and some 
diarrhoea risk factors. Several non-Clostridium difficile-associated diarrhoea risk 
factors have been identified in other studies and include severity of illness (APACHE 
II scores), longer ICU LOS, infection, bolus ETF, previous total parenteral nutrition 
administration, hypoalbuminaemia, fever and hypothermia (Btaiche et al., 2010; 
Thorson et al., 2008). A notable finding of this study was the absence of a 
statistically significant association between the patient’s age, gender, APACHE II 
score and diarrhoea. Severity of illness has previously been associated with diarrhoea 
in critically ill patients (Thorson et al., 2008; Whelan et al., 2004, 2005; Whelan, 
Judd, & Taylor, 2004). Three explanations are proposed to explain the absence of 
statistically significant findings with regard to these common diarrhoea risk factors. 
First, the lack of significant association might be connected with the smaller sample 
size that could have been insufficient to detect significant links. Caution should be 
applied when interpreting these results for this reason. Second, the data were audited 
and collected retrospectively and therefore registered nurses’ assessment and 
documentation practices could not be controlled. Consequently, the reliability of 
clinical records cannot be assured and caution is required when interpreting and 
generalising results to the broad ICU patient population and contemporary literature 
(Btaiche et al., 2010; Ferrie & East, 2007; Horn & Chaboyer, 2003; Thorson et al., 
2008). Third, it is possible that an association between diarrhoea and these common 
risk factors just does not exist. 
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4.7.3.2 Enteral tube-feeding 
The continuous infusion of ETF formulae via the nasogastric or orogastric routes was 
the method of ETF used in this study. Enteral nutritional formula was administered 
continuously over a 24-hour period as this method of tube-feeding is the most 
common method of enteral nutrition delivery in the critical care setting (ESICM 
Systematic Review Group, 2011; Skipper, 2012). 
Enteral tube feeds were prepared and maintained as per the research setting’s ETF 
protocol (see Appendix 4). In this study, the ETF formula was delivered via a closed 
sterile system and the ETF formula and administration flow sets were changed every 
24 hours. All patients were fed via continuous infusion. Diarrhoea associated with 
bolus feeding was therefore expected to be minimised in this study. Gastric residual 
volumes (GRVs) were routinely aspirated to assess patient tolerance to ETF. Gastric 
residual volumes greater than 200 mL were discarded. There is currently no 
agreement regarding the accepted level of GRVs for the monitoring of ETF tolerance 
in critically ill patients (Johnson, 2009; Kattelman, Hise, Russell, Charney, Stokes, & 
Compher, 2006; McClave et al., 2009). The discarding of high GRVs at the research 
setting is consistent with other published reports (Hurt & McClave, 2010; 
Landzinski, Kiser, Fish, Wischmeyer, & MacLaren, 2008; Williams & Leslie, 2005, 
2010). The cleaning of medication injection ports with alcohol-based solution prior 
to the injection of medications was not routinely practiced at the research setting. 
This practice could potentially result in the patient developing infectious diarrhoea. 
There is currently no recommendation in international ETF clinical practice 
guidelines to clean medication injection ports with alcohol-based solution prior to the 
injection of medications (Bankhead et al., 2009; Heyland et al., 2003; Kreymann et 
al., 2006; Martin et al., 2004; McClave et al., 2009; NICE, 2006). However, 
disinfection of connection sites with isopropyl alcohol following manipulation of 
feed sets is suggested by Bankhead et al. (2009) as a strategy to minimise the 
introduction of feed set contamination. Of particular note is that no patient included 
in Study One developed infectious diarrhoea. 
Nearly half of all patients audited in Study One were discharged to the ward with 
ETF insitu. Continuation of ETF at discharge from the ICU to the ward suggests that 
patients may have remained acutely unwell. Currently, the continuation or cessation 
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of ETF at ICU discharge is based upon the individual patient’s clinical needs. 
International ETF clinical practice guidelines have examined the continuation and 
cessation of ETF at ICU discharge with some variability enabling clinical decisions 
to be based upon patient need. Further, patients who have ETF continued at and 
following ICU discharge are potentially at risk of developing or continuing to 
experience diarrhoea. This relationship was not observed in Study One and is 
unlikely to be observed as the majority of research that examines diarrhoea in ETF 
critically ill patients stops once the patient is discharged from the ICU. A more 
accurate identification of ICU-associated diarrhoea requires future research to 
follow-up patients post ICU and possibly post hospital discharge. 
4.7.3.3 Time to ETF commencement 
In the current study, the commencement of ETF was measured in two ways: 1) ETF 
commenced within 24 hours of ICU admission; and 2) the exact time to ETF 
commencement. International ETF clinical practice guidelines recommend that 
enteral nutrition be commenced within 24–48 hours of ICU admission (Heyland et 
al., 2003b; Kreymann et al., 2006; Martin et al., 2004; McClave et al., 2009; NICE, 
2006). Consistent with these international ETF guidelines, the majority of 
participants in Study One (n = 29, 58%,) had their ETF commenced within 24 hours 
of admission to the ICU, with the median time to commencement of ETF being 20 
hours (range 2–86 hours) (Heyland et al., 2003a; Mehta & Compher, 2009; Woo et 
al., 2010). A notable relationship that has not been consistently examined in previous 
research is the relationship between diarrhoea and the timing to commencement of 
ETF following ICU admission. No association was observed between the occurrence 
and incidence rate of diarrhoea and the time to commencement of ETF following 
ICU admission. One explanation for the absence of an association could be the 
smaller sample size, which may have been inadequate to detect a statistically 
significant difference. While this study contributes to the ongoing development of 
knowledge of ETF-associated diarrhoea in critical illness, further research is required 
to clarify and explore this complex relationship and affirm the associations within the 
conceptual framework (see Figure 2.1, page 10). 
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4.7.3.4 Duration of ETF 
In Study One, the median duration of ETF was 9 days (range 3–14 days). The later 
commencement and longer duration of ETF in Study One could be explained by the 
retrospective method of data collection and the minimum ICU LOS of five days. 
Often with prospective data collection, health care professionals are provided with 
information and education regarding the study protocol. The retrospective collection 
of data enabled researcher observation free of any intervention that could potentially 
change a clinician’s clinical practices. 
Through medical chart audit higher proportions of patients (61%) with diarrhoea 
have been reported in patients who are ETF for longer periods of time (greater than 
11 days) (Halmos et al., 2010). Current research examines the duration of ETF 
throughout the patient’s entire ICU stay compared with a period of time (Cahill et al., 
2011; Hise, Halterman, Gajewski, Parkhurst, Moncure, & Brown, 2007), for 
example, up to 14 days as seen in Study One. Of note within the current study was 
that the occurrence of diarrhoea and the incidence rate of diarrhoea were associated 
with the duration of ETF; thereby, supporting the association between the ICU 
patient with diarrhoea and ETF (commencement, duration, delivery and formula) in 
the conceptual framework (see Figure 2.1, page 10). The association between these 
variables might be explained by the longer period of data observation. Similar with 
the time to commencement of ETF following ICU admission, larger scale studies are 
required to further examine the association between the ICU patient with diarrhoea 
and time to ETF commencement as depicted in the conceptual framework (see 
Figure 2.1, page 10). 
4.7.3.5 ETF formula 
Patients in this study received standard polymeric enteral nutrition formulae (Jevity 
Plus, Jevity and Nepro) with the most common formulae being Jevity Plus (n = 37; 
74%). The administration of standard polymeric enteral feed formulae is consistent 
with international practice (Heyland et al., 2003a, 2003b; Mehta & Compher, 2009; 
Skipper, 2012; Woo et al., 2010). These formulae contain energy, protein, fibre and 
fructooligosacchaarides with Jevity Plus containing higher concentrations of these 
formula components (Skipper, 2012). The research site had implemented a standard 
ETF protocol (see Appendix 4) which avoided the use of disease-specific ETF 
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formulae (Chen & Peterson, 2009; Skipper, 2012). Although Jevity Plus and Jevity 
contain the same concentrations of fibre, they differ in that Jevity Plus contains 
higher concentrations of fat and also has a higher osmolality than Jevity formula 
(477mOsm/L versus 365mOsm/L) (Dieticians Association of Australia, 2011; 
Skipper, 2012). The use of enteral nutritional formulae containing lower 
concentrations of fibre, higher concentrations of fat and a higher osmolality (Jevity 
Plus) may partly explain the higher incidence rate of diarrhoea in this study, although 
statistical significance was not identified between diarrhoea and enteral nutritional 
formulae in this study (see Figure 2.1, page 10). This is because formulae with these 
characteristics (hyperosmolar liquid and calorie dense solutions) can lead to 
diarrhoea and particularly when the critically ill patient experiences intestinal 
dysfunction (Bleichner, Thomas, & Sollet, 1993; Luft et al., 2008). 
Interestingly, evidence on this point, that is, the association between diarrhoe and 
ETF formulae is contradictory. Some studies over the past 20 years (Bowling, 
Raimundo, Grimble, & Silk, 1994; Btaiche et al., 2010; Lloyd & Powell-Tuck, 2004; 
Pessola et al., 1990) identified that there was no association between diarrhoea and 
the type or osmolality of the ETF formulae. It is important to note that contemporary 
practice is based on the findings of evidence dating from 1987 to 1990. Isotonic ETF 
formulae are routinely used in the critical care setting as a first line attempt to 
minimise hyperosmolar diarrhoea in critically ill patients (Skipper, 2012). The 
absence of an association between ETF osmolality and diarrhoea in Study One is 
supported by Pessola et al. (1990) who demonstrated that the osmolality of ETF 
formulae did not increase the incidence of diarrhoea in healthy volunteers (n = 5) and 
ward (n = 10) and ICU patients (n = 24). Diarrhoea developed in only three ICU 
patients in the Pessola et al. study (1990) and these patients also had an average 
albumin level of 2.8 g/dL. This finding was not statistically significant (Pessola et al., 
1990). 
4.7.3.6 Medications 
The majority of patients included in Study One received aperient, prokinetic, 
sedation and antibiotic medications (see Figure 2.1, page 10). Just over half of these 
patients also received a neuromuscular blockade medication. These medications are 
routinely administered to critically ill patients for the purpose of intubation and 
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mechanical ventilation and other routine critical illness associated cares (see Figure 
2.1, page 10) (Cullis & Macnaughton, 2006; Lin et al., 2010; MacLaren, Kiser, Fish, 
& Wischmeyer, 2008; Taylor, Manara, & Brown, 2010; Toney & Agrawal, 2008). 
The median duration of administration of these medications was variable with a 
longer median duration of administration of some aperients, all prokinetics and some 
sedation, neuromuscular blockade and antibiotic medications (see Table 4.3). 
Although the association of these medications and diarrhoea have been previously 
examined, little is known about the association between these medications and 
diarrhoea, enteral nutrition and critical illness. In this study, a significant and positive 
association was identified between diarrhoea and combinations of three antibiotics 
only. This is consistent with previous research by Luft et al. (2008) but contradicts 
the research of Aseeri, Schroeder and Zackula (2008) who found no relationship 
between infectious diarrhoea and combinations of three or more antibiotics and also 
the duration of antibiotic administration. The findings of Study One support the 
association between the ICU patient with diarrhoea and medication administration 
presented within the conceptual framework (see Figure 2.1, page 10) in that an 
association exists between diarrhoea and medication (combinations of three 
antibiotics) administration. However, in light of the variable findings across previous 
research, more systemic research is required with a larger sample to understand the 
complex associations between diarrhoea and medication administration in ETF 
critically ill patients. 
4.7.3.7 Clinical indicators 
Clinical indicator derangement (hypoalbuminaemia, hyperglycaemia, elevated WCC, 
elevated INR, infection) was experienced by the majority of patients included in 
Study One (see Figure 2.1, page 10). Of these clinical indicators, no research has 
examined the association between elevated INR, diarrhoea and ETF in critically ill 
patients. Furthermore, the duration of clinical indicator derangement and the 
association between diarrhoea and ETF has not previously been reported in critically 
ill patients. Of the clinical indicator variables selected for investigation, only 
hypoalbuminaemia, hyperglycaemia, elevated INR and infection were significantly 
associated with the critically ill patient experiencing diarrhoea at the bivariate level. 
All clinical indicators were associated with the critically ill patient experiencing a 
higher incidence rate of diarrhoea when the clinical indicators were observed over 
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time. The results of Study One reaffirm previous reports that diarrhoea and clinical 
indicators (hypoalbuminaemia and infection) are associated with diarrhoea (Thorson 
et al., 2008; Whelan et al., 2004, 2005; Whelan, Judd, & Taylor, 2004). 
Infection as a risk factor for ICU-associated diarrhoea has been well established 
(Btaiche et al., 2010; Ehman et al., 2006; Ukleja, 2010; Whelan, Judd, Preedy, & 
Taylor, 2004). Infectious diarrhoea has previously been associated with bacteria such 
as Aeromonas hydrophilia, Salmonella and Shigella (Forbes, Sahm, & Weissfeld, 
2007; Winn et al., 2006). Aeromonas hydrophilia was observed in one patient in 
Study One and in only one of two faecal stool cultures. The stool cultures were 
collected on days four and seven of the patient’s ICU admission. Aeromonas spp 
infections have been associated with gastroenteritis in children, however, the 
correlation between these bacteria and infection remains unclear in the adult patient 
with diarrhoea. Consequently, caution regarding the causality of diarrhoea in this 
patient was applied (Forbes et al., 2007). There were no reports of infectious 
diarrhoea in this study, with no other infectious causes of diarrhoea (Clostridium 
difficile, Salmonella or Shigella) identified by stool microscopy (Forbes et al.; 2007). 
Although Study One reaffirms the significant association between infection and 
diarrhoea, caution must be exercised with regards to interpreting these associations 
as the presence of infection in critical illness may also be associated with higher 
severity of illness scores, antibiotic exposure and increased ICU LOS. 
Study One is the first study to examine individual patient differences between the 
occurrence of diarrhoea, the incidence rate of diarrhoea and the duration of clinical 
indicator derangement (hypoalbuminaemia, hyperglycaemia, elevated WCC, 
elevated INR) and the presence of an infection, in ETF, emergency admission 
critically ill adult patients. These differences have not been examined consistently in 
previous research (Bleichner et al., 1997; Thorson et al., 2008; Whelan et al., 2009). 
Without a considered examination of individual patient responses in critical illness, 
the adequate provision of care for the patient’s intestinal health may be 
compromised. Further research that is adequately powered to detect differences to 
examine individual patient responses associated with diarrhoea and critical illness is 
required. 
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Study One findings support current evidence in that diarrhoea in ETF critically ill 
patients is common and is indeed associated with many factors. The main results 
arising from Study One include a high period prevalence (78%) of diarrhoea and a 
high incidence rate of diarrhoea (0.64 diarrhoea events per patient observation day). 
Patients experienced more than one diarrhoea risk factor in that they: were ETF for a 
longer period of time; developed an infection, hyperglycaemia, hypoalbuminaemia, 
or elevated WCC; had a longer Study ICU LOS; and received combinations of three 
antibiotics. These associations were more likely to be observed the longer the patient 
remained in the ICU and was observed for diarrhoea risk factors. An important 
finding of Study One was that diarrhoea was not associated with the administration 
of most medications and also the duration of administration of most medications, 
except for combinations of three antibiotics; however, due to the limitations of the 
sample, retrospective collection of data and specific time constraints, these findings 
migt be subject to type II error. 
In summary, the findings identified from Study One require further investigation to 
examine other common diarrhoea risk factors including H2 antagonists and PPI 
medications and intestinal microflora dysbiosis (aerobic intestinal microflora) in ETF 
critically ill patients. In addition, the association between diarrhoea, enteral nutrition 
and aerobic intestinal microflora requires investigation up to 14 days into the 
critically ill patients’ ICU admission. Given the interrelationships between diarrhoea 
risk factors and critical illness Study One will progress to examining these 
associations, which will also further examine the conceptual framework (see Figure 
2.1, page 10) in Study Two. To further examine the conceptual framework, the 
following is proposed: 
1. prospectively examine diarrhoea risk factors in critically ill patients to 
determine the associations between ETF, medication administration, clinical 
indicators and aerobic intestinal microflora; and 
2. prospectively examine diarrhoea, enteral nutrition and aerobic intestinal 
microflora associations in critically ill patients. 
4.8 Summary 
This chapter has presented the main findings associated with diarrhoea (occurrence 
and incidence rates) and associated diarrhoea risk factors in a single-centre ICU. The 
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findings suggest that diarrhoea in ETF critically ill patients is associated with 
multiple risk factors; however, the strength of the relationship between these 
diarrhoea risk factors is variable. The differences in diarrhoea risk factors may be 
partly associated with variations in the definition used to define diarrhoea, different 
sample characteristics, the type and duration of ETF and ICU treatments including 
medications and clinical indicators. Chapter Five will present the results of Study 
Two, the Intestinal Flora Study. 
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CHAPTER FIVE: STUDY TWO RESULTS: THE INTESTINAL 
FLORA STUDY 
5.1 Introduction 
Chapter Four presented the results of Study One relating to diarrhoea and enteral 
nutrition relationships in critically ill adult patients. This chapter presents the major 
findings of Study Two, including the study sample characteristics and the 
characteristics of the ICU patient with diarrhoea: the number of diarrhoea events, the 
duration of diarrhoea, the incidence rate of diarrhoea, administration of ETF, the 
administration of medications and selected clinical indicators. This chapter also 
presents results of analyses to examine associations between diarrhoea, enteral 
nutrition and aerobic intestinal microflora. The results of Study Two are presented 
under the headings of the eight research questions. 
5.2 Sample characteristics 
Data were collected on 116 consented patients from September 2008 to November 
2009. The sample size used for final analysis was 101. Fifteen participants were 
excluded from final analysis as they were either not ETF during their ICU admission 
(n = 8), a rectal swab was not collected (n = 6) or a rectal swab was lost (n = 1). 
Those excluded include nine males and six females. The admission diagnoses of the 
excluded participants were spinal injury (n = 1), cardiac condition (n = 5), multiple 
trauma (n = 4), GIT complications (n = 1), sepsis (n = 2) and isolated neurologic 
injury (n = 2). The flow of Study Two is described in the Consort Flow Chart (see 
Figure 5.1). Data reported from this point forward relate only to the final sample (n = 
101). The median age of participants was 49 years (range 18–86 years). 
Approximately two-thirds of study participants were male (n = 69, 68.3%). The 
predominant ethnic background was Australian (n = 84, 83.2%). The sample 
included only two Australian Indigenous persons (2%). Table 5.1 presents the 
characteristics of the sample population of Study Two. 
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Y4 Admitted from a ward/in-patient from another hospital 
Y5 Burns patient 
Y6 Peri-anal trauma 
Y7 Moribund, likely to die within 24 hours of ICU admission 
Y8 Expected ICU LOS < 24 hours 
Y9 Declined, no family, enrolled in another study 
Figure 5.1. Flow chart of Study Two research process. 
Due to the low number of participants (less than 10) with some variables (enteral 
nutrition formula, ETF commencement times, medications and clinical indicators), 
caution is required when interpreting the results of Study Two. For the purpose of 
Study Two, the maximum range of data collection was 14 days; however, 
participants may have received medications and/or experienced clinical indicator 
derangement for a longer period of time during their actual ICU LOS. In addition, 
participants who were admitted to the ICU and observed for a longer period of time 
and who were also ETF for a longer period of time were may have been likely to 
experience diarrhoea and for a longer duration of time as they were also observed on 
more days. This interaction should be considered when interpreting the results. 
A
n
al
y
si
s 
A
ll
o
ca
ti
o
n
 
E
n
ro
lm
en
t 
Assessed for eligibility 
(n = 822) 
Excluded (n = 706) 
    Y4 (n = 387) 
    Y5 (n = 0) 
    Y6 (n = 12) 
    Y7 (n = 47) 
    Y8 (n = 94) 
    Y9 (n = 166) 
Y9 (other) (n = 166) 
Declined (n = 35) 
Unable to contact family (n = 75) 
Enrolled in other study (n = 13) 
Other reasons (n = 43) 
Excluded from final 
analysis 
(n = 15) 
Excluded from final analysis (n = 15) 
No ETF (n = 8) 
Rectal swab not collected (n = 6) 
Rectal swab lost (n = 1) Analysed 
(n = 101) 
Allocated to 
participate (n = 116) 
Consented 
(n = 116) 
Diarrhoea (n = 54) 
No diarrhoea (n = 47) 
Admission swabs (n = 101) 
Discharge swabs (n = 101) 
 
F
o
ll
o
w
-u
p
 
117 
In total, the 101 participants were admitted to the ICU for a total of 925 patient 
admission days. The median actual ICU LOS was 7 days (see Table 5.1). Participants 
were acutely unwell with moderate severity of illness scores according to APACHE 
II and SOFA scores (see Table 5.1). 
Table 5.1  
Sample Characteristics of Study Two (n = 101) 
Variable Number 
(n) 
Percent 
(%) 
Median Range 
Gender     
 Male 69 68 - - 
 Female 32 32 - - 
Admission by body system disorder     
 Respiratory 5 5 - - 
 Neurologic  31 31 - - 
 Gastrointestinal 2 2 - - 
 Spinal 3 3 - - 
 Cardiovascular 18 18 - - 
 Multiple trauma 32 32 - - 
 Sepsis 6 6 - - 
 Overdose 3 3 - - 
 Metabolic/diabetic 
 complication 
1 1 - - 
Age (years)
*
 - - 49
*
 18–86* 
Actual ICU LOS (days)* - - 7* 1–54* 
APACHE II score* - - 27* 17–49* 
SOFA score* - - 6* 0–18* 
Number of observation days per 
patient* 
- - 6* 2–14* 
Note. - = Statistic not reported since it is not appropriate for this variable; 
*
 Data rounded to 
whole numbers for continuously scored variables in all tables. 
5.2.1 Enteral nutrition 
Enteral tube-feeding characteristics, including the duration of ETF are presented in 
Table 5.2. All study participants received full-strength ETF. The majority of 
participants received Jevity formula and had ETF commenced within 24 hours of 
ICU admission. The median time (in hours) to ETF commencement following ICU 
admission was 10 hours; however, some participants experienced a delay to ETF 
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commencement of up to 104 hours. In total, participants were ETF for 707 patient 
admission days. The duration of ETF for the study period ranged from 1–14 
observation days. 
Table 5.2  
Enteral Nutrition Characteristics of Study Two (n = 101) 
Variable Number (n) Percent (%) Median Range 
Enteral nutrition by type   
 Jevity Plus 30 30 - - 
 Jevity 65 64 - - 
 Nepro 6 6 - - 
Time to ETF commence following ICU admission   
 <24 hour 83 82 - - 
 24–48 hour 16 16 - - 
 >48 hour 2 2 - - 
ETF formula changed during ICU admission   
 2 x ETF formulae changes 12 12 - - 
 3 x ETF formulae changes 5 5 - - 
 Other ETF formulae 
 changes 
5 5 - - 
ETF ceased in ICU 72 71 - - 
Time to start ETF (hour)
*
 - - 10
*
 1–104*† 
ETF duration (days)
*
 - - 6
*
 1–14*† 
Note. - = Statistic not reported since it is not appropriate for this variable;
 *
Data rounded to 
whole numbers for continuously scored variables. 
†
Maximum data collection was14 days. 
5.2.2 Medications 
Similar to Study One, the majority of the sample examined in Study Two received 
aperient, prokinetic, H2 receptor antagonists, PPIs, sedation, neuromuscular blockade 
and antibiotic medications (see Table 5.3). 
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Table 5.3  
Medications Administered and Observed Days of Medication Administration (n = 101) 
 Number of participants who 
received the medication 
Number of observed days of 
medication administration 
Medications administered Number (n) Percent (%) Median Range 
Aperients 81 80 5
*
 0–14*† 
 Coloxyl/Senna 78 77 4
*
 0–14*† 
 Bisacodyl supp†† 50 50 0
*
 0–10*† 
 Glycerine supp†† 39 39 0
*
 0–12*† 
 Microlax 21 21 0
*
 0–12*† 
 Lactulose 9 9 - - 
 Sorbitol 1 1 - - 
 Other aperients 1 1 - - 
Prokinetics 78 77 4
*
 0–13*† 
 Maxalon 78 77 4
*
 0–13*† 
 Erythromycin 24 24 0
*
 0–12*† 
H2 antagonists 89 88 5
*
 0–14*† 
 Ranitidine 89 88 5
*
 0–14*† 
PPI 31 31 0
*
 0–14*† 
 Esomeprazole 31 31 0
*
 0–14*† 
 Omeprazole 2 2 - - 
H2 antagonists and PPI 19 19 0
*
 0–12*† 
Sedation and opioids†††     
 Sedation 98 97 3
*
 0–14*† 
 Opioids 97 96 6
*
 0–14*† 
 Morphine 61 60 2
*
 0–14*† 
 Fentanyl 70 69 2
*
 0–14*† 
 Midazloam 85 84 3
*
 0–14*† 
Neuromuscular blocker     
 Vecuronium 46 46 0
*
 0–12*† 
Antibiotic (AB) 
combinations 
87 86 6
*
 0–14*† 
Number of AB     
 One AB 85 84 3
*
 0–14*† 
 Two AB 65 64 1
*
 0–10*† 
 Three AB 47 47 0
*
 0–13*† 
 Four AB 31 31 0
*
 0–7*† 
 Five AB 13 13 0
*
 0–6*† 
 Six AB 4 4 - - 
 Seven AB 2 2 - - 
Note. - = Data not reported for small sample size ≤ 10 participants; *Data rounded to whole 
numbers for continuously scored variables; 
†
Maximum data collection was14 days; 
††
Supp = 
suppository; 
†††
Sedation = medication co-administration, for example, opioid/midazolam, 
morphine/fentanyl. 
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5.2.3 Clinical indicators 
The majority of the sample examined in Study Two experienced hypoalbuminaemia, 
hyperglycaemia, elevated WCC, elevated INR and an infection (see Table 5.4). An 
infection of any description was experienced by 64% of participants (n = 64) and 
very few participants developed a multiresistant infection (n = 5, 5%). The 
characteristics of the duration of clinical indicator derangement are presented in 
Table 5.4. 
Table 5.4  
Clinical Indicators Experienced (n = 101) 
 Number of participants who 
experienced clinical indicators 
Number of observed days 
of clinical indicator 
derangement 
Clinical indicators Number (n) Percent (%) Median Range 
Hyperglycaemia 90 89 4
*
 0–12*† 
Hypoalbuminaemia 96 95 7
*
 0–14*† 
Elevated WCC 91 90 3
*
 0–14*† 
Elevated INR 78 77 2
*
 0–13*† 
Infection 64 64 - - 
Multiresistant infection 5 5 - - 
Note. - = Data not reported for small sample size ≤10 participants or dichotomous scored 
variable; 
*
Data rounded to whole numbers for continuously scored variables; 
†
Maximum 
data collection was 14 days. 
5.3 Research Question 1 
 What is the period prevalence of diarrhoea in ETF patients in the ICU? 
The majority of participants experienced bowel activity during their ICU admission 
and the characteristics of Study Two participants are presented in Table 5.5. In Study 
Two, the period prevalence of diarrhoea was 53% (n = 53). The number of events of 
diarrhoea per participant ranged from 0 to 8 events each day, with the cumulative 
number of diarrhoea events per patient ranging from 0 to 23 events (Mdn = 1). The 
aggregate number of diarrhoea events was 326 events, which were observed over 747 
patient admission days. The incidence rate of diarrhoea was .44 events per patient 
observation day with the individual participants’ incidence rate of diarrhoea ranging 
from 0 to 2.40 events per patient observation day. 
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Table 5.5  
Bowel Activity Characteristics of Study Two (n = 101) 
Bowel activity 
Number 
(n) 
Percent 
(%) 
Median Range 
Bowel activity occurred   - - 
 Males 51/69 74 - - 
 Females 23/32 72 - - 
Time to initial bowel activity (hours)
*
 - - 84
*
 1–291* 
Diarrhoea   - - 
 Males 39/69 57 - - 
 Females 14/32 44 - - 
Number of diarrhoea events
*
 - - 1
*
 0–23* 
Diarrhoea duration (days)
*
 - - 1
*
 0–10* 
Diarrhoea incidence rate per patient 
observation day
*
 
- - 0.1 0–2.40 
Note. - = Statistic not reported since it is not appropriate for this variable; 
*
Data rounded to 
whole numbers for continuously scored variables. 
Characteristics of the 27 participants who experienced no bowel activity during their 
ICU admission are presented in Table 5.6. The majority of study participants who 
experienced no bowel activity were male (n = 18, 67%). Ten participants who had no 
bowel activity developed a non-multiresistant infection. Participants who 
experienced no bowel activity remained multiresistant infection free during the data 
collection period. All participants who experienced no bowel activity had received 
antibiotic medications. 
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Table 5.6  
Characteristics of Participants Who Experienced No Bowel Activity During Study Two (n = 
27) 
Variable Median Range 
Age (years)
*
 48
*
 18–77* 
Actual ICU LOS (days)
*
 2
*
 1–9* 
Time to start ETF (hour)
*
 10
*
 1–32* 
Duration of ETF (days)
*
 3
*
 1–10* 
Duration no bowel activity (hour)
*
 66
*
 31–231* 
Aperients duration (days)
*
 0
*
 0–14* 
Prokinetics duration (days)
*
 1
*
 0–13* 
Antibiotic duration (days)
*
 3
*
 0–14* 
Sedation duration (days)
*
 4
*
 0–10* 
Note. 
*
Data rounded to whole numbers for continuously scored variables. 
5.4 Research Question 2 
 Is there a relationship between the number of events of diarrhoea and the 
duration of diarrhoea in ETF critically ill patients? 
Analyses were conducted using the Spearman’s r correlation coefficient to examine 
the association between the number of events of diarrhoea and the duration of 
diarrhoea in ETF critically ill patients. A statistically significant association was 
identified between the number of events of diarrhoea and the duration of diarrhoea 
(Spearman’s r =.93, p <.001). Similar to Study One, and as would be expected based 
on the definition of diarrhoea, this finding suggests that participants who were 
observed to experience diarrhoea over a longer period of time also experienced more 
events of diarrhoea. 
5.5 Research Question 3 
 Are clinical indicators such as hypoalbuminaemia, hyperglycaemia, elevated 
WCC, elevated INR and infection associated with diarrhoea in this study? 
Bivariate (Chi-squared) analyses were undertaken to determine the association 
between the occurrence of diarrhoea and a range of clinical indicators as presented in 
Table 5.7. There was a statistically significant association between the occurrence of 
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diarrhoea and the occurrence of hypoalbuminaemia, and the occurrence of diarrhoea 
and the occurrence of an infection. Study participants who had hypoalbuminaemia or 
an infection were more likely to have an occurrence of diarrhoea recorded during the 
data collection period. No other statistically significant associations were identified 
in these analyses, suggesting that the occurrence of diarrhoea was not associated with 
the occurrence of the remaining clinical indices including hyperglycaemia, elevated 
WCC and elevated INR. 
Table 5.7  
Association Between Diarrhoea Occurrence and Clinical Indicator Occurrence (n = 101) 
Clinical indicator occurrence Continuity Correction χ21 p value 
Hyperglycaemia 2.11 .15 
Hypoalbuminaemia 3.81 .05* 
Elevated WCC 1.36 .24 
Elevated INR 0.56 .46 
Infection 4.13 .04* 
Note. 
*
Statistical significance at p (two-tailed) <.05. 
Further bivariate analyses were conducted to examine the association between the 
incidence rate of diarrhoea and the occurrence of selected clinical indicators (see 
Table 5.8). There was a statistically significant positive association between the 
incidence rate of diarrhoea and the occurrence of hypoalbuminaemia, and the 
incidence rate of diarrhoea and the occurrence of an infection, with a higher 
incidence rate of diarrhoea associated with the presence of these clinical indicators. 
No significant difference was found between the incidence rate of diarrhoea and 
other clinical indicators. 
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Table 5.8 
Incidence Rate of Diarrhoea by Clinical Indicator Occurrence Associations (n = 101) 
Clinical indicator 
occurrence 
z p value Median incidence 
rate of diarrhoea 
with clinical 
indicator 
Median incidence 
rate of diarrhoea 
without clinical 
indicator 
Hyperglycaemia - 1.89 .06 .13 .00 
Hypoalbuminaemia - 2.42 .02
*
 .13 .00 
Elevated WCC - 1.73 .08 .13 .00 
Elevated INR - 0.66 .51 .13 .00 
Infection - 2.29 .02
*
 .19 .00 
Note.
*
Statistical significance at p (two-tailed) <.05. 
Analyses were also conducted using the Spearman’s r correlation coefficient to 
examine the association between the incidence rate of diarrhoea and the number of 
days of clinical indicator derangement (see Table 5.9). A statistically significant 
association was observed between the incidence rate of diarrhoea and the number of 
days of hyperglycaemia, hypoalbuminaemia and elevated WCC and elevated INR; 
with a higher incidence rate of diarrhoea associated with a higher number of days of 
clinical indicator derangement. These findings might also be associated with the 
duration of participant observation. 
Table 5.9  
Association Between the Incidence Rate of Diarrhoea and the Number of Days of Clinical 
Indicator Derangement (n = 101) 
Number of days of clinical 
indicator derangement 
Spearman’s r p value 
Hyperglycaemia .37 <.001* 
Hypoalbuminaemia .62 <.001* 
Elevated WCC .45 <.001* 
Elevated INR .31 .002* 
Note. 
*
Statistical significance at p (two-tailed) <.05. 
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5.6 Research Question 4 
Is diarrhoea in ETF patients associated with: 
 The type of ETF formulae? 
Analyses using the Kruskal-Wallis test were conducted to examine the association 
between the incidence rate of diarrhoea and the type of ETF formula (see Table 
5.10). A statistically significant difference was identified between the incidence rate 
of diarrhoea and the three ETF formulae of Jevity Plus, Jevity and Nepro. Nepro 
formula had a higher median incidence rate of diarrhoea (Mdn =.94) when compared 
with the other two formulae of Jevity Plus and Jevity; however, the low number of 
participants receiving Nepro formula means that these results should be considered 
with caution. 
Table 5.10  
Incidence Rate of Diarrhoea and ETF Formulae (n = 101) 
ETF formula Number of participants 
receiving formula 
H(2) p value Median 
diarrhoea 
incidence rate 
  10.31 .006
*
  
Jevity Plus 30   0.00 
Jevity 65   0.13 
Nepro 6   0.94 
Note. 
*
Statistical significance at p (two-tailed) <.05; H(2) = two degrees of freedom. 
 The time to commencement of ETF following ICU admission? 
The association between the occurrence of diarrhoea and the time to ETF 
commencement was examined using the Mann-Whitney U test. No statistically 
significant difference was identified between those participants who developed 
diarrhoea and those participants who did not develop diarrhoea and the exact time to 
ETF commencement (z = - 1.39, p =.16). 
Analyses were also conducted using the Mann-Whitney U test to examine the 
association between the incidence rate of diarrhoea and the time to ETF 
commencement. ETF commencement was measured and analysed as a dichotomous 
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variable, being ETF < 24 hours or > 24 hours following ICU admission. Due to the 
low numbers of participants who commenced ETF more than 48 hours following 
ICU admission, the categories of ETF commenced within 24–48 hours and more than 
48 hours following ICU admission were pooled into ETF commenced more than 24 
hours following ICU admission. A statistically significant difference was observed 
between the incidence rate of diarrhoea and ETF commenced < 24 hours (Mdn =.00, 
n = 83) and ETF commenced > 24 hours (Mdn =.35, n = 18) following ICU 
admission (z = - 1.97, p =.05) with a higher incidence rate of diarrhoea associated 
with a longer period of time between ICU admission and the commencement of ETF 
(> 24 hours). 
Further analyses using the Spearman’s r correlation coefficient were conducted to 
examine the association between the incidence rate of diarrhoea and the time to ETF 
commencement. Time to ETF commencement was measured and analysed as a 
continuous variable: time in exact hours following ICU admission. No statistically 
significant associations were observed between the incidence rate of diarrhoea and 
the exact time to ETF commencement (Spearman’s r = 0.08, p =.45). 
 The duration of ETF? 
The association between the occurrence of diarrhoea and the duration of ETF were 
examined using the Mann-Whitney U test. A statistically significant association was 
identified with those participants who had an occurrence of diarrhoea having a higher 
median duration of ETF (Mdn = 10, n = 53) than those participants who did not 
develop diarrhoea (Mdn = 4, n = 48) (z = - 6.02, p = <.001). 
Analyses were conducted using the Spearman’s r correlation coefficient to examine 
the association between the incidence rate of diarrhoea and the duration of ETF. A 
statistically significant association was identified, suggesting that those participants 
who were ETF for a longer period of time were more likely to have a higher 
incidence rate of diarrhoea (Spearman’s r = 0.51, p = <.001). 
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 Gender, age, Study ICU LOS and APACHE II and SOFA scores? 
Analyses were conducted to examine the association between the occurrence of 
diarrhoea and gender. The Chi-square test for independence identified that diarrhoea 
was not associated with gender (Continuity Correction 2 = 0.96, p =.33). 
Furthermore, the association between the occurrence of diarrhoea and age, Study 
ICU LOS and severity of illness (APACHE II and SOFA scores) were examined 
using the Mann-Whitney U test. There was a statistically significant association 
between the occurrence of diarrhoea and Study ICU LOS (see Table 5.11) and the 
occurrence of diarrhoea and SOFA scores. Participants who were admitted to the 
ICU for a longer period of time and who were more acutely ill experienced more 
occurrences of diarrhoea. No other significant associations were identified between 
the occurrence of diarrhoea and other demographic or clinical variables. 
Table 5.11  
Diarrhoea Occurrence by Age, Study ICU LOS and Severity of Illness (n = 101) 
Diarrhoea occurrence z p value Median age, Study 
ICU LOS, 
APACHE II and 
SOFA scores with 
diarrhoea 
occurrence 
Median age, Study 
ICU LOS, APACHE 
II and SOFA scores 
without diarrhoea 
occurrence 
Age (years) - 0.21 .83 46.0 49.5 
Study ICU LOS (days) - 6.65 <.001
*
 12.0 3.5 
APACHE II score - 1.20 .23 28.0 26.0 
SOFA score - 3.12 .002
*
 7.00 5.00 
Note. 
*
Statistical significance at p (two-tailed) <.05. 
Analyses were conducted to examine the association between the incidence rate of 
diarrhoea and gender. The Mann-Whitney U test identified that there was no 
difference between the incidence rate of diarrhoea for male (Mdn = 0.14, n = 69) and 
female (Mdn = 0, n = 32) participants (z = - 0.78, p =.44). 
Analyses were also conducted using the Spearman’s r correlation coefficient to 
examine the association between the incidence rate of diarrhoea and age, Study ICU 
LOS and APACHE II and SOFA scores (see Table 5.12). There was a statistically 
significant association between the incidence rate of diarrhoea and the Study ICU 
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LOS (Spearman’s r =.60, p = <.001) and the incidence rate of diarrhoea and the 
SOFA score (Spearman’s r =.31, p = <.002), with a higher diarrhoea incidence rate 
associated with a longer Study ICU LOS and being a more acutely ill patient. No 
other statistically significant associations were identified between the incidence rate 
of diarrhoea and other demographic or clinical variables. 
Table 5.12  
Association Between the Incidence Rate of Diarrhoea and Age, Study ICU LOS and Severity 
of Illness (n = 101) 
Participant characteristic Spearman’s r p value 
Age (years) .04 .68 
Study ICU LOS (days) .60 <.001
*
 
APACHE II score .17 .10 
SOFA score .31 .002
*
 
Note. 
*
Statistical significance at p (two-tailed) <.05. 
 The duration of aperient, prokinetic, H2 antagonist, PPI, sedation, 
neuromuscular blockade and antibiotic medication administration? 
Analyses were conducted to examine the association between the incidence rate of 
diarrhoea and medication administration (see Table 5.13). The association between 
the incidence rate of diarrhoea and dichotomously scored medications were 
examined using the Mann-Whitney U test, while the Spearman’s r correlation 
coefficient was used to examine the association between two continuous variables: 
the incidence rate of diarrhoea and the duration of medication administration. 
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Table 5.13  
Incidence Rate of Diarrhoea by Medications Administered (n = 101) 
 Number of 
participants 
Medications administered 
 
Number of days 
of medication 
administration 
   Mann-Whitney U test Spearman’s r 
 (n) (%) z p Median 
incidence 
rate of 
diarrhoea 
with 
medication 
Median 
incidence 
rate of 
diarrhoea 
without 
medication 
r p 
Aperient 
combinations 
81 80 - 3.45 .001* 0.21 0.00 .46 <.001* 
Coloxyl/Senna 78 78 - 3.09 .002* 0.19 0.00 .40 <.001* 
Bisacodyl supp 50 50 - 3.64 <.001* 0.25 0.00 .38 <.001* 
Glycerine supp 39 39 - 1.62 .10 0.21 0.00 .22 .03* 
Microlax enema 21 21 - 2.17 .03* 0.36 0.00 .24 .02* 
Lactulose 9 9 - - - - - - 
Sorbitol 2 2 - - - - - - 
Prokinetics 
combinations 
78 78 - 2.88 .004* 0.17 0.00 .32 .001* 
Metoclopramide 78 78 - 2.88 .004* 0.17 0.00 .32 .001* 
Erythromycin 24 24 - 1.70 .09 0.24 0.00 .16 .11 
H2 antagonists 89 89 - 0.23 .82 0.10 0.05 .19 .06 
Ranitidine 89 89 - 0.23 .82 0.10 0.05 .19 .06 
PPI combinations 31 31 - 4.17 <.001* 0.50 0.00 .39 <.001* 
Esomeprazole 31 31 - 3.70 <.001* 0.43 0.00 .39 <.001* 
Omeprazole 2 2 - - - - - - 
Sedation and 
opioids 
        
Sedation 98 98 - 1.68 .09 0.11 0.00 .49 <.001* 
Opioids 97 96 - 1.10 .27 0.10 0.00 .51 <.001* 
Morphine 61 60 - 0.58 .56 0.10 0.00 .19 .06 
Fentanyl 70 70 - 1.50 .14 0.17 0.00 .30 .003* 
Midazolam 85 84 - 3.10 .002* 0.17 0.00 .50 <.001* 
Neuromuscular 
blocker 
        
Vecuronium 46 46 - 1.38 .17 0.21 0.00 .12 .24 
Antibiotic (AB) 
combinations 
87 86 - 1.96 .05* 0.13 0.00 .50 <.001* 
Number of AB         
One AB 87 86 - 1.96 .05* 0.11 0.14 .18 .08 
Two AB 65 64 - 4.02 <.001* 0.25 0.00 .38 <.001* 
Three AB 47 47 - 3.24 .001* 0.30 0.00 .36 <.001* 
Four AB 31 31 - 2.78 .006* 0.30 0.00 .29 .003* 
Five AB 13 13 - 2.00 .05* 0.36 0.00 .20 .04* 
Six AB 4 4 - - - - - - 
Seven AB 2 2 - - - - - - 
Note.      Data not reported for small sample size ≤10 participants; *Statistical significance at 
p (two-tailed) <.05; r = Spearman’s r. 
Significant associations arising from the analyses presented in Table 5.13 are that 
study participants’ higher incidence rates of diarrhoea were associated with both the 
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administration and the longer duration of administration of most medications. The 
exceptions to this were the administration of glycerine suppositories, sedation, 
opioids, fentanyl and one antibiotic; and the duration of erythromycin, ranitidine, 
morphine and vecuronium medication administration. No other statistically 
significant associations were identified between the incidence rate of diarrhoea and 
the administration of the former list of medications and the number of days of 
medication administration (see Table 5.13). 
5.7 Research Question 5 
What is the identity and semiquantitative counts of intestinal aerobic microflora of: 
 emergently admitted ICU patients? 
 patients enrolled into Study Two who are discharged from the ICU? 
Of the 53 participants who experienced diarrhoea, a total of 105 diarrhoea samples 
were collected (range 1–5). The characteristics of participants’ aerobic intestinal 
microflora (referred to as normal faecal flora) at admission to and on discharge from 
the ICU are described using the genus level. The quantitative compositions of the 
normal faecal flora of rectal swabs collected at admission to and on discharge from 
the ICU are presented in Table 5.14. The identity and numbers of intestinal 
microflora subcategorised to the genus level are then presented in Tables 5.15 and 
5.16. 
Table 5.14  
Normal Faecal Flora at Admission to and Discharge From the ICU (n = 101) 
 Number of participants (n, %) 
Normal faecal flora counts At admission to ICU Prior to discharge from 
ICU 
Absent 9 8.9 11 10.9 
Scant 9 8.9 8 7.9 
1+ 9 8.9 14 13.9 
2+ 23 22.8 17 16.8 
3+ 51 50.5 51 50.5 
Total 101 100 101 100 
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Table 5.15  
Aerobic Intestinal Microflora (Genus Level) at ICU Admission (n = 101) 
Intestinal microflora Absent Scant 1+ 2+ 3+ 
  n % n % n % n % n % 
Lactose fermenters (LF) 85 84.1 2 2 0 0 2 2 12 11.9 
Non-lactose fermenters (NLF) 85 84.1 2 2 3 3 3 3 8 7.9 
Gram negative bacilli: 
          
 E.coli 25 24.8 13 12.9 10 9.9 18 17.8 35 34.6 
 Klebsiella sp 91 90 1 
 
0 0 4 
 
5 
 
 Enterobacter sp 101 100 0 1 0 0 0 4 0 5 
 Serratia sp 100 99 0 0 0 0 0 0 1 0 
 Proteus sp 99 98 0 0 1 1 0 0 1 1 
 Klebsiella-Enterobacter-Serratia (KES) group 98 97 1 0 0 0 1 0 1 1 
 Pseudomonas sp 96 95 0 1 4 4 0 1 1 1 
Gram positive bacilli: 
          
 Enterococcus sp 44 43.6 6 5.9 6 5.9 14 13.9 31 30.7 
 Streptococcus sp 101 100 0 0 0 0 0 0 0 0 
  Alpha haemolytic Streptococcus 89 88.1 2 2 2 2 7 6.9 1 1 
  Beta haemolytic Streptococcus 100 99 0 0 0 0 1 1 0 0 
  Other Streptococcus sp 101 100 0 0 0 0 0 0 0 0 
Staphylococcus aureus 98 97 0 0 1 1 0 0 2 2 
Yeasts: 
          
 Candida sp 96 95 3 3 0 0 1 1 1 1 
  Candida albicans 96 95 2 2 1 1 2 2 0 0 
  Candida krusei 101 100 0 0 0 0 0 0 0 0 
  Candida tropicalis 101 100 0 0 0 0 0 0 0 0 
Other yeasts 101 100 0 0 0 0 0 0 0 0 
Skin flora: 
          
 Coagulase negative Staphylococci (CNS) 21 20.8 15 14.8 21 20.8 23 22.8 21 20.8 
 Corynebacterium sp 52 51.5 13 12.9 10 9.9 15 14.8 11 10.9 
Multiresistant organisms: 
          
 MRSA 101 0 0 0 0 0 0 0 0 0 
 VRE 101 0 0 0 0 0 0 0 0 0 
 ESBL 101 0 0 0 0 0 0 0 0 0 
Other: 
          
 Bacillus 99 98 0 0 2 2 0 0 0 0 
Note. n = number of participants; % = percentage of participants.
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Table 5.16  
Aerobic Intestinal Microflora (Genus Level) at ICU Discharge (n = 101) 
Intestinal microflora  Absent Scant 1+ 2+ 3+ 
 n % n % n % n % n % 
Lactose fermenters (LF) 85 84.2 3 3 3 3 2 2 8 7.9 
Non-lactose fermenters (NLF) 87 86.1 3 3 2 2 6 5.9 3 3 
Gram negative bacilli:           
 E.coli 54 44.6 9 8.9 12 11.9 16 15.8 19 18.8 
 Klebsiella sp 83 82.2 0 0 1 1 7 6.9 10 9.9 
 Enterobacter sp 100 99 0 0 0 0 0 0 1 1 
 Serratia sp 100 99 0 0 0 0 0 0 1 1 
 Proteus sp 94 93 1 1 1 1 1 1 4 4 
 Klebsiella-Enterobacter-Serratia (KES) group 99 98 1 1 0 0 0 0 1 1 
 Pseudomonas sp 92 91 3 3 3 3 1 1 2 2 
Gram positive bacilli:           
 Enterococcus sp 31 30.7 10 9.9 10 9.9 17 16.8 33 32.7 
 Streptococcus sp 101 100 0 0 0 0 0 0 0 0 
  Alpha haemolytic Streptococcus 94 93 1 1 2 2 2 2 2 2 
  Beta haemolytic Streptococcus 99 98 0 0 1 1 0 0 1 1 
 Other Streptococcus sp 0 0 0 0 0 0 0 0 0 0 
Staphylococcus aureus 99 98 0 0 1 1 0 0 1 1 
Yeasts:           
 Candida sp 98 97 1 1 0 0 0 0 2 2 
 Candida albicans 91 90.1 6 5.9 2 2 2 2 0 0 
 Candida krusei 101 100 0 0 0 0 0 0 0 0 
 Candida tropicalis 101 100 0 0 0 0 0 0 0 0 
Other yeasts 99 98 1 1 0 0 0 0 1 1 
Skin flora:           
 Coagulase negative Staphylococci (CNS) 21 20.8 9 8.9 19 18.8 33 32.7 19 18.8 
 Corynebacterium sp 69 68.3 8 7.9 7 7 6 5.9 11 10.9 
Multiresistant organisms:           
 MRSA 101 100 0 0 0 0 0 0 0 0 
 VRE 100 99 0 0 0 0 0 0 1 1 
 ESBL 101 100 0 0 0 0 0 0 0 0 
Other:           
 Bacillus 100 99 0 0 2 2 0 0 1 1 
Note. n = number of participants; % = percentage of participants.
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5.8 Research Question 6 
 Does the baseline aerobic intestinal microflora change during ICU 
admission? 
Tables 5.14 to 5.16 present the comparison of normal faecal flora collected via rectal 
swab at admission to and on discharge from the ICU. In addition, Table 5.17 presents 
the characteristics of aerobic intestinal microflora collected at the first three faecal 
samples during the study participant’s data collection period. 
Table 5.17 
Normal Faecal Flora Collected at First Three Faecal Samples (n = 53) 
Aerobic intestinal 
microflora 
Faecal test 1 Faecal test 2 Faecal test 3 
n % n % n % 
Absent 4 7.4 2 6.7 1 6.3 
Scant 2 3.7 0 0.0 0 0.0 
1+ 4 7.4 2 6.7 0 0.0 
2+ 5 9.3 3 9.9 4 24.9 
3+ 38 71.7 23 76.7 11 68.8 
Total 53 100 30 100 16 100 
Note. n = number of participants; % = percentage of participants. 
Correlation analyses were conducted to examine the association between the 
incidence rate of diarrhoea and the normal faecal flora collected at admission to and 
on discharge from the ICU and also the first three faecal samples (see Table 5.18). 
No statistically significant associations were identified between the incidence rate of 
diarrhoea and these normal faecal flora counts. The absence of an association 
between these variables indicates that the incidence rate of diarrhoea is not 
associated with normal faecal flora counts during a critical illness experience. 
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Table 5.18 
Incidence Rate of Diarrhoea and Normal Faecal Flora Counts Associations (n = 101) 
Normal faecal flora by faecal sample Spearman’s r p value 
NFF at admission to ICU .05 .72 
NFF at faecal test one .03 .81 
NFF at faecal test two -.04 .84 
NFF at faecal test three .04 .88 
NFF at discharge from ICU .08 .41 
Note. 
*
Statistical significance at p (two-tailed) <.05; NFF = normal faecal flora. 
Analyses were conducted using the Wilcoxon signed-rank test to examine changes in 
normal faecal flora collected at two time points. These two time points are presented 
in Table 5.19. A statistically significant association was identified in the normal 
faecal flora at admission to the ICU and the first faecal sample, the first faecal 
sample and the normal faecal flora collected on discharge from ICU, and the second 
faecal sample and the normal faecal flora collected on discharge from ICU. These 
findings indicate that the study participants’ normal faecal flora is reduced during 
their critical illness experience. No other statistically significant findings were 
identified. Due to some low cell counts observed with some normal faecal flora 
groups, caution is required when extrapolating these results to the wider ICU patient 
population. 
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Table 5.19 
Normal Faecal Flora During Critical Illness (n = 101) 
Normal faecal flora z p value 
Admission and discharge swabs - 0.02 .99 
NFF at ICU admission rectal swab by:   
 NFF at faecal test one - 2.31 .02
*
 
 NFF at faecal test two - 1.85 .06 
 NFF at faecal test three - 1.63 .10 
 NFF at discharge from ICU - 0.02 .99 
NFF at faecal test one by:   
 NFF at faecal test two - 0.16 .87 
 NFF at faecal test three - 0.33 .74 
 NFF at discharge from ICU - 2.29 .02
*
 
NFF at faecal test two by:   
 NFF at faecal test three - 1.34 .18 
 NFF at discharge from ICU - 2.07 .04
*
 
NFF at faecal test three by   
 NFF at discharge from ICU - 1.82 .07 
Note. 
*
Statistical significance at p (two-tailed) <.05; NFF = normal faecal flora. 
Further repeated measures analyses using the Wilcoxon signed-rank test were 
conducted to examine the relationships between pooled categories of aerobic 
intestinal microflora during the study participant’s critical illness experience (see 
Table 5.20). Due to some low cell counts the categories of scant and 1+ faecal flora 
groups were pooled into one category, that is, scant/1+ normal faecal flora. Owing to 
potential clinical implications, absent and scant normal faecal flora were not pooled. 
The results of these analyses are presented in Table 5.20. A statistically significant 
association was identified between the normal faecal flora collected at the first faecal 
sample and the rectal swab on discharge from the ICU. This finding suggests that the 
study participant’s normal faecal flora are reduced during a critical illness 
experience. No other statistically significant findings were identified. 
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Table 5.20  
Normal Faecal Flora During Critical Illness Using Pooled Normal Faecal Flora Counts (n 
= 101) 
Normal faecal flora z p value 
Admission and discharge swabs -0.02 0.99 
NFF at ICU admission rectal swab by:   
 NFF at faecal test one - 1.83 .07 
 NFF at faecal test two - 1.31 .19 
 NFF at faecal test three - 1.15 .25 
 NFF at discharge from ICU - 0.86 .39 
NFF at faecal test one by:   
 NFF at faecal test two - 0.27 .79 
 NFF at faecal test three - 0.33 .74 
 NFF at discharge from ICU - 2.64 .008* 
NFF at faecal test two by:   
 NFF at faecal test three - 1.3 .18 
 NFF at discharge from ICU - 1.10 .27 
NFF at faecal test three by   
 NFF at discharge from ICU - 1.7 .08 
Note. 
*
Statistical significance at p (two-tailed) <.05; NFF = normal faecal flora. 
5.9 Research Question 7 
Does a relationship exist between intestinal aerobic microflora and: 
 Enteral nutrition and diarrhoea in emergency admission, critically ill adult 
patients? 
The changing aerobic intestinal microflora environment in ETF emergency 
admission critically ill patients has not been previously examined. It is important to 
develop an understanding of this changing environment so that a more contextual 
and theoretical understanding of intestinal homeostasis during critical illness can be 
established. Aerobic intestinal microflora were examined for changes during the 
study participant’s ICU admission. A change in aerobic intestinal microflora was 
defined as either an increase, decrease or no change in aerobic intestinal microflora 
during the study participant’s observation period. Table 5.21 presents aerobic 
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intestinal microflora at the genus level that varied between the study participants’ 
rectal swabs collected at admission to and on discharge from the ICU. 
Table 5.21  
Aerobic Intestinal Microflora Genus Changes During Data Collection Period (n = 101) 
Intestinal microflora Absent Scant 1+ 2+ 3+ 
Lactose fermenters NC   NC  
Non-lactose fermenters      
Gram negative bacilli:      
 E.coli      
 Klebsiella sp      
 Pseudomonas sp      
 Proteus sp   NC   
Gram positive cocci:      
 Enterococcus sp      
 Alpha haemolytic Streptococcus   NC   
 Staphylococcus aureus  NC NC NC  
Yeasts:      
 Candida sp   NC   
 Candida albicans    NC NC 
Skin flora:      
 Coagulase negative Staphylococci (CNS) NC     
 Corynebacterium sp     NC 
Note.  = increased;  = decreased; NC = no change. 
Relationships between aerobic intestinal microflora (lactose fermenter and non-
lactose fermenter bacteria), enteral nutrition and the incidence rate of diarrhoea were 
examined. Enteral nutrition was considered a constant variable as all participants at 
final analyses had received ETF during the data collection period. Only lactose 
fermenter and non-lactose fermenter bacteria will be reported in Table 5.22 due to 
the non-significant statistical results reported in Table 5.18. No statistically 
significant associations were identified between the incidence rate of diarrhoea and 
changes in the lactose fermenter and non-lactose fermenter bacteria in ETF 
participants during the observation period. 
138 
Table 5.22  
Incidence Rate of Diarrhoea by Lactose Fermenter and Non-lactose Fermenter Bacteria 
Changes Relationships (n = 101) 
Diarrhoea incidence 
rate by faecal flora 
Number of participants 
with faecal flora change 
H(2) p value Median 
Lactose fermenters .67 .72  
 Increase 8   .00 
 Decrease 9   .00 
 No change 84   .11 
Non-lactose fermenters .97 .62  
 Increase 11   .00 
 Decrease 13   .13 
 No change 77   .10 
Note. 
*
Statistical significance at p (two-tailed) <.05; H(2) = two degrees of freedom. 
Relationships between the incidence rate of diarrhoea, enteral nutrition and aerobic 
intestinal microflora were examined using the Kruskal-Wallis test (see Table 5.23). 
Aerobic intestinal microflora was scored as an increase, decrease or no change in 
aerobic intestinal microflora counts between admission to and discharge from the 
ICU. Enteral nutrition was considered a constant variable as all study participants 
received enteral nutrition. No statistically significant findings were identified 
between the incidence rate of diarrhoea and an increase, decrease and no change in 
normal faecal flora counts. The absence of a statistically significant finding might be 
due to the low numbers of participants who experienced either an increase or a 
decrease in their aerobic intestinal microflora. 
Table 5.23  
Incidence Rate of Diarrhoea by Changes in Aerobic Intestinal Microflora Relationships (n = 
101) 
Aerobic intestinal 
microflora 
Number of participants with changes 
in intestinal microflora 
H(2) p 
value 
Median 
  .67 .72  
Increase 8   .00 
Decrease 9   .00 
No change 84   .11 
Note. 
*
Statistical significance at p (two-tailed) <.05; H(2) = two degrees of freedom. 
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Aerobic intestinal microflora (normal faecal flora) were pooled into two categories 
due to the small numbers of participants who experienced an increase or a decrease 
in their normal faecal flora. Analyses were conducted using the Mann-Whitney U 
test to examine the difference between the incidence rate of diarrhoea and variations 
in normal faecal flora. No statistically significant findings were identified between 
the incidence rate of diarrhoea and a change in normal faecal flora counts (Mdn =.11, 
n = 54) and no change in the normal faecal flora counts (Mdn =.00, n = 47) during 
the data collection period (z = - 0.12, p =.90). 
 The timing of enteral nutrition commencement? 
The characteristics of the rectal swab and faecal specimen collection measured 
against the time to ETF commencement are presented in Table 5.24. 
Table 5.24  
Characteristics of Time to ETF Commencement and Aerobic Intestinal Microflora (n = 101) 
 Time to commencement of ETF 
Normal faecal flora by sample < 24 hour (n) > 24 hour (n) 
NFF at ICU admission 83 18 
NFF at first faecal test 42 12 
NFF at second faecal test 22 8 
NFF at third faecal test 13 3 
NFF at discharge from ICU 83 18 
Note. n = number of participants who had a rectal swab or faecal specimen collected < 24 
hours or > 24 hours following ICU admission. 
Analyses were conducted using the Mann-Whitney U test to examine the differences 
between aerobic intestinal microflora and the timing to ETF commencement for the 
dichotomous time points of ETF commenced < 24 hours and > 24 hours following 
admission to the ICU (see Table 5.25). No statistically significant associations were 
identified between the timing of ETF commencement (< 24 hours and > 24 hours) 
and the aerobic intestinal microflora collected at admission to and on discharge from 
the ICU or the first three faecal samples. The absence of statistically significant 
results may be due to the low number of participants who had the collection of these 
specimens. 
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Table 5.25  
Time to ETF Commencement (Bivariate Analyses) and Aerobic Intestinal Microflora 
Relationships (n = 101) 
Aerobic intestinal 
microflora 
z p value Median NFF with 
ETF commenced < 24 
hours following ICU 
admission 
Median NFF with 
ETF commenced > 
24 hours following 
ICU admission 
ICU admission swab - 0.06 .94 3.00 2.50 
First faecal test - 1.80 .07 3.00 3.00 
Second faecal test - 0.03 .98 3.00 3.00 
Third faecal test 0.22 .36 3.00 3.00 
Discharge swab - 0.78 .43 2.00 3.00 
Note. 
*
Statistical significance at p (two-tailed) <.05 
Analyses were also conducted using the Spearman’s r correlation coefficient to 
examine the differences between aerobic intestinal microflora and the timing to ETF 
commencement (measured as time in exact hours) following admission to the ICU 
(see Table 5.26). The normal faecal flora groups of scant and 1+ normal faecal flora 
were pooled into one variable (scant/1+ normal faecal flora) due to low cell counts. 
A statistically significant association was found between the exact time to ETF 
commencement following ICU admission and the aerobic intestinal microflora of the 
rectal swab collected at ICU admission, indicating that participants who had ETF 
commenced later in their ICU admission experienced an increase in aerobic intestinal 
microflora early in their critical illness experience. A statistically significant 
association was also identified between the exact time to ETF commencement 
following ICU admission and the aerobic intestinal microflora collected at the first 
faecal specimen, with the earlier commencement of ETF associated with a reduction 
in aerobic intestinal microflora. No other statistically significant associations were 
identified between the time to ETF commencement following ICU admission and the 
other aerobic intestinal microflora specimens. 
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Table 5.26  
Time to ETF Commencement (in exact hours) and Aerobic Intestinal Microflora 
Relationships (n = 101) 
Aerobic intestinal microflora specimen Spearman’s r p value 
ICU admission swab - 0.20 .05* 
First faecal test 0.32 .02* 
Second faecal test 0.10 .59 
Third faecal test 0.17 .54 
Discharge swab 0.07 .47 
Note. 
*
Statistical significance at p (two-tailed) <.05. 
5.10 Research Question 8 
 Are the differences in aerobic intestinal microflora of ETF critically ill 
patients who develop and those who do not develop diarrhoea associated 
with: 
 Age? 
 Pre-admission diet? 
 APACHE II and SOFA scores? 
 Antibiotic therapy? 
 Clinical indicators (the number of events and duration of 
hypoalbuminaemia, hyperglycaemic, elevated WCC, elevated INR and 
infection)? 
 Study ICU LOS? 
Analyses were conducted to examine the association between the occurrence of 
diarrhoea and the aerobic intestinal microflora of rectal swabs collected at admission 
to and discharge from the ICU and the initial two faecal tests (see Table 5.27). No 
statistically significant relationships were identified between the aerobic intestinal 
microflora at admission to and on discharge from the ICU and the first and second 
faecal tests. 
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Table 5.27  
Diarrhoea Occurrence by Aerobic Intestinal Microflora Relationships (n = 101) 
Diarrhoea occurrence z p value Median NFF 
with diarrhoea 
Median NFF 
without diarrhoea 
NFF at ICU admission  - 0.12 .91 4.00 4.00 
NFF at first faecal test - 0.77 .44 4.00 4.00 
NFF at second faecal test - 0.34 .74 4.00 4.00 
NFF at ICU discharge - 0.80 .43 4.00 4.00 
Note. 
*
Statistical significance at p (two-tailed) <.05 
Bivariate (Chi-squared) analyses were conducted to examine the association between 
the occurrence of diarrhoea and a variation in the aerobic intestinal microflora of 
critically ill participants. No statistically significant associations were identified in 
these analyses, suggesting that the occurrence of diarrhoea was not associated with a 
change in the aerobic intestinal microflora (Continuity Correction 2 =.22, p =.64). 
Common diarrhoea risk factors associated with critical illness were examined using 
univariate regression modelling (see Table 5.28). Variables that were found to be 
statistically significant were then incorporated into multivariate regression and GEE 
modelling (see Tables 5.29, 5.30, 5.31 and 5.32). 
The significant associations arising from this bivariate regression model suggests that 
participants were more likely to experience a higher incidence rate of diarrhoea when 
the Study ICU LOS was of a longer duration (see Table 5.28). There was also a 
statistically significant association between a higher incidence rate of diarrhoea and 
some ICU treatments, including (a) the longer duration of ETF and a longer time 
delay from ICU admission to the participant’s initial bowel activity; (b) the longer 
duration of some medication administration (antibiotics, combinations of three and 
four antibiotics, PPI medications, esomeprazole, sedation, opioids, fentanyl and 
vecuronium); and (c) the longer duration of some clinical indications 
(hypoalbuminaemia and elevated WCC). No other statistically significant 
associations were identified. 
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Table 5.28  
Bivariate Regression Relationships Between the Incidence Rate of Diarrhoea and Common 
Diarrhoea Risk Factors (n = 101) 
Diarrhoea Risk Factors R Square F β p value 
Hypoalbuminaemia duration .13 15.28 .04 <.001* 
Duration PPI medications .10 10.83 .04 .001* 
Duration of esomeprazole .10 10.48 .04 .002* 
Study ICU LOS .08 9.10 .02 .003* 
Duration of elevated WCC .08 8.55 .04 .004* 
Duration of three antibiotics .08 8.17 .06 .005* 
Antibiotic duration  .07 7.81 .04 .006* 
Number of antibiotics .07 7.84 .08 .006* 
Delay to bowel activity (hours) .07 7.72 -.003 .007* 
Duration of opioid medications .06 5.83 .03 .02* 
Duration of midazolam .50 5.56 .04 .02* 
Duration of four antibiotics .05 4.91 .07 .03* 
ETF duration .05 4.79 .03 .03* 
Duration of sedation medications .05 4.83 .04 .03* 
Duration of fentanyl .04 4.53 .03 .04* 
APACHE II score .03 3.22 .02 .08 
Duration of aperient medications .03 3.11 .02 .08 
Duration of two antibiotics .03 2.95 .03 .09 
SOFA score .03 2.60 .03 .11 
Hyperglycaemia duration .02 2.43 .03 .12 
Duration of elevated INR .02 2.41 .02 .12 
Duration of bisacodyl suppositories .02 2.44 .03 .12 
Duration of coloxyl Senna .02 1.50 .02 .22 
Age (years) .01 1.32 .004 .25 
Duration of one antibiotic .01 0.99 .02 .32 
Duration of metoclopramide .01 0.67 .01 .42 
Duration of prokinetics medications .01 0.62 .01 .43 
Duration of morphine .01 0.49 .01 .49 
Duration of five antibiotics .004 0.36 .03 .55 
Duration of glycerine suppositories .003 0.32 .01 .57 
Time to ETF (hours) .00 0.05 .001 .83 
Duration H2 antagonist medications and ranitidine .00 0.01 .001 .94 
Duration of erythromycin .00 0.00 9.70 .99 
Duration of vecuronium .00 0.00 .00 .99 
Note. 
*
Statistical significance at p (two-tailed) <.05; Unless otherwise stated, duration 
measured as days. 
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The significant associations arising from the multivariate analyses in Table 5.29 
indicate that participants have a higher incidence rate of diarrhoea when the severity 
of illness score (APACHE II) is higher and when there is a delay to initial bowel 
activity following ICU admission. This suggests that the patient may have impaired 
intestinal motility, impaired splanchnic perfusion or ineffective splanchnic 
oxygenation. Other ICU treatment variables associated with a higher incidence rate 
of diarrhoea include a longer Study ICU LOS, more days with hypoalbuminaemia, 
and the longer duration of combinations of three antibiotics, esomeprazole and PPIs. 
Table 5.29  
Multivariate Standard Regression Relationships Between the Incidence Rate of Diarrhoea 
and Common Diarrhoea Risk Factors (n = 101) 
Diarrhoea Risk Factors R Square F β p value 
Model 1(df = 4) .11 3.05 .34 .02
*
 
 Age - - .03 .80 
 Study ICU LOS - - .28 .006
*
 
 APACHE II score - - .15 .29 
 SOFA score - - .001 .10 
Model 2 (df = 3) .21 8.54 .39 <.001
*
 
 Study ICU LOS - - .17 .25 
 ETF duration (days) - - .25 .11 
 Delay to bowel activity - - -.40 <.001
*
 
Model 3 (df = 4) .18 5.10 .03 .001
*
 
 Duration of hyperglycaemia - - -.23 .08 
 Duration of hypoalbuminaemia - - .49 .001
*
 
 Duration of elevated WCC - - .19 .13 
 Duration of elevated INR - - -.12 .29 
Model 4 (df = 5) .14 3.17 .09 .01
*
 
 Duration of AB combinations - - .04 .83 
 Number of AB combinations   .18 .20 
 Duration of PPI - - .25 .02
*
 
 Duration of sedation - - .02 .90 
 Duration of opioids - - .01 .97 
Model 5 (df = 5) .10 2.19 .19 .06 
 Duration of 1 x AB combinations - - .05 .60 
 Duration of 2 x AB combinations - - .04 .71 
 Duration of 3 x AB combinations - - .23 .03
*
 
 Duration of 4 x AB combinations - - .15 .21 
 Duration of 5 x AB combinations - - -.10 .39 
Model 6 (df = 4) .17 4.88 .14 .001
*
 
 Duration of 3 x AB combinations - - .16 .13 
 Duration of 4 x AB combinations - - .15 .15 
 Duration of esomeprazole - - .25 .02
*
 
 Duration of fentanyl - - .07 .48 
Note. - = Statistic not reported since it is not appropriate for this variable; 
*
Statistical 
significance at p (two-tailed) <.05; Unless otherwise stated, duration measured as days; df = 
number of degrees of freedom. 
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Table 5.30  
Multivariate Relationships using GEE Analyses and the Incidence Rate of Diarrhoea and 
Common Diarrhoea Risk Factors (n = 101) 
Diarrhoea risk factors Estimated 
coefficient 
95% confidence 
interval 
p value 
Model 1 (df = 3) -.76 -.59 –.42 .76 
 Age .002 -.01 –.01 .59 
 APACHE II score .01 -.03 –.04 .66 
 SOFA score .02 -.03 –.45 .50 
Model 2 (df = 3) .39 .12 –.65 .004* 
 Study ICU LOS .01 -.01 –.03 .26 
 ETF duration (days) .03 -.004 –.07 .08 
 Delay to bowel activity -.004 -.007 – -.002 .001* 
Model 3 (df = 4) .03 -.13 –.19 .70 
 Duration of hyperglycaemia -.04 -.08 –.002 .06 
 Duration of hypoalbuminaemia .06 .02 –.09 <.001* 
 Duration of elevated WCC .03 .001 –.05 .04* 
 Duration of elevated INR -.02 -.05 –.01 .21 
Model 4 (df = 5) .08 -.049 –.20 .20 
 Duration of AB combinations .05 -.04 –.15 .28 
 Number of AB combinations .01 -.03 –.04 .78 
 Duration of PPI .03 .05 –.06 .02* 
 Duration of sedation .002 -.04 –.04 .91 
 Duration of opioids .04 -.12 –.19 .56 
Model 5 (df = 5) .16 -.05 –.33 .06 
 Duration of AB combinations .04 -.01 –.08 .17 
 Duration of 1 x AB combinations -.02 -.07 –.03 .52 
 Duration of 2 x AB combinations -.02 -.07 –.04 .61 
 Duration of 3 x AB combinations .03 -.01 –.08 .13 
 Duration of 4 x AB combinations .02 -.07 –.12 .65 
Model 6 (df = 4) .14 .02 –.27 .03* 
 Duration of 3 x AB combinations .03 -.01 –.74 .11 
 Duration of 4 x AB combinations .05 -.03 –.13 .18 
 Duration of esomeprazole .03 .01 –.06 .01* 
 Duration of fentanyl .01 -.02 –.04 .56 
Note. 
*
Statistical significance at p (two-tailed) <.05; Unless otherwise stated, duration 
measured as days; df = number of degrees of freedom. 
The significant association identified within the multivariate regression model 
indicates that participants have a higher incidence rate of diarrhoea when there is a 
delay from ICU admission to initial bowel activity (see Table 5.30). Although Model 
3 (clinical indicators) did not achieve a statistically significant result, it is noted that 
some clinical indicator derangement (hypoalbuminaemia and elevated WCC) was 
significantly associated with the incidence rate of diarrhoea. The absence of a 
statistically significant finding from Model 3 might be due to the smaller sample size 
for some diarrhoea risk factors, or due to the participants’ Study ICU LOS. 
Furthermore, participants were more likely to experience a higher incidence rate of 
diarrhoea when multiple medications were administered over a longer period of time; 
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for example, the longer duration of esomeprazole administration. Of note, when the 
incidence rate of diarrhoea was regressed against combinations of antibiotics only, 
no statistically significant associations were identified. As the potential for 
confounding exists between some diarrhoea risk factors within clustered data 
analyses, further GEE analyses were conducted to control for the participant’s ICU 
LOS (see Table 5.31). 
Table 5.31  
Multivariate Relationships using GEE Analyses and the Incidence Rate of Diarrhoea, 
Common Diarrhoea Risk Factors and control for Study ICU LOS (n = 101) 
Diarrhoea risk factors Estimated 
coefficient 
95% Confidence 
interval 
p value 
Model 1 (df = 3) - 9.43 - 15.20 – - 3.66 .01* 
 Age -.06 -.15 – .02 .15 
 APACHE II score .34 .06 – .63 .02* 
 SOFA score -.84 - 1.22 – -.45 <.001* 
Model 2 (df = 4) 1.09 -.19 – 2.36 .09 
 Duration of hyperglycaemia -.51 -.92 – -.10 02* 
 Duration of hypoalbuminaemia - 1.03 - 1.41– -.64 <.001* 
 Duration of elevated WCC .21 -.26– .67 .38 
 Duration of elevated INR -.20 -.57 – .16 .28 
Model 3 (df = 5) - 1.09 - 2.64 – .46 .17 
 Duration of AB combinations -.75 - 1.22– -.28 .002* 
 Number of AB combinations 1.05 .51 – 1.59 <.001* 
 Duration of PPI -.05 -.52– .43 .85 
 Duration of sedation - 1.15 - 1.94 – -.36 .004* 
 Duration of opioids - 2.19 - 5.77 – - 1.38 .23 
Model 4 (df = 5) - 2.19 - 3.65 – .73 .003* 
 Duration of AB combinations - 1.65 - 2.50 – -.79 <.001* 
 Duration of 1 x AB combinations .36 -.42 – 1.23 .37 
 Duration of 2 x AB combinations .76 -.11 – 1.67 .09 
 Duration of 3 x AB combinations .24 -.21 – .69 .29 
 Duration of 4 x AB combinations .06 - 1.28 – 1.40 .93 
Model 5 (df = 4) - 4.88 - 6.63– - 3.13 <.001* 
 Duration of 3 x AB combinations -.30 -.90 – .29 .32 
 Duration of 4 x AB combinations - 1.12 - 2.40 – .16 .09 
 Duration of esomeprazole -.43 -.85 – -.01 .05* 
 Duration of fentanyl -.35 -.62 – -.07 .02* 
Note. 
*
Statistical significance at p (two-tailed) <.05; Unless otherwise stated, duration 
measured as days; df = number of degrees of freedom. 
After controlling for study ICU LOS, significant associations were identified 
between the incidence rate of diarrhoea and severity of illness (APACHE II and 
SOFA scores); the duration of both hyperglycaemia and hypoalbuminaemia; the 
duration of combinations of antibiotics; the number of antibiotics administered and 
the number of days of sedation, esomeprazole and fentanyl administration; indicating 
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that the rate of diarrhoea is higher when these variables are experienced by the 
participant during a critical illness experience (see Table 5.31). 
Table 5.32  
Aerobic Intestinal Microflora Variations and Diarrhoea Risk Factor Relationships (n = 101) 
Diarrhoea risk factors Estimated 
coefficient 
95% Confidence 
interval 
p value 
Model 1 (df = 4) .83 - 1.35 – 3.02 .46 
 Age .03 -.004 –.06 .09 
 Study ICU LOS -.04 -.11 –.02 .17 
 APACHE II score -.09 -.19 –.02 .11 
 SOFA score .07 -.10 –.24 .43 
 Incidence rate of diarrhoea .43 -.41 – 1.28 .32 
Model 2 (df = 3) .93 -.05 – 1.91 .06 
 Study ICU LOS .02 -.07 – .11 .63 
 ETF duration (days) -.12 -.30 – .06 .18 
 Delay to bowel activity -.01 -.02 – .004 .27 
 Incidence rate of diarrhoea .21 -.81 – 1.21 .69 
Model 3 (df = 5) .25 -.54 – 1.05 .53 
 Duration of hyperglycaemia .20 -.01 – .42 .07 
 Duration of hypoalbuminaemia -.24 -.41 – -.06 .007* 
 Duration of elevated WCC .001 -.14 – .15 .99 
 Duration of elevated INR .07 -.08 – .21 .38 
 Incidence rate of diarrhoea .72 -.31 – 1.76 .17 
Model 4 (df = 6) .14 -.63 – .90 .73 
 Duration of AB combinations -.08 -.23 – .07 .28 
 Number of AB combinations .14 -.18 – .46 .39 
 Duration of PPI .04 -.08 – .15 .51 
 Duration of sedation -.06 -.22 – .10 .43 
 Duration of opioids -.22 -.86 – .41 .49 
 Incidence rate of diarrhoea .30 -.70 – .34 .56 
Model 5 (df = 6) .26 -.49 – 1.01 .49 
 Duration of AB combinations -.13 -.39 – .13 .33 
 Duration of 1 x AB combinations -.05 -.27 – .17 .68 
 Duration of 2 x AB combinations .07 -.18 – .32 .59 
 Duration of 3 x AB combinations .12 -.08 – .31 .24 
 Duration of 4 x AB combinations .13 -.22 – .47 .47 
 Incidence rate of diarrhoea .24 -.75 – 1.22 .64 
Model 6 (df = 5) -.24 -.84 – .36 .44 
 Duration of 3 x AB combinations .06 -.12 – .23 .54 
 Duration of 4 x AB combinations .01 -.28 – .30 .94 
 Duration of esomeprazole -.02 -.14 – .09 .69 
 Duration of fentanyl -.004 -.12 – .11 .95 
 Incidence rate of diarrhoea .20 -.65 – 1.05 .64 
Note. 
*
Statistical significance at p (two-tailed) <.05; Unless otherwise stated, duration 
measured as days; df = number of degrees of freedom. 
Multivariate analyses were conducted using GEE modelling to examine the clustered 
data effects between aerobic intestinal microflora variations (intestinal microflora 
varied or did not vary during ICU LOS), the incidence rate of diarrhoea and common 
diarrhoea risk factors (see Table 5.32). Although Model 3 (clinical indicators) did not 
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achieve statistical significance, it is noted that a longer duration of 
hypoalbuminaemia was significantly associated with a variation in aerobic intestinal 
microflora during the participants’ critical illness experience. The absence of a 
statistically significant finding from Model 3 might be due to the smaller sample size 
for some clinical indicators, or due to the participants’ diarrhoea incidence rate. No 
other statistically significant associations were identified. 
5.11 Summary of main results 
The findings from Study Two confirm that some common diarrhoea risk factors were 
associated with diarrhoea. A notable finding of Study Two is the association between 
diarrhoea incidence rates and the time to commencement of ETF following ICU 
admission, with a higher incidence rate of diarrhoea observed when ETF was 
commenced more than 24 hours following ICU admission. The direction of the 
relationship between diarrhoea incidence rate and time to ETF commencement 
following ICU admission was unexpected. A higher diarrhoea incidence rate would 
have been expected with the earlier commencement of ETF and therefore, the longer 
duration of ETF. 
No statistically significant associations were identified between the occurrence of 
diarrhoea, the incidence rate of diarrhoea and some binary variables, including the 
participant’s age, gender and some medications (see Tables 5.13, 5.28 to 5.32). The 
occurrence of diarrhoea and the higher incidence rate of diarrhoea were both 
associated with the longer duration of aperient, prokinetic, stress ulcer prophylaxis 
medications, sedation and antibiotic medication administration. The presence of an 
infection was significantly associated with the occurrence of diarrhoea and a higher 
incidence rate of diarrhoea. 
A notable finding from Study Two is the diversity and variability of aerobic 
intestinal microflora observed during critical illness. Intestinal microflora were more 
likely to change if the study participant was older, experienced a higher severity of 
illness score (APACHE II score), received multiple medications and had a longer 
duration of hypoalbuminaemia and hyperglycaemia. It is acknowledged that the more 
acutely ill patient may have higher APACHE II scores, be exposed to more ICU 
associated interventions, develop an infection and receive multiple antibiotics which 
in turn may directly affect aerobic instestinal microflora. Consequently, independent 
149 
predictor variables associated with diarrhoea becomes difficult to identify as is the 
case with most critical care research. 
5.12 Summary 
This chapter has presented the analyses and findings between diarrhoea, diarrhoea 
risk factors and aerobic intestinal microflora relationships in ETF, critically ill ICU 
patients. The findings support contemporary literature regarding diarrhoea risk 
factors and critical illness. It is important to note that the level of involvement of 
these diarrhoea risk factors varied between critically ill patients and across critically 
ill patient populations. The differences identified between Study Two and current 
literature may be associated with the diverse and variable approaches to identifying 
and defining diarrhoea and its associated risk factors. The results of Study Two will 
now be discussed. 
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CHAPTER SIX: DISCUSSION 
6.1 Introduction 
The purpose of this chapter is to discuss the results of Study Two in relation to the 
research aims, questions and hypotheses, relevant past research and empirical and 
contemporary literature. The conceptual framework (Figure 2.1, page 10) that 
underpins this study will be used to guide the discussion. The chapter will begin with 
a discussion of the Study Two sample characteristics. This will be followed by a 
discussion of the results of diarrhoea and diarrhoea risk factors including ICU 
treatments (enteral nutrition, medications and clinical indicators) and aerobic 
intestinal microflora associations. This chapter will conclude with a summary of the 
main findings presented within a revised conceptual framework (see Figure 6.1, page 
170). 
6.2 Sample characteristics 
In the current study the patient characteristics of age (Mdn = 49 years, range 18–86 
years), gender (n = 69, 68% males), actual ICU LOS (Mdn = 7 days, range 1–54 
days), admission diagnoses and severity of illness (APACHE II score [Mdn = 27, 
range 1–49]) were reflective of national population trends in ICU (ANZICS CORE 
Report, 2011). Similarly, the SOFA score collected for the day of ICU admission 
also reflects the higher acuity of critical illness observed at the research site, a Level 
III ICU (ANZICS CORE Report, 2011; Doig et al., 2008; Ferreira, Bota, Bross, 
Melot, & Vincent, 2001; Ho, Lee, Williams, Finn, Knuiman, & Webb, 2007). The 
similarities between the characteristics of the study sample and the general 
population provide some confidence that the study findings could be generalised to 
other similar ICU populations, although the small study sample size is 
acknowledged. 
6.3 Diarrhoea and critical illness 
In this study, the period prevalence, the occurrence and the incidence rate of 
diarrhoea were examined. The definition of diarrhoea used in this study incorporated 
the same characteristics that were used in Study One and included stool 
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weight/volume, frequency and consistency (the Bristol Stool Chart; see Lewis & 
Heaton, 1997; O’Donnell et al., 1990; Pares et al., 2009). There is no consensus 
regarding the use of a standardised definition of diarrhoea or a standardised faecal 
output measurement tool to consistently identify, measure and quantify diarrhoea in 
ETF, critically ill patients and in general clinical practice (Lee & Auyeung, 2003; 
Whelan et al., 2003; Whelan, Judd, Preedy, et al., 2008; Whelan, Judd, Tuohy, et al., 
2008). This culminates in various ways that researchers examine diarrhoea and its 
associated risk factors. Unlike the current study, the Ferrie and East (2007) study 
defined diarrhoea using a higher volume of faecal stool output, namely a daily stool 
output exceeding 300 mL or three or more liquid/unformed stools per day. In 
comparison, the current study defined diarrhoea as the passage of three or more 
liquid or loose stools and/or a stool weight >200 g/day. Of note, the Ferrie and East 
(2007) study redefined diarrhoea during the implementation of the study protocol to 
include four or more stools of any consistency over a 24-hour period. The 
implication of this is that stool quantity may have been over-estimated, thereby over 
inflating diarrhoea prevalence figures. Researchers will continue to interpret 
diarrhoea in varied ways as different definitions are used to explain diarrhoea and a 
range of risk factors continue to be used to examine diarrhoea. Consequently, 
without a standardised definition the actual incidence of diarrhoea will remain poorly 
examined. 
The period prevalence of diarrhoea (n = 53, 53%) in this study is consistent with 
prevalence reports in other studies: 2% to 95% (Ferrie & East, 2007; Whelan, Judd, 
& Taylor, 2004; Whelan et al., 2009) and in particular studies that employed a 
prospective design to collect data regarding diarrhoea. Two explanations are 
proposed for the similarities between diarrhoea period prevalence in this study and 
other studies (Ferrie & East, 2007; Whelan, Judd, & Taylor, 2004; Whelan et al., 
2009). First, a higher period prevalence of diarrhoea was expected to be observed in 
the prospective study (Study Two) due to the inclusion of a validated diarrhoea 
definition and measurement tool (the Bristol Stool Form Scale). However, it is 
difficult to compare this prevalence rate specifically with other intensive care studies 
using the same diarrhoea assessment tool due to marked variability in quantifying 
diarrhoea and the diversity of faecal stool assessment tools used in the literature 
(Bishop et al., 2010; Hall, 2011; Horn & Chaboyer, 2003; Nguyen, Ching, et al., 
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2008). Second, education of health care clinicians regarding the study protocol may 
have increased their awareness of ETF and bowel care protocols. Health care 
clinician education has been used in some similar studies (Ferrie & East, 2007; 
Whelan et al., 2004) but not in another study (Whelan et al., 2009). In the current 
study, bedside clinicians were educated about the study protocol. This may have 
contributed to more patients being commenced on these treatments, thereby 
increasing the period prevalence of diarrhoea identified in this study. 
A finding rarely reported in the literature is the positive and linear association 
between the higher number of events and longer duration of diarrhoea as identified in 
the current study. This reflects that patients who experience increased frequency of 
diarrhoea will experience diarrhoea over a longer time frame. Such patients are 
clinically exposed to an increased risk of complications such as perianal skin 
breakdown, wound contamination and infection (Whelan et al., 2004, 2009) and fluid 
and electrolyte imbalance (Garey et al., 2006; Halmos et al., 2010; Martin, 2007). It 
is acknowledged that the current study did not examine the aforementioned 
complications; however, a more broad understanding of diarrhoea events and 
duration is required to understand the phenomenon of diarrhoea in critical illness. 
The current study examined the association between the incidence rate of diarrhoea 
and commonly known diarrhoea risk factors in ETF, emergency admission critically 
ill adult patients. The diarrhoea incidence rate was lower in Study Two (cumulative = 
0.44 events, range 0–2.40 events per patient observation day) than Study One 
(cumulative = 0.64 events, range 0–2.90 events per patient observation day). Study 
One had a later recruitment period (five to 14 days) compared with Study Two (two 
to 14 days) resulting in longer actual ICU stays. Although patient characteristics 
were similar between the two studies, APACHE II scores were higher and the actual 
ICU LOS was shorter in Study Two. It is possible that the diarrhoea incidence rate 
was lower in Study Two owing to the shorter actual ICU stay and therefore may 
simply be an artefact of the available time for observation. 
Central to this research is the conceptual framework (see Figure 2.1, page 10) that 
guided Study Two. The findings reaffirm the association between the number of 
events, duration and the incidence rate of diarrhoea in ETF critically ill patients 
identified in the conceptual framework. The number of days of observation and 
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severity of patient illness might explain this association. While this study contributes 
to knowledge about diarrhoea and associated risk factors it is acknowledged that the 
required sample size for Study Two was not achieved and this may have resulted in 
type II error. 
6.4 Diarrhoea risk factors 
In the current study, the occurrence of diarrhoea and the incidence rate of diarrhoea 
were associated with several commonly known diarrhoea risk factors including 
patient characteristics, ICU treatments (ETF, medications and clinical indicators) and 
aerobic intestinal microflora. Diarrhoea and its associated risk factors and 
complications have been extensively described in the literature (Lee & Auyeung, 
2003; McNaught et al., 2005; Weisen et al., 2006; Whelan et al., 2003; Whelan et al., 
2009). No research in the past 15 years has examined diarrhoea risk factors in a 
single cohort of critically ill patients (Bengmark, 2002; Bowling, 1998; Cole et al., 
1998; DeMao et al., 1998; Lee & Auyeung, 2003; McNaught et al., 2005; Weisen et 
al., 2006; Whelan et al., 2001; Whelan et el., 2003; Whelan et al., 2009). A 
substantial proportion of previous research excluded critically ill patients or used 
mixed patient cohorts that included critically ill and general ward patients and 
healthy volunteers. 
6.4.1 Patient characteristics 
In the current study, the incidence rate of diarrhoea was associated with only one 
commonly known patient characteristic: the study ICU LOS (period of data 
collection). It is acknowledged that the critically ill patient who has a longer ICU 
LOS and a higher severity of illness score might also have a higher diarrhoea 
incidence rate because they are critically ill and exposed to ICU treatments. These 
include enteral nutritional therapy, medications (sedation and antibiotics), and they 
may also experience a derangement of clinical indicators over a longer period of 
time. It is also acknowledged that the development of diarrhoea in itself is not 
associated with the patient experiencing a longer study and actual ICU stay. Findings 
of this study confirm the conceptual framework associations between the ICU patient 
with diarrhoea, the patient’s study ICU LOS and severity of illness as proposed in 
Figure 6.1 (page 170) with longer ICU stays associated with a higher diarrhoea 
incidence rate. 
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Using multivariate analyses, this study found that patients who were acutely ill, with 
higher APACHE II and SOFA scores (see Table 5.31), had a higher occurrence and 
incidence rate of diarrhoea. This might be explained by subtle interactions between 
intestinal perfusion and oxygenation that were not measured in the current study, and 
the differences between multivariate and bivariate analyses, where multivariate 
analyses explored the associations between a group of variables (diarrhoea risk 
factors) (Pallant, 2011). These associations might also be reflective of the sensitivity 
of the two scores, with the SOFA score being more reflective of organ failure 
compared with the APACHE II score that reflects severity of acute illness and the 
prediction of mortality at ICU admission (Ferreira et al., 2001; Gursel & Demirtas, 
2006; Ho et al., 2007). Given the international acceptance of these tools this is an 
important finding. 
The current study found that patients who had a longer period of time from ICU 
admission to initial bowel activity progressed to experiencing a higher diarrhoea 
incidence rate. Often reported in the literature is posttraumatic and postoperative 
ileus (hypo/hyper intestinal activity) (Btaiche et al., 2010). The association of this 
phenomenon and diarrhoea has not been reported in critically ill patients. This is a 
new finding that was not proposed in the conceptual framework in Chapter Two (see 
Figure 2.1, page 10) and is now identified within the green Patient Characteristic 
circle of the revised conceptual framework (see Figure 6.1, page 170). Standardised 
protocols that promote gastrointestinal motility in the critical illness context are 
essential and international ETF clinical practice guidelines (Heyland et al., 2003b; 
Jacobs et al., 2004; Kreymann et al., 2006; Martin et al., 2004; Martindale et al., 
2009; McClave et al., 2009; NICE, 2006) recognise this. The implementation of 
standardised promotility protocols was not examined in the current study. Findings in 
the area of diarrhoea, gastrointestinal hypomotility and delay to bowel activity 
following ICU admission will continue to remain poorly understood until the 
aforementioned associations are further examined with regard to intestinal 
hypoperfusion, medication administration and clinical indicator derangement. 
6.4.2 Enteral tube-feeding 
Enteral nutritional formula was administered continuously over a 24-hour period at 
the research site in Study Two. This method of tube-feeding is the most common 
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method of enteral nutrition delivery in the critical care setting (Skipper, 2012) and 
this is similar to other studies (Heyland et al., 2003b; Jacobs et al., 2004; Kreymann 
et al., 2006; Martin et al., 2004; Martindale et al., 2009; McClave et al., 2009; NICE, 
2006). The majority of participants in this study (n = 72, 71%) had their ETF ceased 
in the ICU. 
6.4.3 Time to ETF commencement 
Enteral tube feeding commencement was measured in two ways: (1) ETF 
commenced within 24 hours of ICU admission; and (2) the exact time (in hours) to 
ETF commencement. In the critically ill patient, delay to ETF commencement has 
been associated with diarrhoea (Artinian et al., 2006; Penniman, 2010; Singer et al., 
2009; Skipper, 2012); however, relationships between these two events remain 
inadequately examined in the literature. This study found that the majority of 
participants (n = 83, 82%) commenced ETF within 24 hours of ICU admission with 
the median time to ETF commencement of 10 hours (range 1–104 hours). Although 
the findings of the current study substantiate international enteral nutritional clinical 
practice guidelines (Heyland et al., 2003b; Jacobs et al., 2004; Kreymann et al., 
2006; Martin et al., 2004; Martindale et al., 2009; McClave et al., 2009; NICE, 2006) 
with regards to early ETF commencement following ICU admission, some patients 
did not receive ETF for up to four and a half days in the current study. It is proposed 
that underfeeding the GIT may contribute to its dysbiosis, thereby predisposing the 
critically ill patient to splanchnic hypoperfusion, stress-related mucosal damage and 
commensal bacteria imbalance. This may culminate with changes to GIT motility 
(periods of hypo activity followed by periods of hyperactivity), and osmotic gradient 
changes that lead to diarrhoea. These patients therefore require critical examination 
as to the reasons explaining the delay to ETF commencement to identify policy, 
education and research strategies to improve this practice for this vulnerable patient 
cohort. The higher number of participants who commenced early ETF in the current 
study might be explained by the research site’s ETF algorithm that promoted early 
commencement of ETF. Similar studies (Doig et al., 2008; Heyland et al., 2003b) 
have found that implementing an ETF algorithm decreases the time to ETF 
commencement and ameliorates some adverse complications associated with ETF. 
The similarities between early ETF commencement in the current study, similar 
studies (Doig et al., 2008; Heyland et al., 2003b) and international ETF clinical 
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practice guidelines (Heyland et al., 2003b; Kreymann et al., 2006; Martin et al., 
2004; McClave et al., 2009; NICE, 2006) suggests that the findings of the current 
study could be generalised to similar ICU populations; however, the small study 
sample, severity of illness and the study and actual ICU LOS should be 
acknowledged. 
In the current study, a higher incidence rate of diarrhoea was associated with the later 
commencement of ETF (more than 24 hours) following ICU admission. This was an 
unexpected finding as early commencement of ETF (< 24 hours) would expose 
patients to a longer duration of ETF (osmotic enteral feeds), which has previously 
been associated with diarrhoea (Artinian et al., 2006; Penniman, 2010; Singer et al., 
2009; Skipper, 2012). It is postulated that the later commencement of ETF (more 
than 24 hours) may lead to more days with splanchnic hypoperfusion and hypoxia 
(intestinal perfusion–reperfusion injury) and stress-related mucosal injury—
diarrhoea risk factors that were not examined in this study. This finding might also 
be associated with the larger sample size of the current study compared with other 
studies (Cahill et al., 2011; Cahill et al., 2012; Khalid, Doshi, & DiGiovine, 2010). 
Evidence-based enteral feeding algorithms insufficiently address ETF-associated 
diarrhoea relationships. The findings between diarrhoea and the time to ETF 
commencement following ICU admission identified in this study are a reminder that 
the early commencement of ETF may reduce some secondary complications 
associated with critical illness. It is important to note that these complications may, 
in fact, be perpetuated and delayed due to the increased incidence rate of diarrhoea, 
which is often not seen until later in the patient’s ICU admission or following 
discharge from the ICU (Bowling, 2010). 
A new finding identified in this study is that those patients who commenced ETF 
within 24 hours of ICU admission experienced lower diarrhoea incidence rates 
compared with those patients who commenced ETF more than 24 hours following 
ICU admission. International ETF clinical practice guidelines (Heyland et al., 2003b; 
Kreymann et al., 2006; Martin et al., 2004; McClave et al., 2009; NICE, 2006) 
promote the importance of early ETF and the finding between later ETF 
commencement and higher diarrhoea incidence rates in this study support these 
guidelines from an alternate angle; reduction in diarrhoea incidence rates. Findings 
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of this study support the association between the ICU patient with diarrhoea and ETF 
(commencement, duration, delivery and formula) in the revised conceptual 
framework (see Figure 6.1, page 170). 
A notable finding of this study is that there was no association between diarrhoea and 
the exact timing of ETF commencement following ICU admission. It is postulated 
that diarrhoea prevention often remains a low priority in the research and clinical 
contexts as it is often not observed until later in the patient’s critical illness or 
following the patient’s discharge from the ICU. The immediate lifesaving nature of 
the ICU requires prioritisation of health-related cares and, as such, diarrhoea is often 
not a priority physiological function.A consequence of this lower prioritisation of 
intestinal physiological dysfunction may result in further complications including 
bacterial translocation (Artinian, Kreyman, & DiGiovine, 2006; Btaiche et al., 2010; 
Fink, 2003; Heyland et al., 2003b; Marik & Zaloga, 2001), wound contamination and 
increased risk of infection (Bleichner et al., 1997; Bliss et al., 1998; Bliss, Guenter, 
& Settle, 1992; Btaiche et al., 2010; Ehman et al., 2006; Gray, Ratliff, & Donovan, 
2002; Ukleja, 2010), electrolyte imbalance (Bleichner et al., 1997; Martin, 2007), 
dehydration (Meier, Burri, & Steuerwald, 2003) and increase costs to the limited 
health care budget (Bleichner et al., 1997; Edmondson, 2007; Landzinsky et al., 
2008). It is acknowledged that the  aforementioned complications between diarrhoea, 
ETF and critical illness were not examined in the current study and this may 
therefore limit the generalisation of some findings. 
6.4.4 Duration of ETF 
In the current study, the median duration of ETF was 6 days (range 1–14 days). The 
earlier commencement and shorter duration of ETF observed in Study Two might be 
associated with the participants’ shorter lengths of study ICU stay. In the current 
study, a higher diarrhoea incidence rate was associated with a longer duration of 
ETF. Although diarrhoea and ETF relationships (time to ETF commencement, ETF 
algorithms, bowel care, feeding tube maintenance) have been extensively described 
in the literature (Bankhead et al., 2009; Best, 2008; de Aguilar-Nascimento, Bicudo-
Salomao, & Portari-Filho, 2012; Dorman et al., 2004; Halmos et al., 2010; Lau & 
Girard, 2011; McPeake et al., 2011), the relationships between diarrhoea and the 
duration of ETF have been examined with less frequency (Jacobs et al., 2004). 
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Capturing the incidence rate of diarrhoea provided a comprehensive examination of 
the phenomenon (diarrhoea) and ETF duration associations over a period of time (1–
14 days). A higher diarrhoea incidence rate was observed when patients were ETF 
for a longer timeframe and this confirms the association between the ICU patient 
with diarrhoea and ETF (commencement, duration, delivery and formula) in the 
revised conceptual framework (see Figure 6.1, page 170). It is acknowledged that 
patients who are ETF for a longer period of time would be expected to experience a 
higher occurrence and duration of diarrhoea; however, other predictor variables, such 
as patient characteristics, ICU treatments (ETF and medications), clinical indicators 
and other intestinal microflora require examination in appropriately powered models. 
6.4.5 ETF formula 
Consistent with international practice (Chen & Peterson, 2009; Heyland et al., 2003a, 
2003b; Mehta & Compher, 2009; Skipper, 2012; Woo et al., 2010) participants in 
Study Two received standard polymeric nutritional formulae (Jevity, Jevity Plus and 
Nepro) with the most common formula being Jevity (n = 65, 64%). The current study 
found that patients who received Nepro enteral nutritional formula also experienced a 
higher diarrhoea incidence rate compared with Jevity and Jevity Plus formulae. 
Caution is required when extrapolating these findings to the clinical context because 
of the low number of participants who received Nepro. It is interesting to note that 
similar research over the past 20 years has yielded conflicting findings between 
diarrhoea and ETF formulae, with some research confirming the association between 
the type of feed and diarrhoea development (Bowling, Raimundo, Grimble, & Silk, 
1994; Btaiche et al., 2010; Lloyd & Powell-Tuck, 2004; Pessola et al., 1990) and 
other research refuting these same associations (Bowling et al., 1993; Whelan et al., 
2001). Interestingly, international enteral nutritional clinical practice guidelines 
(Heyland et al., 2003b; Jacobs et al., 2004; Kreymann et al., 2006; Martin et al., 
2004; Martindale et al., 2009; McClave et al., 2009; NICE, 2006) make no reference 
to a relationship between diarrhoea and ETF formulae. The ingredients of the ETF 
formulae may indeed be associated with the higher diarrhoea incidence rates 
observed in the current study; for example, hyper-osmolar feeds (Nepro) have a 
higher osmolality (>500 mOsm) compared with the lower osmolality of Jevity and 
Jevity Plus (300–500 mOsm) (Dieticians Association of Australia, 2011; Skipper, 
2012). Of note in this study is that the research site’s ETF protocol (see Appendix 4) 
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avoids the use of disease-specific ETF formulae. Evidence supporting this practice 
remains inconclusive with negative consequences such as underfeeding, overfeeding 
and diarrhoea far outweighing the potential benefits (Chen & Peterson, 2009; 
Skipper, 2012). 
6.4.6 Medications 
Over 75% of participants observed in Study Two received aperient, prokinetic, H2-
receptor antagonists, PPIs, antibiotics, sedation and opioid medications (see Table 
5.3). Fewer patients received lactulose, erythromycin, morphine and vecuronium 
while more patients received microlax enemas and fentanyl compared with Study 
One. This difference might be associated with clinical practice changes that occurred 
to the bowel care and ETF algorithms between Study One and Study Two at the 
research site. Specifically, during Study Two a new bowel care algorithm was 
implemented that included increased use of bisacodyl and glycerine suppositories to 
stimulate and soften bowel motions and increased use of erythromycin to treat ETF 
intolerance (high gastric residual volumes). The changes in the bowel care algorithm 
may have contributed to more homeostatic intestinal motility; thereby, mitigating the 
higher period prevalence of diarrhoea observed in Study One. The duration of 
medication administration in Study Two differed to the duration of medication 
administration observed in Study One. Of note is that there is little consensus 
between the duration of medication administration in the current study and the 
literature (Hayakawa, Asahara, Henzan, Murakami, & Yamamoto, 2011; Shimizu et 
al., 2006; Whelan et al., 2009) suggesting that variety of and duration of medications 
administered to critically ill patients is reflective of the complexity, individuality and 
acuity of the critical illness itself. As previously noted, clinicians might have been 
more vigilant in adhering to the study protocol, including the research site’s bowel 
care and ETF protocols due to the prospective design of Study Two, thereby 
facilitating timely bowel care of the critically ill patient that possibly culminated in a 
lower diarrhoea incidence rate in Study Two compared with Study One. 
In the current study, the majority of medications examined were associated with a 
higher diarrhoea incidence rate, with the exception of some aperients, H2-antagonist 
and neuromuscular blockade medications (see Table 5.13). Of note is that the 
administration of multiple antibiotic combinations (combinations of three, four and 
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five antibiotics) was associated with the higher incidence rate of diarrhoea in this 
study, indicating a physiological interaction between intestinal homeostasis and 
antibiotic administration. Some previous studies have shown associations between 
medications and diarrhoea, while others have not (Aseeri et al., 2008; Luft et al., 
2008). Medication as a causal link with diarrhoea has not been definitively 
established. Given the association between medication administration and diarrhoea, 
it is suggested that subtle relationships might exist between diarrhoea, some 
medications, severity of illness, duration of ETF and the study ICU LOS. It is 
interesting to note that changes in the patient’s physiological condition may require 
the ICU patient with diarrhoea to receive increased or continuing doses of some 
medications, such as fentanyl and PPI medications, all of which may further 
contribute to diarrhoea. The associations found in this study between the higher 
incidence rate of diarrhoea and medication administration reaffirms associations 
between the ICU patient with diarrhoea and the two circles of medications depicted 
within the revised conceptual framework (see Figure 6.1, page 170). Findings in this 
area will continue to show wide variation because of the individuality and acuity of 
critically ill patients and the importance of medications in bowel care protocols 
(Doig et al., 2004; Ferrie & East, 2007; McPeake et al., 2011) in the management of 
intestinal health in this patient cohort. Standardised bowel care protocols that 
incorporate medications to soften the stool and promote gastrointestinal motility are 
essential and international enteral nutritional clinical practice guidelines (Heyland et 
al., 2003b; Jacobs et al., 2004; Kreymann et al., 2006; Martin et al., 2004; Martindale 
et al., 2009; McClave et al., 2009; NICE, 2006) recognise this. 
6.4.7 Clinical indicators 
In the current study, the majority of patients experienced a derangement of clinical 
indicators including hyperglycaemia, hypoalbuminaemia, elevated WCC and 
elevated INR. In addition, more than half of all participants experienced an infection 
(n = 64, 64%). Of the clinical indicators selected for examination in the current study 
only the occurrence of hypoalbuminaemia and infection were associated with the 
critically ill patient experiencing diarrhoea. However, when the duration of clinical 
indicator derangement in ETF in critically ill patients was examined, all clinical 
indicators were associated with the critically ill patient experiencing a higher 
incidence rate of diarrhoea. Factors contributing to these findings include the severity 
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of patient illness, possible delays to ICU treatments and the superfluity of ICU 
treatments required to maintain and restore health; for example, invasive monitoring, 
systemic inflammatory responses to critical illness and mechanical ventilation 
(Grealy & Chaboyer, 2012; Whelan & Schneider, 2011). 
The association between some clinical indicators (inflammatory and coagulation 
markers), enteral nutrition and patient outcomes in critically ill patients with acute 
lung injury and acute respiratory distress syndrome has been established (Bastarache, 
Ware, Girarg, Wheeler, & Rice, 2012). In the current study, the occurrence of an 
infection and the duration of derangement of all clinical indicators 
(hypoalbuminaemia, hyperglycaemia, elevated levels of WCC and INR) were 
associated with an increased diarrhoea incidence rate. The findings of Study Two 
differ from Study One in that in the latter only hypoalbuminaemia and infection were 
associated with an increased rate of diarrhoea. The difference in diarrhoea incidence 
rates and clinical indicators noted between the two studies could be explained by the 
differences in sample sizes, the heterogeneity of the two different samples—although 
critically ill patients are a heterogeneous group of patients, the period of data 
observation or alternatively, an association between diarrhoea and some clinical 
indicators just did not exist in Study One. The results of the current study reaffirm 
the wide variability in findings between diarrhoea and other clinical indicator risk 
factors including fever, hypothermia, malnutrition, hypoalbuminaemia, suspension of 
oral feeding and the presence of an infection noted in other studies (Thorson et al., 
2008; Whelan, Judd, & Taylor, 2004; Whelan, Judd, Preedy, et al., 2004; Whelan et 
al., 2005). 
The relationships between gastrointestinal physiological and pathophysiological 
functioning in critical illness remains poorly examined in the literature. Some studies 
(Marshall & West, 2004; Whelan et al., 2001) have identified that a reduction in 
colloidal osmotic pressure leads to intestinal mucosal oedema in the 
hypoalbuminaemic patient. Consequently, diarrhoea occurs because of the increased 
secretion of fluid into the intestine of the ETF patient. Similarly, hyperglycaemia has 
been reported to exhibit a pro-inflammatory effect on gastrointestinal function 
(Kellow et al., 1999), relax the proximal stomach, and impair gastric motility and 
emptying in healthy and diabetic patients (Nguyen, Ching, Fraser, Chapman, & 
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Holloway, 2007) resulting in diarrhoea. This pathophysiological sequelae warrant 
further exploration in the context of critical illness and ETF. 
The value of understanding each patient’s response to critical illness and 
individualising their critical care health care needs, particularly the intestinal health 
care needs in the ICU environment may expedite recovery from critical illness. This 
might then minimise or avoid some adverse outcomes associated with critical illness 
and reduce the patient’s ICU and hospital lengths of stay. The findings between the 
ICU patient with diarrhoea and clinical indicators (hypoalbuminaemia, 
hyperglycaemia, elevated WCC, elevated INR and an infection) are reflected in the 
revised conceptual framework (see Figure 6.1, page 170). It is postulated that the 
aforementioned associations might occur because of the patient’s clinical response to 
critical illness where changes in intestinal oncotic pressure occurs from 
hypoalbuminaemia and hyperglycaemia (Kellow et al., 1999; Weisen et al., 2006). 
Critically ill patients who are admitted to the ICU often develop an infection (a 
clinical indicator in this study) and these may include enteropathogenic, systemic and 
wound infections (Marik & Zaloga, 2001; Shannon, 2004; Shimizu et al., 2006; 
Whelan & Schneider, 2011). To treat infections, critically ill patients often receive 
antibiotics that have been associated with intestinal microflora dysbiosis resulting in 
infectious diarrhoea (Clostridium difficile) (Bliss et al., 1998; Eisenberg, 2002); 
however, there are disparate numbers and durations of antibiotics administered to 
critically ill patients reported and this might be associated with the heterogeneity of 
this group of patients. Infectious diarrhoea has previously been associated with the 
bacteria Aeromonas hydrophilia (Forbes, Sahm, & Weissfeld, 2007; Winn et al., 
2006), Clostridium difficile, Salmonella and Shigella (Bishara, Peled, Pitlik, & 
Samra, 2008; Btaiche et al., 2010). No infectious causes of diarrhoea were returned 
on stool culture in this study. Many critically ill patients also receive concomitant 
ETF and antibiotics and a number of studies have shown that diarrhoea is associated 
with the both the number and duration of antibiotics administered (Halmos et al., 
2010; Trabal, Leyes, Hervas, Herrera, & de Tallo Forga, 2008; Whelan & Schneider, 
2011). Importantly, the absence of enteropathogenic infection as a risk factor for 
diarrhoea in the current study might be attributed to the clinical diagnoses of patients 
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admitted to the ICU, the severity of illness, the duration of observation and the small 
number of patients who received multiple antibiotics. 
6.5 Aerobic intestinal microflora and critical illness 
While modulating intestinal bacteria with prebiotics, symbiotics and probiotics has 
gained favour over recent years, little is understood about intestinal microflora as 
they naturally occur during a critical illness experience. How and when intestinal 
microflora change during critical illness remains elusive. In this study, more 
participants experienced a higher proportion of absent and 3+ colonisation of E. coli 
and absent, scant, 1+ and 2+ of Corynebacterium sp. collected from rectal swabs on 
admission to, and discharge from, the ICU. The total bacteria counts of other 
intestinal microflora (LF, NLF, gram positive bacilli, yeasts and skin flora) remained 
relatively unchanged or recovered to normal or baseline concentrations. No previous 
studies have explored the aerobic intestinal bacteria reported in Study Two. 
A noteworthy finding of this study was the significant associations between normal 
faecal flora at multiple time points (see Table 5.19) indicating that normal faecal 
flora are modulated throughout the critical illness experience. It is postulated that the 
diversity of normal faecal flora throughout a critical illness experience is associated 
with the patient’s severity of illness, the ICU LOS, the complexity of physiological 
responses to critical illness and the multiplicity of ICU treatments including ETF. 
Reasons explaining these aerobic intestinal microflora changes during a critical 
illness experience remain elusive. Intestinal microflora dysbiosis has previously been 
reported at one week following hepatectomy (Kanazawa et al., 2005) and changes in 
intestinal microflora have been detected at one to two weeks in critically ill patients 
with severe systemic inflammatory response syndrome (Shimizu et al., 2006). It is 
difficult, however, to compare the findings of the current study with the Kanazawa et 
al. (2005) and Shimizu et al. (2006) studies due to the heterogeneity of the current 
study’s sample, the different intestinal microflora that were cultured and examined in 
the current study, the different methods and timing of specimen collection and the 
different methods of specimen processing. 
Only one other study (Hayakawa et al., 2011) has examined changes in intestinal 
microflora during the early phase of critical illness in ETF patients. Dissimilar to the 
current study, the Hayakawa et al. (2011) study collected faecal specimens by rectal 
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swab within six hours of admission to the emergency department, prior to the 
administration of the first dose of antibiotics and with serial collection on days, 1, 3, 
4, 7, 10 and 14. Bacterial counts were significantly reduced on the day of admission 
while Pseudomonas and Enterococcus colonisation increased during the study. 
Findings of the Hayakawa et al. (2011) study and the current study are similar in that 
intestinal microflora counts reduced significantly immediately following a sudden 
physiological insult, such as critical illness. However, the current study differed in 
that Hayakawa et al. (2011) found Pseudomonas and Enterococcus concentrations 
increased during the study period. Significant differences were noted between the 
current study and the Hayakawa et al. (2011) study in that the current study 
examined diarrhoea, enteral nutrition and aerobic intestinal microflora associations 
and the Hayakawa et al. (2011) study examined anaerobic intestinal microflora 
changes only during the early phases of severe and sudden critical illness. Further, all 
participants in the current study received enteral nutrition; however, some patients in 
the Hayakawa et al. (2011) study received enteral and parenteral nutrition that may 
have resulted in a higher proportion of those patients experiencing hyperglycaemia, 
intestinal oncotic pressure disequilibrium and infections of some description. Of note 
is that these aforementioned clinical complications were not reported in the 
Hayakawa et al. (2011) study. The implications of pathogenic microorganism 
overgrowth and diarrhoea were also not reported in the Hayakawa et al. (2011) study. 
Participants in the current study were more acutely ill (APACHE II scores Mdn = 27, 
range 17–49) compared with the Hayakawa et al. (2011) study population (Mdn = 21, 
range 18–26), which may have culminated with a longer duration of antibiotic 
administration and longer actual ICU LOS. The ICU LOS was not specifically 
reported in the Hayakawa et al. (2011) study, making generalisation of findings 
across critically ill patient cohorts difficult. Finally, the Hayakawa et al. (2011) study 
used different methods and timing of specimen collection that may have resulted in 
dissimilarities to the current study. 
Relationships between diarrhoea, diet and aerobic intestinal microflora have been 
insufficiently examined in the critical illness context. Changes in western diets have 
demonstrated insignificant changes in the intestinal microflora in healthy individuals 
(Schneider et al., 2000). The relationships between extreme dietary changes such as 
those associated with ETF, aerobic intestinal microflora and a critical illness have, 
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however, yielded different outcomes (Schneider et al., 2000). In this study, changes 
in intestinal microflora were not associated with a change of pre-hospital diet and 
enteral nutrition in newly admitted critically ill patients. The results of this study 
confirm the conflicting associations between extreme dietary changes and 
adaptations in participants’ normal faecal flora in the Schneider et al. (2000) study. 
Only one other study (Whelan et al., 2009) has examined diarrhoea, enteral nutrition 
and intestinal microflora relationships; however, the Whelan et al. (2009) study was 
conducted in non-critically ill patients. Similar to this study, Whelan and colleagues 
(2009) found that there were very few changes in intestinal microflora in ETF 
patients; however, significant individual variation was noted between the 
participants’ intestinal microflora in faecal samples. Higher concentrations of 
Clostridia (p =.026), and lower concentrations (p =.069) and proportions (p =.029) of 
Bifidobacteria were found in the Whelan et al. (2009) study. A notable finding of the 
Whelan et al. (2009) study was that the proportion of Bifidobacteria was 
significantly different (Mdn = 0.4%, p =.035) in those participants who did not 
develop diarrhoea. This finding suggests that other unknown factors may be 
associated with diarrhoea. Diarrhoea was experienced by 50% (n = 10) of their 
sample. Consistent between the current study and the Whelan et al. (2009) study is 
that critically ill and non-critically ill hospitalised and ETF patients displayed 
significant diversity in their intestinal microflora. This GIT microflora dysbiosis may 
predispose the patient to an array of pathological states that might be minimised or 
avoided with more effective management of the GIT microflora. 
Significant differences are evident between the findings of diarrhoea and aerobic 
intestinal microflora in the current study and intestinal microflora in other studies 
(Hayakawa et al., 2011; Kanazawa et al., 2005; Schneider et al., 2000, Shimizu et al., 
2006). Each of these studies used a different set of intestinal microflora to examine 
as a primary outcome measure. No rationale was provided in any of these studies for 
this choice and thus it is difficult to see why there would be such diversity. The 
choice of intestinal microflora that have been examined in these studies is possibly 
associated with the fact that anaerobic bacteria colonisation outnumbers aerobic 
bacteria colonisation in the large intestine by a proportion of 1000:1 (Engelkirk & 
Burton, 2007; Forbes et al., 2007; Guarner, 2008). Consequently, anaerobic bacteria 
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counts are easier to measure. Of note between the Hayakawa et al. (2011), Kanazawa 
et al. (2005), Schneider et al. (2000) and Shimizu et al. (2006) studies is that the 
relationship between intestinal microflora, diet and critical illness just has not been 
established. 
Of the medication and clinical indicator variables examined in this study, only the 
duration of hypoalbuminaemia was associated with changes in intestinal microflora. 
This was not expected as some medications (H2-receptor antagonists and PPI 
medications) have previously been associated with modulating gastric acidity and 
therefore the gastric and intestinal tract’s microflora (Beaugerie, 2004; Cunningham 
& Dial, 2008; Gorkiewicz, 2009; Leonard, Marshall, & Moayyedi, 2007). The longer 
duration of hypoalbuminaemia was associated with greater diversification in aerobic 
intestinal microflora, further supporting the association between the ICU patient with 
diarrhoea and medications, clinical indicators and aerobic intestinal microflora 
depicted within the revised conceptual framework (see Figure 6.1, page 170). The 
absence of any association between the ICU patient with diarrhoea, aerobic intestinal 
microflora and medications, and clinical indicators examined in the current study 
might be attributed to the small study sample or the small number of participants 
who received the medications and experienced a derangement of clinical indicators. 
Alternatively, a relationship between the aforementioned variables simply did not 
exist. For these reasons, caution is required when generalising the findings of this 
study to the broad ICU population until further studies corroborate or refute the 
findings of the current study. 
This is the first study to report the association between aerobic intestinal microflora 
and the time to ETF commencement following ICU admission. In the current study, 
the time from ICU admission to the commencement of ETF was significantly 
associated with changes in the colonisation counts of normal faecal flora collected 
from the rectal swab at ICU admission and also the first faecal sample. 
Gastrointestinal tract disuse is reflected through delay to ETF commencement. 
Longer periods of GIT disuse disrupt intestinal epithelial cell homeostasis. 
Gastrointestinal tract disuse has been associated with intestinal epithelial apoptosis, 
which may result in intestinal bacteria translocation (Marshall et al., 2012), release of 
inflammatory mediators (Chapman et al., 2007) and intestinal reperfusion injury 
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(Marshall, 2009; Marshall et al., 2012; Putensen, Wrigge, & Hering, 2006) in critical 
illness. More change in normal faecal flora colonisation counts were observed when 
there was a longer timeframe from ICU admission to the commencement of ETF 
reconfirming the association between the ICU patient with diarrhoea, ETF 
(commencement, duration, delivery and formula) and aerobic intestinal microflora 
(see Figure 6.1, page 170). 
6.6 Summary of findings: Conceptual framework revised 
It was hypothesised in Chapter Three that diarrhoea and enteral nutrition were 
associated with aerobic intestinal microflora changes in critically ill patients. 
Relationships between diarrhoea and enteral nutrition have previously been 
demonstrated (Bodoky & Kent-Smith, 2009; Halmos et al., 2010; Shimoni et al., 
2007); however, no literature exists to substantiate the associations between 
diarrhoea, enteral nutrition and aerobic intestinal microflora in critically ill patients. 
The current study proposes five main diarrhoea risk factors that are associated with 
the ICU patient with diarrhoea. These are patient characteristics (study and actual 
ICU LOS, severity of illness, delay to bowl activity), ETF (commencement >24 
hours, duration, formula), medications (aperients, prokinetics, PPI, sedation, 
neuromuscular blockade), clinical indicators (hypoalbuminaemia, hyperglycaemia, 
elevated WCC and INR, infection) and aerobic intestinal microflora. These risk 
factors are consistent with some reported literature (Barbut & Meynard, 2002; 
Bastarache, Ware, Girard, Wheeler, & Rice, 2012; Ferrier & East, 2007; Heyland, 
2000; Huang, Chang, Hsu, Chang, Kang, & Liu, 2012; Lopez-Herce, 2009; Whelan 
et al., 2009). These associations are identified within the revised conceptual 
framework (see Figure 6.1, page 170) by the bolded red arrows between the ICU 
patient with diarrhoea and the green patient characteristic circle (study ICU LOS, 
severity of illness, delay to bowel activity), the pink circles including ETF 
(commencement > 24 hours, duration, formulae) and medications (aperients, 
prokinetics, PPI, sedation, antibiotics), and clinical indicators depicted by the purple 
circles (hypoalbuminaemia, hyperglycaemia, elevated WCC, elevated INR, 
infection) and aerobic intestinal microflora. Risk factors proposed in the original 
conceptual framework (see Figure 2.1, page 10) found to have no association with 
the ICU patient with diarrhoea have been removed from the revised conceptual 
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framework (see Figure 6.1, page 170) and include patient characteristics (age, 
gender) and medications (neuromuscular blockers, H2 receptor antagonists). The 
current study did not examine some associations between the ICU patient with 
diarrhoea and ETF (delivery, preparation, administration, bowel care) and these risk 
factors are identified in the revised conceptual framework (see Figure 6.1, page 170) 
as a pink circle with a black dashed outline linked with the ICU patient with 
diarrhoea by a black dashed line. 
Study Two identified that aerobic intestinal microflora changes occur immediately 
following an acute or severe insult. This finding is consistent with the recent research 
of Hayakawa et al. (2011). Study Two also identified that changes in aerobic 
intestinal microflora collected following admission to the ICU and the first faecal 
sample were associated with the participant experiencing diarrhoea. Another 
noteworthy finding is the significant association between the exact time to ETF 
commencement (measured in hours) and the normal faecal flora collected from rectal 
swab at ICU admission and then again with the first diarrhoea faecal sample and 
particularly following a severe and acute critical illness. These findings add weight to 
the argument that changes in aerobic intestinal microflora and common diarrhoea 
risk factors are associated with the critically ill patient experiencing diarrhoea. No 
relationship was found between the diarrhoea incidence rate and aerobic intestinal 
microflora in this study; however, the required sample size was not attained and 
therefore, the results should be treated with caution. 
In Chapter Two, the literature identified conflicting evidence with regard to risk 
factors associated with diarrhoea in ETF, critically ill patients and, in particular, 
where aerobic intestinal microflora was concerned. The most common diarrhoea risk 
factors of ICU LOS, severity of illness, ETF, some medications and some clinical 
indicators were associated with diarrhoea in the current study. Of note in the current 
study is the association between a higher diarrhoea incidence rate when ETF was 
commenced more than 24 hours following ICU admission. In regards to risk factors 
identified with aerobic intestinal microflora, ETF, antibiotics and hypoalbuminaemia 
were associated with more changes in aerobic intestinal microflora (Hayakawa et al., 
2011; Whelan et al., 2009). These diarrhoea risk factor characteristics provide some 
confidence that the study findings can be generalised across critically ill and non-
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critically ill populations; however, the small study sample, severity of illness and 
study and actual ICU LOS should again be acknowledged. 
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Figure 6.1 (page 170) highlights the risk factors associated with the key construct of 
this study, the ICU patient with diarrhoea in relation to the conceptual framework 
introduced in Chapter Two (see Figure 2.1, page 10). The revised conceptual 
framework (see Figure 6.1, page 170) comprises three main elements: the ICU 
patient with diarrhoea, the ICU environment and the critical illness experience. In 
Figure 2.1 (page 10), the hypothesised diarrhoea risk factors were represented as 
black compound or dashed linking arrows. The revised conceptual framework (see 
Figure 6.1, page 170) shows the findings between the ICU patient with diarrhoea and 
patient characteristics (Study ICU LOS, severity of illness, delay to bowel activity), 
ICU treatments including ETF (commencement > 24 hours, duration, formula), GIT-
associated medications (aperients, prokinetics, PPI, sedation, neuromuscular 
blockade), clinical indicators (hypoalbuminaemia, hyperglycaemia, elevated WCC 
and INR, infection) and aerobic intestinal microflora. Of note is that the revised 
conceptual framework (see Figure 6.1, page 170) shows that aerobic intestinal 
microflora dysbiosis affirms the associations between the ICU environment, the 
critical illness experience and patient characteristics. 
6.7 Summary 
The discussion of the major findings of this study has been presented in this chapter. 
Diarrhoea risk factors associated with this study were comparable to those of other 
contemporary studies (Hayakawa et al., 2011; Thorson et al., 2008; Whelan et al., 
2009). Conducting this study in a single-centre ICU enabled an insightful 
understanding of the associations between diarrhoea, enteral nutrition and aerobic 
intestinal microflora. The knowledge generated from this study identified gaps in 
theoretical knowledge that underpins current clinical practice with regard to the 
intestinal health of critically ill patients. This paucity of knowledge incorporates 
interchangeable definitions of diarrhoea, ineffective diarrhoea measurement tools in 
the critical care context, variable understanding of ETF and diarrhoea relationships, 
and dysbiosis of GIT microflora in ETF, critically ill patients. This study has 
established that aerobic intestinal microflora dysbiosis varies widely following an 
acute and severe insult and that GIT dysbiosis and diarrhoea are significantly 
associated. The clinical implication of the associations identified in the current study 
increases the occurrence and incidence rate of diarrhoea in critically ill patients. The 
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implications of results from this study for future clinical practice, education, policy 
development and research are significant and will be discussed in the final chapter. 
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CHAPTER SEVEN: CONCLUSION 
7.1 Introduction 
The purpose of this final chapter is to summarise the findings of both Study One and 
Study Two in relation to the research questions and hypotheses. This will be 
followed by a discussion of the strengths and limitations of this research. 
Recommendations for future clinical practice, education, policy development and 
research will then be offered. This will be followed by a final conclusion to the 
thesis. 
7.2 Summary of findings 
The aim of this study was to examine diarrhoea, enteral nutrition and aerobic 
intestinal microflora associations in critically ill, emergency admission adult ICU 
patients. This research comprised two studies: a retrospective, repeated measures, 
observational cohort study (Study One); and a prospective, repeated measures, 
correlational, cohort study (Study Two). Eight research questions and six hypotheses 
were proposed and these will guide the summary of the main findings of this 
research. A conceptual framework (see Figure 2.1, page 10) derived from the 
literature guided this study. 
Research Question 1. What is the period prevalence of diarrhoea in ETF patients in 
the ICU? 
The period prevalence of diarrhoea was 78% in Study One and 53% in Study Two. 
The diarrhoea incidence rate in Study One (cumulative = 0.64 events, range 0–2.90 
events per patient observation day) was higher compared with the diarrhoea 
incidence rate in Study Two (cumulative = 0.44 events, range 0–2.40 events per 
patient observation day). 
Research Question 2. Is there a relationship between the number of events of 
diarrhoea and the duration of diarrhoea in ETF critically ill patients? 
A statistically significant and positive association was identified between the number 
of events and the duration of diarrhoea in both Study One and Study Two. Results 
174 
from both studies revealed that a higher number of events of diarrhoea were 
positively and linearly associated with a longer duration of diarrhoea, thereby 
rejecting the null hypothesis. 
Research Question 3. Are clinical indicators such as hypoalbuminaemia, 
hyperglycaemia, elevated WCC, elevated INR and infection associated with 
diarrhoea in this study? 
A higher occurrence and higher incidence rate of diarrhoea was observed when the 
patient experienced an occurrence of hypoalbuminaemia or an occurrence of an 
infection. In addition, a higher incidence rate of diarrhoea was experienced by 
patients in this study when there were more days with hypoalbuminaemia, 
hyperglycaemia, elevated WCC and elevated INR derangement. The association 
between the higher diarrhoea incidence rate and the number of days of elevated 
WCC was observed in Study Two only. The null hypothesis was rejected. 
Research Question 4. Is diarrhoea in ETF patients associated with: 
 the type of ETF formulae? 
 the timing to commencement of ETF following ICU admission? 
 the duration of ETF? 
 gender, age, Study ICU LOS and APACHE II scores? 
 the duration of aperient, prokinetic, sedation, neuromuscular blockade, H2 
antagonist, PPI and antibiotic medication administration? 
The incidence rate of diarrhoea was not associated with the type of enteral nutritional 
formulae (Jevity, Jevity Plus, Nepro) administered to patients audited in Study One. 
In comparison, a higher diarrhoea incidence rate was associated with Nepro and 
Jevity formulae in Study Two with those participants who received these nutritional 
formulae experiencing more diarrhoea, thereby, rejecting the null hypothesis. 
In both Study One and Study Two the occurrence and incidence rate of diarrhoea 
was not associated with the exact time (in hours) of ETF commencement following 
admission to the ICU. However, a higher diarrhoea incidence rate was observed 
when ETF was commenced more than 24 hours following ICU admission in Study 
Two only. The null hypothesis was therefore rejected. 
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Results from both Study One and Study Two identified that critically ill patients 
experienced an occurrence of diarrhoea and higher diarrhoea incidence rates when 
ETF occurred over a longer periods of time. The null hypothesis is consequently 
rejected. 
Gender, age and severity of illness (APACHE II scores) were not associated with 
diarrhoea in the present study, thus the null hypothesis is accepted. In comparison, a 
higher severity of illness (SOFA) score was associated with a higher diarrhoea 
incidence rate in Study Two only. A longer Study ICU LOS (period of data 
collection) was associated with a higher diarrhoea incidence rate in both Study One 
and Study Two, thereby rejecting the null hypothesis. 
Higher diarrhoea incidence rates were associated with the administration of 
combinations of three antibiotics and also the duration of combinations of three 
antibiotics in both Study One and Study Two. 
In Study Two only, a higher diarrhoea incidence rate was associated with the 
administration of aperients, coloxyl/senna, bisacodyl and microlax enema; prokinetic 
combinations and metoclopramide; PPI combinations and esomeprazole; midazolam; 
an antibiotic and combinations of two, three, four and five antibiotics (see Table 
5.13). 
In addition, in Study Two only, a higher incidence rate of diarrhoea was associated 
with both the administration of and the duration of medication administration with 
aperients, coloxyl/senna, bisacodyl and glycerine suppositories and microlax enema; 
prokinetic combinations and metoclopramide; PPI combinations and esomeprazole; 
sedation, opioids, fentanyl and midazolam; and combinations of two, three, four and 
five antibiotics (see Table 5.13). These findings indicate that participants 
experienced a higher incidence rate of diarrhoea when these medications were 
administered and particularly when these medications were administered over a 
longer period of time. 
The diverse association between diarrhoea and medications identified in both Study 
One and Study Two suggests that multiple medication interactions and ICU 
treatments are associated with diarrhoea in this patient cohort and that a more 
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comprehensive understanding of these complex associations is required. The results 
of the current study therefore, reject the null hypothesis. 
Research Question 5. What are the identity and semiquantitative counts of aerobic 
intestinal microflora of: 
 emergently admitted ICU patients? 
 patients enrolled into Study Two who are discharged from the ICU? 
Over half of all emergently admitted ICU patients were found to have 3+ normal 
faecal flora colonisation counts cultured at both admission to and discharge from the 
ICU (see Table 5.14). Patients had proportionally higher concentrations of absent, 1+ 
and 2+ normal faecal flora colonisation counts cultured at discharge from the ICU 
compared with those normal faecal flora colonisation cultured on ICU admission. 
Rectal swabs at ICU admission showed that the proportion of lactose fermenter and 
non-lactose fermenter bacteria remained unchanged when swabbed again at 
discharge from the ICU (see Tables 5.15 and 5.16). The absent colonisation of gram 
negative bacilli increased (approximately doubled) between ICU admission and 
discharge. Most other bacteria (gram positive bacilli, yeasts, skin flora, multiresistant 
organisms and bacillus) cultured at the genus level remained unchanged during the 
patients’ critical illness experience or returned to baseline colonisation counts 
following ICU admission. 
Research Question 6. Does the baseline aerobic intestinal microflora change during 
ICU admission? 
Aerobic intestinal microflora concentrations changed throughout the critical illness 
experience. Significant changes were observed between the normal faecal flora 
collected at ICU admission and the first faecal sample, again between the first faecal 
sample and discharge from the ICU, and again between the second faecal sample and 
discharge from ICU, thereby the null hypothesis was rejected. 
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Research Question 7. Does a relationship exist between aerobic intestinal 
microflora and: 
 enteral nutrition and diarrhoea in emergency admission, critically ill, adult 
patients? 
 the timing of enteral nutrition commencement? 
No association was identified between aerobic intestinal microflora and the 
administration of enteral nutrition in the current study, thereby the null hypothesis 
was accepted. 
Changes in aerobic intestinal microflora were not associated with ETF commenced 
within 24 hours of ICU admission. The null hypothesis was accepted. In comparison, 
the exact time to ETF commencement (measured as whole hours) was associated 
with changes in aerobic intestinal microflora collected via rectal swab following ICU 
admission and compared with the aerobic intestinal microflora colonised at the first 
faecal sample. These findings reject the null hypothesis. 
Research Question 8. Are the differences in aerobic intestinal microflora of ETF 
critically ill patients who develop and those who do not develop diarrhoea associated 
with: 
 age? 
 pre-admission diet? 
 APACHE II and SOFA scores? 
 antibiotic therapy? 
 clinical indicators (the number of events and duration of hypoalbuminaemia, 
hyperglycaemia, elevated WCC, elevated INR and infection)? 
 Study ICU LOS? 
No association was found between aerobic intestinal microflora, diarrhoea and age, 
pre-admission diet and the Study ICU LOS. The null hypothesis was accepted. 
Higher severity of illness scores, combinations of antibiotics, a longer duration of 
antibiotic administration and a longer duration of hypoalbuminaemia and elevated 
WCC were all associated with increased diversity of aerobic intestinal microflora in 
patients who experienced diarrhoea; thereby, the null hypothesis was rejected. 
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In summary, the current study contributes to the broad understanding of the 
complexities between diarrhoea, enteral nutrition, aerobic intestinal microflora and 
critical illness. The associations between the ICU patient with diarrhoea and patient 
characteristics (study ICU LOS, severity of illness, delay to bowel activity), ICU 
treatments including ETF (commencement > 24 hours, duration, formula), GIT-
associated medications (aperients, prokinetics, PPI, sedation, neuromuscular 
blockade), clinical indicators (hypoalbuminaemia, hyperglycaemia, elevated WCC 
and INR, infection) and aerobic intestinal microflora are significant and support the 
possibility of improving the intestinal health and minimising the complications 
associated with diarrhoea in critically ill patients. Results from this study should be 
considered pertinent to the broader body of knowledge of diarrhoea and intestinal 
health in critically ill patients. It is recommended that the results of this study be used 
to inform future research that aims to improve the understanding and clinical 
prevention and management of diarrhoea in ETF critically ill patients. 
7.3 Strengths and limitations 
The strengths of this research were considered when evaluating the contributions of 
this study to current and historic knowledge. Identified strengths of this study are the 
conceptual framework developed from empirical literature, use of a standardised 
diarrhoea definition, observational methodology, continuity of specimen processing, 
and the use of multivariate regression modelling, specifically GEE modelling. 
As far as could be determined, this was the first study to examine diarrhoea, enteral 
nutrition and aerobic intestinal microflora relationships in critically ill, emergency 
admission adult ICU patients. This study examined diarrhoea risk factors that both 
have and have not previously been associated with diarrhoea in critically ill patients. 
The conceptual framework (see Figure 2.1, page 10) developed for this study 
highlights the complex interrelationships between the diarrhoea risk factors that were 
examined and establishes a clinical pathway to further examine diarrhoea and its 
associated risk factors in future research. 
A significant strength of the current study was the conceptual framework (see Figure 
2.1, page 10) that was derived from empirical literature. This conceptual framework 
guided the examination of diarrhoea and associated risk factors as it recognised the 
clinical complexities of diarrhoea associated with ETF and critical illness. Results 
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from the present study affirmed the revised conceptual framework (see Figure 6.1, 
page 170) by enabling a broader understanding of specific clinical variables 
associated with diarrhoea in the ICU patient and those clinical variables that require 
further examination with appropriately powered models. Importantly, the revised 
conceptual framework demonstrated associations between the ICU patient with 
diarrhoea and patient characteristics (Study ICU LOS, severity of illness, delay to 
bowel activity), ICU treatments including ETF (commencement > 24 hours, 
duration, formula), GIT-associated medications (aperients, prokinetics, PPI, sedation, 
neuromuscular blockade), clinical indicators (hypoalbuminaemia, hyperglycaemia, 
elevated WCC and INR, infection) and aerobic intestinal microflora. These 
associations are identified by the bold, red compound arrows. Importantly, the 
revised conceptual framework (see Figure 6.1, page 170) affirms associations 
between the ICU patient with diarrhoea, intestinal microflora disequilibrium and the 
ICU environment, the critical illness experience and patient characteristics. 
Furthermore, the revised conceptual framework (see Figure 6.1, page 170) identified 
diarrhoea risk factors that were not associated with diarrhoea in the current study that 
require further investigation. These diarrhoea risk factors are patient characteristics 
(age, gender) and medications (neuromuscular blockers, H2 antagonists) and 
importantly, these risk factors have been deleted from the revised conceptual 
framework. It is acknowledged that Study Two did not attain statistical significance 
and that the deletion of diarrhoea risk factors from the Conceptual Framework (see 
Figure 6.1, page 170) requires further examination with an adequately powered 
model. 
A strength of the present study was the use of one standardised definition of 
diarrhoea that was used across two studies to quantify, measure and validate 
diarrhoea. An over or under-estimation of diarrhoea may result from the 
interchangeable use within and between research studies of the 33 definitions of 
diarrhoea available in current literature (Lebak et al., 2003; Majid et al., 2012). The 
potential to skew the findings of diarrhoea in the current study was therefore 
minimised due to the consistent diarrhoea definition used across the two studies. In 
addition, the validity of diarrhoea period prevalence rates and incidence rates was 
strengthened in the current study owing to the repeated use of a validated diarrhoea 
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diarrhoea measurement tool, the Bristol Stool Form Scale Tool (Lewis & Heaton, 
1997). 
A further strength of Study Two was the use of an observational design to examine 
aerobic intestinal microflora in their natural environment, free from manipulation by 
intervention. The results of this study enabled an understanding of the phenomenon, 
intestinal microflora as they respond to critical illness. This new knowledge 
establishes the foundation on which to develop interventional research to more 
effectively manage the intestinal health of critically ill patients. 
Another strength of Study Two was the continuity of specimen plating and 
interpretation of specimen results for rectal swabs and faecal specimens. Specimen 
processing and colonisation interpretation was undertaken by one senior and one 
junior scientist in the Department of Microbiology at the research site. Inter-rater 
reliability was achieved through cross-checking the first five samples. 
A significant strength of the current study was the use of GEE modelling. Patients in 
this study had different entry and exit points, variable lengths of stay, repeated 
measurements of some data (rectal swabs, faecal specimens, clinical indicators), and 
clustering of data because of the repeated measurements (Mitchell, Teno, Roy, 
Kabumoto, & Mor, 2003). GEE modelling adjusted for clustered data effects that 
could otherwise not be adjusted for using standard or forced multivariate logistic 
regression models. This appears to be one of the first studies to use GEE modelling 
in the critical care context (Jack, Coyer, Courtney, & Venkatesh, 2010; Thibault et 
al., 2010) and particularly where diarrhoea and associated diarrhoea risk factors were 
examined. The use of multivariate GEE modelling has enabled a more contextual 
understanding of diarrhoea and associated diarrhoea risk factors in critically ill 
patients. 
Regardless of the significance of the findings of this study, a number of limitations 
must be considered when interpreting these results. These include the observational 
design and repeated measures design, sample size, lipid proponents of enteral 
nutritional formulae and propofol, and the duration of data observation. 
The current study used a repeated measures observational cohort design 
(retrospective and prospective) to examine the phenomena of diarrhoea and aerobic 
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intestinal microflora as they naturally occurred in the critical illness context. Thus the 
principles of true experimental research—manipulation, control and randomisation—
were not applied. Consequently, observational design precludes any suggestion of 
causality and is therefore a limitation of this study and the generalisation of findings 
to the wider ICU population. Despite this design limitation, a comprehensive 
understanding of diarrhoea and aerobic intestinal microflora was attained as no 
attempt was made to manipulate the aerobic intestinal microflora throughout the 
study protocol. 
The sample for Study One was a small, retrospective convenience sample of 50 
patient medical records that were audited using comprehensive inclusion criteria. 
Overall, the sample was representative of critically ill patients as diarrhoea 
prevalence reflected the diarrhoea prevalence reported in other studies (Ferrie & 
East, 2007; Whelan, Judd, & Taylor, 2004, Whelan et al., 2009). 
Two historic methodological flaws of repeated measures designs have been 
identified. First, there is the potential for missing data in the medical records. 
Episodes of care were cross-checked between patient observation charts, medication 
records, laboratory results and nursing and medical notation entries into the patient’s 
chart. Second, a data dictionary was applied to this study to optimise data 
interpretation. 
An acknowledged limitation of Study Two was that the required sample size was not 
achieved. This was due to significant infrastructure growth and redevelopment at the 
research site resulting in the decommissioning of the aero-medical landing pad. As a 
direct consequence, the number of emergency admissions to the research site 
decreased from 73 to 21 per month. The loss of aero-medical retrieval of patients 
also resulted in changes to the ICU’s patient demographics, acuity of illness and 
reasons for ICU admission, which directly slowed study participant recruitment. 
Although the fat or lipid proponents of enteral nutritional formulae and the sedation 
medication propofol were not examined for diarrhoea association in the current 
study, future research could consider this interrelationship. The implications of lipid-
based proponents of enteral nutritional formulae, propofol and diarrhoea remain 
relatively unexamined with regard to gastrointestinal function in critical illness 
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(Nguyen et al., 2008). The association between diarrhoea and the lipid proponents of 
enteral nutritional formulae and propofol could have been considered secondary 
study endpoints. 
Finally, it is acknowledged that patients who were admitted to the ICU for a longer 
period of time had a greater chance of experiencing the phenomena under 
investigation: diarrhoea and aerobic intestinal microflora changes. Patients were also 
at risk of experiencing diarrhoea following discharge from the ICU and/or after the 
completion of the study protocol (14 days). These missed occurrences of diarrhoea 
following ICU discharge were likely to be unrecorded and therefore, not associated 
with the patient’s critical illness experience. The accurate identification of ICU-
associated diarrhoea may therefore be unknown. 
7.4 Future directions 
The results arising from the two studies in this research provide sound evidence of 
diarrhoea and associated risk factors in critical illness. Future directions arising from 
this study will be presented according to implications for clinical practice, education, 
policy development and research. 
7.4.1 Implications for clinical practice 
From a clinical perspective, the implications of this research are significant. First, the 
consistent use of a standardised definition of diarrhoea and validated faecal stool 
measurement tool (the Bristol Stool Form Scale) facilitated reliable identification of 
diarrhoea in the current study. Standardised definition and measurement tools may be 
useful in the clinical setting to facilitate local, national and international data with 
regard to the extent and severity of diarrhoea in the critical illness context, thereby 
generalising research findings between ICUs. 
Second, ETF should be commenced as early as safely possible where the GIT is 
functional and there are no contraindications to commencing ETF. International ETF 
clinical practice guidelines (Heyland et al., 2003b; Kreymann et al., 2006; Martindale 
et al., 2009; McClave et al., 2009) recommend that all critically ill patients should 
have ETF commenced within 24 hours of ICU admission to ameliorate complications 
associated with starvation and hypermetabolism. In addition, the early 
commencement of ETF is suggested to ameliorate the occurrence and incidence rate 
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of diarrhoea. While future research will determine the most effective interventions to 
improve the intestinal health of critically ill patients, clinicians must be aware of the 
need for monitoring gastrointestinal hypo/hyper activity and time to initial bowel 
activity following ICU admission. In addition to monitoring, clinicians are advised to 
implement evidence-based ETF and bowel care protocols to minimise 
gastrointestinal complications such as diarrhoea and aerobic microflora dysbiosis. 
Third, clinicians need to make frequent and comprehensive assessments of 
medication histories and plans and clinical indicators when caring for the ETF 
critically ill patient with diarrhoea. Clinicians need to be aware of the gastrointestinal 
physiological implications of medication administration and clinical indicator 
derangement to minimise the severity and implications of diarrhoea and intestinal 
microflora dysbiosis. 
Finally, a key to good results in patients requiring resuscitation is rapid definitive 
care (the golden hours) (Bansal et al. 2009; Dellinger et al., 2012) using a 
standardised and systematic approach. Most importantly, it is recommended that 
clinicians consider intestinal health care through the early initiation of ETF within 
the initial four hours of resuscitation to minimise the effects of splanchnic 
hypoperfusion and consequently, intestinal microflora dysbiosis. There is a need for 
RNs to incorporate clinical practice changes to explore the intestinal health 
(intestinal microflora) regularly throughout the patient’s critical illness experience; 
for example, twice-weekly rectal swabs with the routine collection of multiresistant 
organism surveillance screening. Early detection of significant changes in intestinal 
microflora could result in clinical practice changes with the administration of gut-
modulating bacteria (prebiotics, symbiotics, probiotics). 
7.4.2 Implications for education 
It would appear that effective care of the critically ill patient’s intestinal health would 
benefit the patient. Although nursing clinician education regarding gastrointestinal 
complications associated with medication administration and clinical indicator 
derangement was not a study endpoint, results from this study highlight the need for 
continued education regarding these diarrhoea risk factors. The educational 
implications arising from this research are significant and should be considered and 
implemented through undergraduate and postgraduate curricula and also through 
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continuing nursing education. Registered nurses need to have a sound understanding 
of bowel care and enteral nutrition to safely provide the nursing care required for 
patients who experience diarrhoea. This baseline knowledge is recommended for 
incorporation into undergraduate curricula design using sound theoretical and clinical 
curricula pedagogies. Additionally, ICU RNs need to have a comprehensive 
understanding of the critical illness experience and diarrhoea risk factors including 
the role of patient characteristics, ICU treatments (ETF and medications), clinical 
indicators and intestinal bacteria so that a contextual understanding of intestinal 
health and diarrhoea in the critically ill patient is possible. Education exploring the 
intestinal health of critically ill patients is recommended for inclusion in postgraduate 
curricula and via nursing education forums at local health care facilities and through 
state and federal professional bodies. Health care clinicians are advised to participate 
in regular continuing education regarding international enteral nutritional therapy 
clinical practice guidelines and local health care facility ETF and bowel care 
algorithms. 
7.4.3 Implications for policy development 
Policy development associated with intestinal health of the critically ill patient 
should become more widespread. The implications for policy development arising 
from this research include the establishment of a standardised diarrhoea definition for 
critically ill patients so that diarrhoea can be consistently quantified and measured. 
This will facilitate comparison of research findings to more concisely develop policy 
and educational forums to improve the intestinal health care of critically ill patients. 
Furthermore, a standardised national ETF and bowel care algorithm that incorporates 
diarrhoea risk management strategies requires debate and development. Finally, it is 
recommended that a national working party to develop an ‘intestinal health care 
bundle’ that incorporates the timing to ETF commencement and bowel care is 
created. Only then can agreement be achieved between clinicians, researchers and 
academics. 
7.4.4 Implications for research 
Examination of diarrhoea, diarrhoea risk factors and aerobic intestinal microflora 
using the conceptual framework (see Figure 2.1, page 10 and Figure 6.1, page 170) 
has contributed significant new information to the body of knowledge regarding 
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diarrhoea in critically ill patients. This is the first study to examine diarrhoea, ETF 
and aerobic intestinal microflora in emergency admission critically ill adult patients. 
The extent of the knowledge generated from this research requires further 
examination. Future research could include the development, testing and validation 
of an internationally standardised definition of diarrhoea and the validation of an 
internationally agreed tool to measure diarrhoea in the ICU. This will facilitate 
consistent quantification and measurement of diarrhoea by international standards. 
Further research incorporating national auditing is required to examine the incidence 
rate of diarrhoea in Level I, II and III ICUs so that national figures can be sufficiently 
compared. Future research studies should incorporate internationally agreed 
diarrhoea management strategies and longitudinal studies randomising patients to 
receive specific enteral nutritional formulae so that diarrhoea causality can be 
elucidated. Finally, prospective observational studies are required to examine 
gastrointestinal hypo and hyper activity in association with posttraumatic ileus, 
diarrhoea and intestinal microflora in critically ill patients and RCTs manipulating 
and measuring the effects of intestinal microflora on diarrhoea using prebiotics, 
symbiotics and probiotics are required. 
7.5 Conclusions 
In summary, associations between diarrhoea, enteral nutrition and aerobic intestinal 
microflora in emergency admission, critically ill adult ICU patients have been 
discovered by the results of this study. As the first study to examine these 
associations in the critical care context, this study identified a number of diarrhoea 
risk factors evident among critically ill patients including patient characteristics (ICU 
LOS, severity of illness, delay to bowel activity), ETF (commencement > 24 hours 
following ICU admission, duration, formula), medications (aperients, prokinetics, 
PPI, sedation, antibiotics) and clinical indicator derangement duration 
(hypoalbuminaemia, hyperglycaemia, elevated WCC, elevated INR, infection). Of 
note is that aerobic intestinal microflora significantly changes during the early and 
late stages of the ICU patient’s critical illness experience. The continuity of the 
diarrhoea definition used between the two studies facilitated consistent measurement 
of diarrhoea. In conclusion, the findings of this study will move beyond this thesis to 
inform a multi-site, national program of research with the intent of changing clinical 
practice and improving the care of the critically ill patient’s intestinal health. 
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Appendix 1: Study One data collection tool 
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Appendix 2: Study Two data collection tool 
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Section I: ICU Admission Rectal Swab 
 
1. Admission Rectal Swab:    -          -                     : 
 (1=Yes; 2=No)                  (DD-MM-YY)   (HR:MIN) 
2. Semi-Quantitative Count:   
(0 = No Growth; 1+ = Small Growth; 2+ = Moderate Growth; 3+ = Large Growth) 
 
3. Observed intestinal bacteria:       
           
           
           
            
 
 
 
Section J: ICU Discharge Rectal Swab 
 
1. Discharge Rectal Swab:                -          -                     :  
 (1=Yes; 2=No)                  (DD-MM-YY)   (HR:MIN) 
2. Semi-Quantitative Count:         
(0 = No Growth; 1+ = Small Growth; 2+ = Moderate Growth; 3+ = Large Growth) 
 
3. Observed intestinal bacteria:       
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Section K: Study Protocol Faecal Specimens 
 
Day Date Time Results 
D1   _______________________________________________ 
 
D2   _______________________________________________ 
 
D3   _______________________________________________ 
 
D4   _______________________________________________ 
 
D5   _______________________________________________ 
 
D6   _______________________________________________ 
 
D7   _______________________________________________ 
 
D8   _______________________________________________ 
 
D9   _______________________________________________ 
 
D10   _______________________________________________ 
 
D11   _______________________________________________ 
 
D12   _______________________________________________ 
 
D13   _______________________________________________ 
 
D14   _______________________________________________ 
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Appendix 3: Enteral nutrition formula administered at the research site during 
Study One and Study Two 
 
Enteral Feed Type of Feed Nutritional 
Information/100 mL 
Jevity Fibre and fructo-
oligosaccharide (FOS) 
enriched, isotonic formulae 
300 mOsm/kg H2O 
 
105 kcal energy 
4g protein 
14.05g carbohydrates 
3.47g fat 
1.76g dietary fibre 
Jevity Plus Fibre and FOS enriched, 
formulae 
449 mOsm/kg H2O 
120 kcal energy 
5.55g protein 
15.07g carbohydrates 
3.93g fat  
1.20g dietary fibre 
Nepro Moderate protein, high 
calorie for patients with 
renal disease 
745 mOsm/kg H2O 
180 kcal energy 
8.1g protein 
16g carbohydrates 
9.6g fat 
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Appendix 4: Evidence-based algorithms for nutritional support 
(Algorithm based on the ACCEPT trial) 
 
 
     No 
 
       Yes 
 
         
                              Yes 
 
 
 
 
 
 
 
 
 
       Yes 
 
 No 
 
 
 
     Yes 
 
 
 
 
         Yes     No 
 
 
 
 
 
 
 
 
 
 
Note. ICU: intensive care unit; EN: enteral nutrition; TPN: total parenteral nutrition; 
PN: parenteral nutrition; q12hr: every 12 hours.  
Should this patient be 
fed at ICU admission? 
Acceptable conditions: 
 Tolerating adequate diet 
 <24 hr to oral intake 
 Palliative care 
Can ETF be started 
within 24 hours? 
Gastric challenge: use 
full strength 
concentration. 
Consider prokinetic 
with challenge 
Goal: at least 80% of 
requirements at 72 hr 
Assess q12h 
Acceptable conditions: 
 Acute pancreatitis 
 Enteric anastomosis 
 Ischaemic bowel 
 Enteric fistula 
 Imminent bowel resection 
 Imminent endoscopy 
 Bowel obstruction 
 High nasogastric losses 
 Severe exacerbation of 
inflammatory bowel disease 
 Is progression of target 
to reach at least 80% 
by 72 hr? 
Increase rate to 100% 
of requirements 
 Use prokinetic 
 Use post pyloric tube 
 Begin TPN 
 Reassess q12hr for 
ETF eligibility 
Is goal met?  Continue ETF to 
maximum tolerated 
 Supplement with PN 
 Continue ETF 
challenges q12hr 
No 
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Appendix 5: Bowel care regimen flow chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Daily, morning review of bowel 
motions (BM) 
No BM in last 24 
hours? 
1–2 BM in last 24 
hours 
>2 BM in last 24 
hours 
Step 1: Start Coloxyl 
& Senna tablets 2 BD 
No action. Continue 
current bowel care 
Reduce bowel 
regimen by 1–2 steps 
Step 2: 
No bowel motion in last 24 hours? 
Add Bisacodyl and Glyceryl suppositories OD 
Step 3:  
No bowel motion in last 24 hours?  
Rectal exam by doctor; faecal disempaction if 
required 
Give Microlax enema 1–2 
Step 2:  
No bowel motion in last 24 hours?  
Add Movicol 15 mL BD 
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Appendix 6: Monthly Screening Log, Study Two 
Exploring Diarrhoea, Enteral Nutrition and Intestinal Microbial Flora Relationships in 
Critically Ill Patients 
 
DAILY SCREENING LOG (Month and Year)  
The screening log is used to document identification of participants who entered pre-study screening. It is important to know the reason for screen failures. 
INCLUSION CRITERIA EXCLUSION CRITERIA 
1 = Emergency admission to ICU; 
2 = Aged > 18 years; 
3 = Speaks English. 
 
4 = ICU admission from ward or another hospital; 
5 = Burns patient; 
6 = Trauma patient with severe peri anal trauma; 
7 = Patient moribund & likely to die within 24 hours; 
8 = Expected length of ICU stay ≤ 24 hrs. 
9 = Other. 
Patient Name 
(First/last) 
MRN Date of ICU 
admission 
(dd/mm/yyyy) 
Date of 
ICU D/C 
(dd/mm/yyyy) 
Discharge 
Ward 
Hospital 
D/C Date 
(XX:XX) 
Exclusion Criteria Met (Y or N) 
(if Yes, provide reason from list below 
If No, patient is eligible - notify Leanne Jack) 
       
       
       
       
       
       
       
       
       
       
220 
Appendix 7: Study One Enrolment Log 
Exploring Diarrhoea, Enteral Nutrition and Intestinal Microbial Flora Relationships in Critically Ill Patients 
 
ENROLMENT FORM  
The enrolment form is used to document subjects who participated in this study. 
Study ID 
Number 
MRN Date 
Enrolled 
DD/MM/YY 
Patient L_Name Patient F_Name ICU admission 
date 
ICU discharge 
date 
Hospital discharge 
date 
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Appendix 8: Study Two Enrolment Log 
Exploring Diarrhoea, Enteral Nutrition and Intestinal Microbial Flora Relationships in Critically Ill Patients 
 
ENROLMENT FORM 
The enrolment form is used to document subjects who agreed to participate in the study. 
 
Part. 
No. 
MRN Date 
Enrolled 
DD/MM/YY 
Patient L_Name Patient 
F_Name 
 
Family Member 
L_Name 
Family Member 
F_Name 
Relationship 
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Appendix 9: Staff Information Sheet, Study Two 
 
 
    Miss 
Leanne Jack, 
Centre for Health Research (Nursing)  Intensive Care Unit, 
Princess Alexandra Hospital, 
      Ipswich Road, 
Woolloongabba. Qld. 4102. 
 
 
Exploring Diarrhoea, Enteral Nutrition and Intestinal Microbial Flora  
Relationships in Critically Ill Patients 
 
Staff Information Sheet 
 
 
Thank you for your interest in the intestinal flora, enteral nutrition and diarrhoea 
study in critically ill, emergency admission patients. The following will provide you 
sufficient information about this study. 
I am Doctor of Philosophy Candidate at the Queensland University of Technology 
(QUT) in Brisbane. The purpose of this study prospective, cohort study is to explore 
the relationships between intestinal flora, enteral nutrition and diarrhoea in critically 
ill, emergency admission patients. The research being undertaken will contribute to 
my final dissertation. 
The cohort study will consecutively enrol all emergency admission, adult patients 
admitted to the intensive care unit (ICU) over a 3 to 6 month time frame who meets 
the inclusion/exclusion criteria. Randomisation of patients will not occur. All patient 
cares will follow the usual Princess Alexandra Hospital’s (PAH) ICU usual 
treatment regimens. 
The cohort study will implement current practices used in the daily routine care of 
the critically ill patient at the PAH’s ICU. Routine nursing and medical cares will 
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include early commencement of enteral nutrition within 48 hours of admission as per 
the Australian College of Critical Care Nurse’s Association (ACCCN), collection of 
routine blood assays, elevation of the head of the patient’s bed to 30° (provisional 
diagnosis enabling), 4
th
 hourly nasogastric (NGT) or orogastric (OGT) tube 
aspiration, 4
th
 hourly bowel sound auscultation, administration of stool softeners and 
prokinetic agents as prescribed, routine changing of invasive lines including central 
venous lines (CVL), intra arterial lines (IAL) and indwelling urinary catheters (IDC) 
and frequent, routine documentation (at least once per shift) of patient assessment 
and cares. In addition, you may be required to collect the following: 
 
1. Faecal swab following consent; 
2. Second daily faecal specimens; and 
3. Rectal swab prior to discharge from the ICU. 
It is anticipated that approximately 320 study participants in total will be enrolled 
into this single centre cohort study. 
No foreseeable risk to you is envisaged through your participation in this study. 
However, should the study process worry or concern you in any way please feel free 
to discuss this further with myself or any member of the supervisory team. The 
supervisory team’s contact details will be found in the study protocol information 
folders located in both the post operative and general ICU nurses stations and on the 
PAH ICU intra net website. 
Your participation in and throughout the study is voluntary. Your participation in 
this study will comprise the PAH’s ICU’s routine nursing and medical cares. The 
only foreseeable increase in nursing and medical cares is the collection of a faecal 
swab following consent, second daily faecal specimens for fourteen days and a rectal 
swab prior to the patient’s discharge from the ICU. This study has ethical approval 
from the PAH and QUT Human Research and Ethics Committees (HREC). 
An email will be disseminated prior to the commencement of the study enabling staff 
the opportunity to identify any potential objections to participation in the research. 
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Should you have concerns regarding the collection of rectal swabs or faecal 
specimens please discuss this with the nurse in-charge of the shift at the 
commencement of your shift so that patient re-allocation may occur with minimal 
disruption to the human resource management of the ICU and patient cares. All data 
obtained will be kept secure and confidential. No data will be collected from nursing 
and medical staff and you will not be identified any report. A summary of the final 
results will be made available to the Nurse Unit Manager and Medical Director of 
the PAH ICU after the final analysis – approximately December, 2009. 
If you wish to discuss any aspect of this study please feel free to contact myself on 
the number below, or my academic supervisor Dr. Fiona Coyer on (07) 3138 3895. 
Should you have any concerns about the ethical conduct of the study you may 
contact the QUT Research Ethics Officer on (07) 3138 2340. 
Yours Sincerely, 
 
 
 
Leanne Jack (Clinical Nurse) 
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Appendix 10: Routine Intensive Care Unit Cares 
Study One and Study Two 
 
Standard intensive care unit patient cares 
 Enterally tube fed within 48 hrs 
of ICU admission or as indicated 
by medical/surgical teams 
 4th hourly NGT/OGT aspirates 
 Change NGT/OGT syringe daily 
 Bowel regimen as indicated 
 4th hourly bowel sound 
auscultation 
 Elevate HOB 30° when indicated 
 Daily ABG as indicated 
 Daily blood assays (liver 
function, coagulation, 
blood/urea/nitrogen, full blood 
count) as indicated 
 Septic screen as indicated 
 Electrolyte replacement as 
required 
 Any other investigations or 
procedures as required 
 Daily data collection: Study One 
(Appendix 1) and Study Two 
(Appendix 7) 
In addition, Study Two study participants will have: 
 A rectal swab within 48 hrs of ICU admission and following informed 
consent 
 2nd daily faecal tests if diarrhoea present to maximum of 14 days into ICU 
admission 
 A rectal swab prior to discharge from the ICU 
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Appendix 11: Participant Information Sheet and Consent Form, Study Two 
 
 
Miss Leanne Jack, 
Centre for Health Research (Nursing)   Intensive Care Unit, 
      Princess Alexandra Hospital, 
       Ipswich Road, 
 Woolloongabba. Qld. 4102.  
 
Intestinal Flora, Enteral Nutrition and Diarrhoea Study 
Legally Authorized Representative Information and Consent Form 
 
Version: 5 
Dates:  18
th
 May, 2008 
Site:  The Intensive Care Unit, Princess Alexandra Hospital 
Full Project Title: 
 
Exploring Intestinal Microbial Flora, Enteral Nutrition and 
Diarrhoea Relationships in Critically Ill Patients 
 
Principal Researcher (Staff Contact): Leanne Jack, Clinical Nurse (PhD 
Candidate), 
      Princess Alexandra Hospital, 
Telephone: 07 3240 2393; 
Supervisory Staff Contact:   Professor Bala Venkatesh 
      Princess Alexandra Hospital, 
Telephone: 07 3240 2704; 
Academic Supervisors:   Dr. Fiona Coyer, 
Telephone: 07 3138 3895; and 
Professor Mary Courtney,  
Telephone 07 3138 3887, 
Queensland University of Technology. 
 
 
This legally authorised representative information sheet and consent form is 9 pages 
long. Please make sure you have read all the pages. 
 
1. Your consent 
As the legal representative for the patient, you are invited to consider their 
participation in this research project. Where the patient is unable to provide consent 
for themselves, Queensland law allows the legal representative for a patient to 
consent to the patient taking part in nursing and medical research. 
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This Information Sheet and Consent Form contain detailed information about this 
project. The purpose of this Information Sheet is to explain to you as openly and as 
clearly as possible all the procedures involved in this project before you decide 
whether or not you wish for the patient to participate in the study. 
 
Please read this Information Sheet carefully. Please feel free to ask any questions 
about any information in the document. You may also wish to discuss this study with 
another relative or friend or even your local health care worker. Please feel free to do 
this. If you agree for the patient to participate in the project, you may have additional 
questions throughout the duration of the study. Please feel free to discuss this with a 
member of the research team at any time. 
 
Once you understand what this project is about and you have had all of your 
questions answered and if you agree that the patient should participate in the project, 
you will be asked to sign a Consent Form. By signing the Consent Form, you 
indicate that you understand the information and that you give consent for the patient 
to participate in the research project. 
 
You will be provided a copy of the Information Sheet and Consent Form to keep as a 
record of this project. 
 
2. Purpose and Background 
The purpose of this study is to examine the relationships between intestinal flora 
(bacteria), artificial tube feeding (enteral nutrition) (EN) and diarrhoea in critically ill 
patients. As part of the normal treatment, you will receive artificial feeding (EN) 
through a tube inserted in your nose or mouth that will then sit in the stomach. This 
tube is called a nasogastric (NGT) or an orogastric (OGT) tube. Through this tube, 
artificial feeding, medications and fluids can be administered. Although artificial 
feeding carries many benefits, it also carries the potential to develop diarrhoea. There 
are several ways we try to reduce the risk of diarrhoea. Some of these methods 
include frequent aspiration of the NGT or OGT tubes, ongoing monitoring of body 
systems, listening to bowel sounds, monitoring bowel activity & administering 
medications to facilitate bowel activity. We are undertaking this study to investigate 
1) whether the intestinal bacteria changes when patients are artificially fed; and 2) 
then to see if these gut changes are associated with the diarrhoea in critically ill 
patients. 
 
Current practice in our intensive care unit (ICU) has been to commence artificial 
feeding within 48 hours of admission to the ICU.  
 
Currently, our ICU does not routinely investigate gut bacterial changes that may be 
associated with diarrhoea when a patient is artificially tube fed. Research suggests 
that healthy people who receive an artificially tube fed diet show changes in the gut’s 
normal bacteria. However, the relationships between diarrhoea, EN and the gut’s 
bacteria are poorly examined in critically ill patients. We believe that by 
understanding the changes in the gut’s bacteria when critically ill patients are 
enterally fed, we may be able to address ways to minimise these bacterial changes 
and lessen the incidence, frequency, duration and complications associated with 
diarrhoea in critically ill patients. 
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3. Procedures 
Participation in this project will involve information from the patient’s medical 
record being recorded on an information sheet by the research investigator. The 
patient will be sequentially enrolled into the study. The patient will receive the 
normal, routine Princess Alexandra Hospital’s (PAH) ICU cares and treatments for 
critically ill patients.  
 
Full details of all procedures and additional laboratory tests are described below: 
 Information about the patient’s medical history and current condition which 
is already in their medical record will be checked and recorded by the 
research investigator; 
 All patients will be artificially tube fed within 48 hours of ICU admission 
following medical assessment; 
 A rectal swab will be collected within the 2 days of ICU admission to 
determine the presence of admission bacteria; 
 Diarrhoea will be monitored for signs of infection by sending specimens to 
microbiology every 2 days to a maximum of 14 days; 
 The patient’s NGT or OGT will be aspirated every 4 hours to determine the 
patient’s tolerance to artificial tube feeding; 
 Bowel sounds will be listened to every 4 hours; 
 The patient’s head of bed will be elevated if not contraindicated; 
 Medications to stimulate bowel activity will be commenced and administered 
as part of the ICU’s standard patient cares; and 
 All incidence of infection will be monitored and treated in the ICU’s usual 
way. 
 
4. Collection and Use of Faecal Samples for Research Purposes 
By consenting for the patient to participate in the study, you also consent to the 
collection, storage and use of 2 rectal swabs and a maximum of 7 faecal specimens 
as specified below. Some rectal swabs and faecal specimens will be stored in a 
central laboratory for testing at the PAH. All samples collected for this study will be 
stored in an appropriately accredited laboratory and destroyed at the end of the study. 
 
If resistant organisms are found, the rectal swabs and/or faecal specimens may be 
subjected to further analysis which above routine investigation. A small portion of 
these samples may be subjected to viral analysis. 
 
5. Possible Benefits 
You may not directly benefit from this study. However, future critically ill patients 
who are artificially tube fed and develop diarrhoea may benefit from the knowledge 
gained by this study. We cannot guarantee or promise that the patient will receive 
any benefits from this project. 
 
6. Possible Risks / Side Effects 
There are no foreseen risks to the patient through participation in this study. All 
patients will be informed of the collection of the rectal swab prior to its collection. 
The patient’s privacy and dignity will be maintained at all times through the drawing 
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of bedside doors and/or curtains prior to the collection of any and all rectal swabs 
and faecal specimens. 
 
Pregnancy and Breast Feeding 
There are no increased foreseen risks to the immunocompromised or pregnant 
patient through participation in this study. 
 
7. Other Treatments Whilst on the Study 
It is important to tell the medical staff of the ICU and the research investigator(s) 
about any allergies that the patient may have including latex. 
 
8. Alternatives to Participation 
If the patient does not participate in the study or choses to withdraw from 
participation in the study, they will receive the standard nursing, medical, and health 
care treatment for their critical illness or injury. The patient does not have to 
participate in this study to receive the standard treatment for their condition. 
 
9. Privacy, Confidentiality and Disclosure of Information 
Your confidentiality and anonymity will be maintained and assured at all times 
throughout this study and will only be used for the purpose of this research project. 
Any patient information will only be disclosed with the patient’s permission, except 
as required by law. If you give us permission by signing the Consent Form, we plan 
to publish the results in health care journals. No hospital unit record number, patient 
name or individual will be identifiable within the final report and any and all 
subsequent publications resulting from this study. Coding mechanisms will be 
applied to patient records and data collection tools. 
 
The patient’s health records and any information obtained during this study are 
subject to inspection (for the purpose of verifying the procedures and data) by the 
Human Research and Ethics Committees that have provided ethical approval for the 
conduct of this research proposal. By signing the attached Consent Form, you 
authorise release of or access to this confidential information to the relevant study 
personnel and regulatory authorities as noted above. 
 
A database with study information will be generated and this will be kept on a 
computer that is password protected at the PAH ICU. All information and data will 
be maintained and kept in the strictest confidence in a locked filing cabinet 
accessible only to the researcher; that is, a research office at the PAH. Records will 
then be kept for 5 years in accordance with the National Health and Medical 
Research Committee (NHMRC) guidelines and after this time destroyed. 
 
Consent to participate in this study is entirely voluntary. All participants are free to 
withdraw from participation from the study at any point in time without penalty; that 
is, the standard of care that you will receive as a patient at the PAH will not be 
affected in any way. The ICU’s usual treatment will be implemented to all study 
participants which consists of commencement of artificial tube feeding within 48 
hours of admission, commencement of bowel care medications within 48 hours of 
artificial tube feeding and routine nursing, medical and health cares. 
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10. Results of the Project 
A copy of any publication resulting from this study will be available on request from 
Leanne Jack whose number is listed below. 
 
11. Further Information or Any Problems 
If you require further information or you have any problems in relation to this study 
you can contact: 
Principal researcher (PhD Candidate):Leanne Jack on (07) 3240 2393; 
 
Supervisory Staff Contact:  Prof Bala Venkatesh on (07) 3240 2393; 
 
Academic Supervisor Contact: Dr Fiona Coyer on (07) 3138 3895; 
     Prof Mary Courtney on (07) 3138 3887. 
 
12. Participation is Voluntary 
Participation in this research project is entirely voluntary. If you do not wish for the 
patient to participate in the research project you are not obliged to include them. If 
you decide that the patient should participate in the study and later change your 
mind, you are free to withdraw the patient from the project at any time without 
penalty; that is, the standard of care that you will receive as a patient at the PAH will 
not be affected in any way. Any decision that you make will not affect yours or the 
patient’s treatment or relationship at the PAH ICU. 
 
If you decide that the patient would like to participate in the study, then the 
researcher(s) will make sure they discuss the study with the patient when he/she is 
well enough to understand if required. The patient can then make the decision about 
whether they want to continue with the study. Once again, any decision that the 
patient or yourself makes will not affect the patient’s or your treatment or 
relationships at the PAH ICU. 
 
Before you make you decision about the patient’s participation in the study, a 
member of the research team will be able to discuss any questions that you may have 
about this research project. You can ask for any information that you require. Please 
sign the Consent Form only after you have had the chance to ask your questions and 
have satisfactory answers. 
 
13. Reimbursement for your costs 
Participation in this study is entirely voluntary and patients will not be paid for their 
participation. 
 
14. Ethical Guidelines 
This research project will be carried out under the National Statement on Ethical 
Conduct in Research Involving Humans (November 2007) which is produced and 
released by the National Health and Medical Research Council of Australia. 
 
Queensland law and hospital policy require the Courts, the Guardianship Tribunal, 
the Princess Alexandra Hospital (Authority) and Queensland University of 
Technology to consider consent for research on behalf of unconscious patients. The 
Human Research Ethics Committee has approved this study. If you have any 
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questions or concerns please contact the Intensive Care staff, any of the nursing staff 
or any of the academic staff listed above. In addition, if you have any questions 
about your rights as a participant in this study, or you feel that you have been placed 
at risk, you can contact the Ethics Manager, Human Research Ethics Committee, 
Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Qld 4102 or telephone 
(07) 3240 5856 or the Queensland University of Technology’s Research Ethics 
Officer on (07) 3138 2340. 
 
15. Injury 
In the event that the patient suffers an injury as a result of participation in this 
research project, hospital treatment and care will be provided by the public health 
service at no extra cost to them. 
 
16. Termination of the Study 
This research project may be stopped for various reasons such as unacceptable side 
effects or the patient is discharged from the PAH ICU prior to completion of the 
study. 
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Miss Leanne Jack, 
Centre for Health Research (Nursing)   Intensive Care Unit, 
            Princess Alexandra Hospital, 
       Ipswich Road, 
 Woolloongabba. Qld. 4102.  
 
 
Intestinal Flora, Enteral Nutrition and Diarrhoea Study 
Legally Authorized Representative Information and Consent Form 
 
 
Principal Researcher (Staff Contact): Leanne Jack, Clinical Nurse (PhD 
Candidate), 
      Princess Alexandra Hospital, 
Telephone: 07 3240 2393; 
Supervisory Staff Contact:   Professor Bala Venkatesh 
      Princess Alexandra Hospital, 
Telephone: 07 3240 2704; 
Academic Supervisors:   Dr. Fiona Coyer,  
Telephone: 07 3138 3895; and 
Professor Mary Courtney,  
07 3138 3887, 
Queensland University of Technology. 
 
Project Title:  Exploring intestinal microbial flora, enteral nutrition and 
diarrhoea relationships in critically ill patients 
 
 
The investigator conducting this research project abides by the principles governing 
the ethical conduct of research, and at all times, avows to protect the interests, 
comfort and safety of all participants. 
 
My signature below will indicate that: 
 
1. I have read and understood the participant Legally Authorised Representative 
Information Sheet outlining the nature and purpose of the study Version 1, 
18
th
 May 2008; 
 
2. I have had the opportunity to ask questions and I am satisfied with the 
answers I received; 
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3. I clearly understand the extent of the patient’s involvement and possible risks 
involved; 
 
4. I will be provided a copy of the Information and Consent Form to keep; 
 
5. I consent to allow the patient’s inclusion in the study which is voluntary and 
may be terminated by myself or the patient at any time without comment or 
penalty, and without jeopardising the ongoing care of the patient; 
 
6. I understand that the information obtained will be kept confidential, and that 
no identifying information will be made available within the final report and 
any and all subsequent publications resulting from this study; 
 
7. I can contact the Princess Alexandra Hospital’s, Guardianship Tribunal 
and/or Queensland University of Technology’s Research Ethics Officer if I 
have any questions or concerns about the conduct of the research; 
 
8. I consent to the patient to be included in the study. 
 
I understand that I can contact Leanne Jack (07) 3240 2393, Dr. Fiona Coyer (07) 
3138 3895 or the Research Ethics Officer at QUT on (07) 3138 2340 if I have any 
enquiries about this study. 
 
 
Participant’s Name (print):   
     
 
Name of Legally Authorised Representative (print):      
 
Relationship to the Participant (print):       
 
Signature:       Date:    
 
Witness Name (print):         
 
Witness Signature:      Date:    
 
Researcher Name (print):         
 
Researcher Signature:      Date:    
 
 
Note: All parties signing the Consent Form must date their own signature. 
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Substitute Decision-maker’s Consent to Participate 
In Approved Clinical Research Project 
 
 Yes No 
1. Has the patient made an advanced health directive in which they 
have written their views about participation in this type of research? 
 If yes, the patient’s views must be followed. 
 If no, someone else may be able to consent on their behalf. 
  
The following questions will guide you: 
2. Has the Guardianship and Administration Tribunal appointed any 
guardians for health care for the patient? 
 If yes, the guardian can make the decision. 
 If no, please go to Q3. 
  
3. Has the person made any enduring powers of attorney for personal 
decisions? 
 If yes, the attorney can make the decision. 
 If no, please go to Q4. 
  
4. Do you belong to any of the following categories? (Please note that 
a paid carer does not mean a person receiving a carers payment from 
Centrelink) 
   i)       Are you the patient’s spouse and is your relationship close and 
continuing? 
   ii)      Are you the patient’s carer (this does not include a paid carer)? 
   iii)    Are you over the age of eighteen (18) and a close friend or 
relative of the patient 
           (this does not include a paid carer)? 
 If you answered yes to any of these questions, then as the 
statutory health attorney you can make a decision about 
whether the patient may participate in the study. 
 If you answered no to all three (3) questions, then you cannot 
make a decision about whether or not the patient may 
participate in the study. 
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Miss Leanne Jack, 
Centre for Health Research (Nursing)   Intensive Care Unit, 
      Princess Alexandra Hospital, 
       Ipswich Road, 
 Woolloongabba. Qld. 4102.  
 
Intestinal Flora, Enteral Nutrition and Diarrhoea Study 
Revocation of Consent Form 
 
 
Full Project Title: Exploring intestinal microbial flora, enteral nutrition and 
diarrhoea relationships in critically ill patients. 
 
 
 
I hereby wish to WITHDRAW my consent to participate in the research proposal 
described above and understand that such withdrawal WILL NOT jeopardise any 
treatment my relative may receive or my relationship with the Princess Alexandra 
Hospital Intensive Care Unit. 
 
 
 
Participant’s Name (printed):         
 
 
Signature:        Date:   
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-----Original Message----- 
From: Research Ethics [mailto:ethicscontact@qut.edu.au] 
Sent: Monday, 18 August 2008 1:52 PM 
To: Miss Leanne Carolyn Jack 
Cc: Ms Janette Lamb 
Subject: Ethics Variation – 0600000931 
 
Dear Miss Leanne Jack 
 
Project #: 0600000931 
Project Title: "Promoting better bowel care within the adult ICU: does probiotic 
therapy and early enteral nutrition reduce the incidence of diarrhoea in the critically 
ill, emergency admission, adult IC patient?" 
End Date: 16/02/2010 
 
This email is to advise that your application for a variation has been received by the 
Research Ethics Unit. 
 
Approval has been provided for the new study design and associated documentation 
for your project. We understand you have approval from the Princess Alexandra 
Hospital's Human Research Ethics Committee.  
 
This decision is subject to ratification at the next meeting of the University Human 
Research Ethics Committee and you will only be contacted again in relation to this 
matter if the Committee raises any additional questions or concerns. 
Regards 
 
Research Ethics Unit   |   Office of Research 
O Block Podium   |   Gardens Point Campus 
p  +61 7 3138 5123   |   f  +61 7 3138 1304 
e  ethicscontact@qut.edu.au 
w  http://www.research.qut.edu.au/ethics/ 
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Appendix 14: Ethics approval, Study One and Study Two, the Queensland 
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